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SUMMARY 
The aim in this thesis, was to synthesize novel platinum coordination 
compounds, in order to develop compounds with improved anticancer action 
which could lead to an improved understanding of the mechanism by which 
they operate and at the same time, improve synthetic methods for their 
products.  
The initial work included the development of a novel synthetic method for 
1R,2R-diaminocyclohexaneoxalato-platinum(II) (oxaliplatin), by using an 
essentially non-aqueous solvent medium and direct ligand exchange at 
elevated temperatures. This was done by a study of the kinetics of the 
reaction in a variety of conditions; such as relative reagent concentrations and 
ratios as well as solvent mixtures. An effective method was developed which 
could be applied industrially. An international patent was taken out on this 
method.  
Various amine complexes of platinum(II) were synthesized using chloro, 
bromo and oxalato groups as leaving groups. The non-leaving groups were 
selected having certain specific characteristics in mind. 
Novel mononitroplatinum(IV) complexes were synthesized, mostly with 
oxalato leaving groups. One of these in particular, had excellent anticancer 
behaviour. Another trichloromononitro complex was also synthesized with 
very good anticancer properties. Two international patents were filed for the 
latter two compounds. 
As far as possible, all compounds were studied by spectrometric, 
chromatographic and thermal methods. They were also tested against 3 
cancer cell lines namely cervical (Hela), Colon (HT29) and Breast (MCF7) 
cancer cells. 
 
1 
CHAPTER 1 
INTRODUCTION 
1.1 BACKGROUND 
What is cancer? 
Cancer is a class of diseases in which a group of cells display uncontrolled growth 
and are able to invade other tissues. This disease shows no preference for race, 
gender or age and could be termed a “silent killer”, since the symptoms for it are 
sometimes not as easily detected and may even go unnoticed. To date, there are 
more than 100 different types of cancer known and thus a means of remedying 
this “pandemic” is of humanitarian importance. 
Treatment 
Conventional types of cancer treatment include; surgery, radiation therapy and 
chemotherapy. Chemotherapy is treatment by use of antineoplastics in an attempt 
to kill cells, specifically those of micro-organisms or cancer. Platinum 
antineoplastics, in particular, are unique, in that they employ an inorganic 
coordination complex as the active entity. 
The discovery of the pioneering drug 
It all started almost 40 years ago, when a physicist-turned biochemist wanted to 
determine whether the application of electromagnetic radiation to bacterial and 
mammalian cells would indicate whether electric or magnetic dipole fields might 
be involved in cell division. Inadvertently, or in retrospect rather serendipitously, in 
his early experiments using Escherichia coli, he noticed that a set of platinum 
electrodes (considered to be inert) was present in the growth chamber. When the 
field was turned on, the bacteria appeared as very long filaments rather than as 
the normal short rods. This effect was shown not to be due to the electric field, but 
rather to electrolysis products arising from the platinum electrodes instead. 
Detailed chemical analysis followed, which revealed two active complexes viz. the 
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neutral cis-Pt(II)(NH3)2Cl2 or cis-diamminedichloroplatinum(II), now more 
commonly known as cisplatin (See Figure 1-1) and a platinum(IV) analogue; 
cisPt(IV)(NH3)2Cl4 or cis-diamminetetrachloroplatinum(IV); as the causative 
molecules of this intriguing biological effect.  
 
Pt
Cl NH3
NH3Cl  
Figure 1-1 Structure of cisplatin, the first successful anticancer drug developed in 
1965 and approved by the FDA in 1978. 
As it turned out, Rosenberg, Van Camp, Trosko and Mansour1,2 had rediscovered 
an already known platinum coordination complex that was originally synthesized 
and described in 1845, known as Peyrone’s chloride.  In 1968, cis-
diamminedichloroplatinum(II), i.e. cisplatin, was administered to mice, bearing a 
standard murine transplantable tumour, namely sarcoma-180, and it was shown 
to cause marked tumour regression. By 1971, after in vivo confirmatory tests 
performed at the Chester Beatty Institute in the U.K., the first patients were 
treated with the original “bench” discovery drug. Thus began what can now be 
referred to as the renaissance of inorganic chemistry, in the synthesis and 
biological evaluation of numerous cisplatin analogues.  
How well does cisplatin work? 
Cisplatin is known to be particularly effective against solid tumour types, such as 
testicular, ovarian, head and neck cancers and against small-cell lung cancers, 
with a cure rate as high as 90%.3 In fact, testicular cancer went from a disease 
that normally killed about 80% of its patients, to one which is almost 95% curable 
since the inception of cisplatin.  
Crossing the barrier … from bloodstream into cell 
Whether by injection or infusion, after cisplatin enters the bloodstream, the drug is 
well known to be transported all over the body, with some ligand substitutions 
occurring. The presence of excess chloride in the blood (~100 mM), to some 
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degree, limits the extent of the ligand exchange. Cisplatin enters the cell by 
diffusion, be it passive or active. In the latter case via specific transporters, good 
evidence is now available that in addition to the passive process, the so-called 
constitutive triple response 1 (CTR1)  receptor mechanism, (by which copper is 
naturally transported), assists the platinum species to enter the cell. In the 
process of excretion however, ATP (adenosine thriphosphate) plays a role.4 
Once inside the cell, cisplatin has a number of options available with which to 
bind. These include DNA, proteins, membrane phospholipids and sulphur 
containing enzymes, to mention a few. It has even been suggested that, upon 
entering the cell, cisplatin binds temporarily to membrane components such as 
phosphatidylserine.5 However for the neutral cisplatin to become useful inside the 
cell, it has to be activated. Intracellular activation is a result of aquation of one of 
the two chloride leaving groups. This required aquation is facilitated by the much 
lower intracellular chloride concentration (~3-20 mM). Figure 1-2 represents how 
cisplatin enters the cell and the subsequent reactions that can occur, whether 
favourable or not. 
Reactions 1-5 describe the process of intracellular aquation. 
[(NH3)2PtCl2]  +  H2O [(NH3)2PtCl(H2O)]
+  +  Cl-
[(NH3)2PtCl(H2O)]+ +  H2O
k1
k2
[(NH3)2Pt(H2O)2]2+  +   Cl-
cis- cis-
cis-cis-
(1)
(2)  
Where k1 = 2.5x10-05 and k2 = 3.3x10-05 s-1, suggesting that the rate determining 
step in the reaction with DNA is aquation. Reactions 1-2 describe the hydration 
equilibria. Aside from this, three acid-base equilibria are also feasible, as indicated 
in  reactions 3-5. These equations show six hydrolysis monomeric species in 
equilibrium. 
[(NH3)2PtCl(H2O]+cis- [(NH3)2PtCl(OH)]  +  H+cis-
[(NH3)2Pt(H2O)2]2+cis- [(NH3)2Pt(OH)(H2O)]+  +  H+cis-
[(NH3)2Pt(OH)(H2O)]+cis- [(NH3)2Pt(OH)2]  +  H
+cis-
(3)
(4)
(5)  
4 
In addition to these mononuclear species, µ-hydroxo complexes containing more 
than one bridge, have been shown to form in solution and have been isolated.6 
The formation of µ-hydroxo bridged platinum(II) complexes, under biological 
conditions, however is generally considered unlikely. 
 
 
Figure 1-2 This illustration depicts the cell-wall transport of cisplatin as well as 
possible reactions which can occur inside the cell.7 
Cisplatin’s Achilles heel … 
Despite the success achieved in the use of cisplatin in treating cancers such as, 
testicular, ovarian, head and neck cancers, as well as some lymphomas, one of 
its major drawbacks is its toxicity.  
The use of cisplatin has been linked with severe side-effects such as; 
nephrotoxicity (renal or kidney toxicity which could lead to kidney failure), 
ototoxicity (difficulty in hearing, a ringing in the ears or loss of balance). The 
severe nausea and vomiting experienced, due to use of cisplatin, is less related 
to gastrointestinal problems but more neurotoxic, i.e. an effect on the central 
nervous system. About 25-30% of patients treated with cisplatin, experience 
myelosuppression, (a decreased bone-marrow function, that results in lower 
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numbers of red blood cells, white blood cells and platelets). 
In addition to these toxic side-effects and the further issue of drug resistance, its 
application is limited. 
These disadvantages have been the motivation for the development of “improved” 
platinum antineoplastics, of which thousands have been synthesized. These 
complexes may be broadly classified into four structurally distinct groups and are 
listed below. 
Type 1: 
 By far, the most well-studied group of complexes, are the mononuclear square planar 
platinum(II) compounds. These contain either two monodentate or one bidentate ligand 
which functions as the non-leaving group and two monodentate or one bidentate 
anionic group, which acts as the leaving group. The cis-configuration of the leaving 
group resembles that of its predecessor, cisplatin (the so-called cisplatin analogues). 
The most merited successor in this regard (due to its lower toxicity and activity in 
cisplatin-resistant cells) is carboplatin or cis-diammine(1,1-cyclobutanedicarboxylato) 
platinum(II). A common feature of these complexes is that they follow the structure-
activity relationship developed by Clear and Hoeschele,8,9 in that they are electronically 
neutral complexes, possessing two leaving groups in preferably a cis position and inert 
non-leaving groups (usually non-tertiary amines). Some variations of the diamines, 
which had properties different to cisplatin, have recently been developed e.g. 
oxaliplatin or trans-(1R,2R-diaminocyclohexaneoxalato)platinum(II), this type is called a 
second generation development. In the latter case, the non-leaving group was proved 
to have characteristics which assist the platination of the DNA.  
Type 2:  
These complexes are similar to those in Type 1, except that they have a trans 
configuration about the platinum centre. In the recent past, several such 
compounds have been reported to have promising antitumor activity. These can 
be divided into the following subgroups10. Trans-platinum(II) complexes with 
either; planar ligands or iminoether-ligands or aliphatic amine-ligands.  
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Type 3:  
Due to cost and ease of administration, the development of orally administered as 
opposed to intravenously administered anticancer agents, began to take 
preference. This implied the use of more kinetically inert complexes, thus attention 
was given to developing platinum(IV) complexes. The first hopeful platinum(IV) 
complex was bis(acetato)amminedichloro(cyclohexylamine)platinum(IV) or more 
commonly known as satraplatin, JM216. Its kinetic stability rendered it able to resist 
hydrolysis in the acidic medium of the stomach and made it a successful candidate for 
oral administration. It is believed that the active DNA-binding species is the platinum(II) 
species, which is produced upon reduction of the platinum(IV) ‘parent’ drug11.  
Advantages of these types of complexes, are their reduced toxicity (due to their kinetic 
inertness), as well as the presence of axial ligand sites at which their lipophilicity can be 
altered. 
Type 4: 
 The development of multinuclear compounds with two or more platinum centres per 
molecule has occurred over the past 15-20 years.   In 1981, the first of its kind was 
developed by Nicholas Farrell et al.12   It was two cisplatin entities linked together by an 
alkyldiamine chain. Later transplatin derivatives were employed in an analogous13 
manner and work on trinuclear complexes was then initiated. Since then, a numerous 
amount of multinuclear platinum complexes have been developed with varying 
numbers of  either platinum centres; DNA binding sites per platinum centre, 
configuration around each centre, charge on the complex, etc.14,15,16,17,18  BBR3464, 
trans-{bis[trans-diamminechloro-platinum(II)(µ-1,6-hexadiamine)]}diammine 
platinum(II)tetranitrate is an example of such a complex which has exhibited better 
potency and lower toxicity than cisplatin and is undergoing clinical development.14 
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Figure 1-3 Schematic representation of anticancer drugs developed since cisplatin.19 
The result of an extensive literature survey of known anticancer agents, revealed 
at least eight factors as influential in anticancer action. Although these factors will 
be treated individually, it must be borne in mind that they are very strongly 
interrelated and a certain amount of overlapping is bound to occur in the 
treatment. These parameters will be discussed in the following paragraphs. 
1. The Nature of the Metal Ion 
2. Kinetics (Ligand exchange and the trans effect) 
3. Stereochemistry (Hydrophobicity and Lipophilicity) 
4. Nature of the anion (and chelation) 
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5. Nature of the non-leaving group 
6. Platinum and Biomolecule Interaction  
7. The Role of S-donors 
8. Some biological aspects of anticancer action 
1.2 IMPORTANT FACTORS INFLUENCING ANTICANCER ACTION 
1.2.1 THE NATURE OF THE METAL ION 
Complexes of a number of the transition metals have been employed as 
anticancer agents. It is safe to say that platinum is the most important of these 
and the most generally used. Attention will be given to platinum and to some of 
the properties of palladium, also occurring in the Nickel–group. The common 
compounds of both these metals in the +2 oxidation state are spin-paired, square 
planar complexes. These are therefore d8 electronic systems (see diagram 
below). 
                             
5d
5p
    
6sE
 
Thus they are 16e- systems forming square planar dsp2 hybrids, with one 
potentially vacant valency orbital; thus having potential for the formation of higher 
activated complexes e.g. penta-coordinated. This tendency decreases drastically 
with increase in nephelauxetic character, from Pd → Pt, so much so that the 
ligand exchange rate of palladium(II) is 105 faster than for platinum(II). This is the 
main reason why palladium complexes are in general not efficient as anticancer 
agents. (Although some relatively stable penta-coordinated palladium(II) 
complexes can be synthesized, this is not possible in the case of platinum(II)).  In 
general, the ligand exchange rate of platinum(II) complexes is within a range 
which facilitates their anticancer action. However, it is influenced by a number of 
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secondary parameters which will be discussed in the next paragraphs. 
The application of platinum(IV) has become advantageous due to its greater 
kinetic stability. Platinum(IV) complexes are 18e- systems, d2sp3 hybridized, six 
coordinated complexes, which have very low ligand exchange rates, (the only 
viable mechanism is bond-breaking, SN1). These can, however, be used as 
prodrugs for their platinum(II) analogues, with the additional advantage that they 
can be taken orally. The first, satraplatin (mentioned earlier), is a typical example 
of this type.  
Further detail on ligand exchange will be discussed in the next paragraphs. 
1.2.2 KINETICS 
A large part of the antitumor activity of platinum-based drugs is related to the 
kinetics of their ligand-exchange. A too rapid ligand exchange rate would imply 
that the leaving group of the complex will be substituted with, say, thiol groups of 
peptides, which may be irreversible. Complexes in this state are then referred to 
as detoxified and will not be able to form the required DNA-adducts. Another 
consequence of too rapid ligand exchange ability, is that the platinum complex will 
interact with sulphur containing peptides in proteins and enzymes, which often 
leads to inactivation of the protein involved, which may contribute to toxic side-
effects. 
Alternatively, if the ligand exchange rate is so slow that the complex may be 
termed inert, then even if the complex does enter the cell, it may not be able to 
bind to the DNA in any case, thus showing a lack of anticancer activity.  
Thus an intermediate ligand exchange rate is required. 
1.2.2.1 Ligand Exchange 
Although a vacant orbital in the valence band of platinum(II) is available, relatively 
high activation energy is required for its involvement, in which case an activated 5 
co-ordinate complex (trigonal bypyrimidal or square planar) needs to be formed. 
The result is that its kinetics are relatively slow. This is, however, influenced by 
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the nature of the leaving group (anion). The square planar platinum(II) complexes 
are therefore relatively inert, although ionization can be achieved.  
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Figure 1-4  Illustration of the mechanism by which ligand exchange occurs.20 
In very recent literature21 a study of the solution behaviour of the 
tetraaquaplatinum(II) complex, indicated that it exists in aqueous solution as a 
distorted square pyramidal complex, with the fifth oxygen of the water at the apex 
in a somewhat elongated position. It was stated that the hydrated cis-
diamineplatinum(II), has a similar coordination environment in aqueous solution.  
Platinum chemistry, in its refining and normal application in general, is chloro-
chemistry. Chloride has a moderately high electronegativity, which means 
significant ionic character is present in the Pt-Cl bond. The result being that some 
ionization occurs in an aqueous medium, which, if it is too high, is a negative 
factor, resulting in too high toxicity of the platinum anticancer agent. Cisplatin is a 
good example of this (see above). 
More recently, researchers were therefore looking for slower kinetics (see later 
paragraph on stereochemistry). Octahedral platinum(IV) on the other hand is an 
18 electron system, which is more kinetically stable. Research is therefore 
increasingly concentrated in this direction. These complexes can therefore act as 
prodrugs for the platinum(II) counterpart. The formation of the platinum(II) species 
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will therefore depend on the redox potential of the specific platinum(IV) complex. 
1.2.2.2 Trans effect 
The ionization of square planar platinum(II) complexes is also dependant on the 
co-ligands, especially those trans to the specific anion. Experimental results lead 
to the observation that some ligands were more able than others in promoting 
substitution in the position trans to themselves in square planar platinum(II) 
complexes. It was possible to set an order of effectiveness which was maintained, 
irrespective of the nature of the reaction concerned. This is a trans-labilizing effect 
namely the so-called trans-effect. A sequence of trans-effectiveness of 
nucleophiles can be assembled22 viz. 
H2O ~ HO- ~ NH3 ~ amines < Cl- ~ Br- < SCN- ~ I- ~ NO2- ~ C6H5- < CH3- ~ 
SC(NH2)2 < phosphines ~ arsines ~ H- ~ thioethers < olefins ~ CO ~ CN- 
The above sequence was based on the kinetics of reaction of these complexes 
with pyridine22. In the biochemical context the most important of these are amine 
nitrogen donors, halides (excepting F-); NO2- and S-donor ligands. From the above 
list, it can be observed that S-donors will have a dominant effect.  
There are, however, some situations where deviations of this observed sequence 
is found.  
 In the presence of two weak trans-effect ligands e.g. Cl- and NH3. In such 
cases the so-called cis-effect tends to dominate the activity. Cisplatin is a good 
example of the cis-effect, where chloride (Cl-) ionizes rather than ammonia 
(NH3). 
 In the case of a sterically hindered system, where the size or shape of the 
nucleophile may contribute to a deviation from the rule. A bulky ligand would 
slow down ligand exchange, in that it would obstruct the formation of a penta-
coordinate intermediate. Furthermore, the position of this bulky ligand will add 
to this observation. These factors are clearly illustrated in the complex ZD0473 
or JM473 or cis-amminedichloro(2-picoline)-platinum(II). This complex was 
developed with the aim at reducing inactivation caused by high levels of 
glutathione found in certain cisplatin-resistant cells23,24. The crystal structures 
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of this complex and its 3-picoline analogue were reported to show that the 
pyridine ring was tilted by 102.7° with respect to the PtN2Cl2, in the case of the 
former, and only by 48° in the case of the 3-picoline analogue. This, in effect, 
places the 2-picoline ring of JM473, directly over the square plane, hindering 
an axial approach of the platinum metal from above, thereby slowing down the 
rate of substitution.23,24  Furthermore, studies showed that the rate of 
hydrolysis of the Cl- ligand trans to the NH3 (i.e. cis to picoline) was about five 
times slower than cisplatin and two to twelve times slower than the 3-picoline 
analogue (due to less steric hindrance in the latter complex).23,24,25 
Pt
H3N C l
ClN
Pt
H3N Cl
ClN
 
Figure 1-5 Comparing the steric effect of cis-amminedichloro(2-
methylpyridine)platinum(II), JM473 (left) and its analogue cis-amminedichloro(3-
methylpyridine)platinum(II) (right) 
 Other factors such as the bond length could also play a role. Having an 
electronegative donor atom trans to a Pt-Cl bond, will determine its bond 
length and in turn its lability. For instance, when Cl is trans to NH3, the Pt-Cl 
bond length is 2.31Å, but if phosphorous was to be trans to the Cl then the Pt-
Cl bond length would be 2.37Å.26 
 The presence of a bidentate ligand, as opposed to a monodentate ligand, will 
also alter this rule. Bidentate ligands imply the chelate effect which helps to 
alter the rate of ligand exchange. Examples of this are ethylenediammine 
(bidentate) vs ammonia (monodentate), in the case of non-leaving groups and 
oxalate (bidentate) vs carboxylate (monodentate), in the case of leaving 
groups. Carboplatin is an example of an oxalate present as a leaving group, 
and it is reported that the rate of aquation (kinetics) was a hundred times 
slower than for cisplatin.27  
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 1.2.3 STEREOCHEMISTRY 
As stated earlier, the two generally accepted mechanisms of ligand exchange are 
SN1 and SN2. The SN1 mechanism, is a bond-breaking or dissociative mechanism, 
whereas the SN2 mechanism, which involves the formation of an activated penta-
coordinate intermediate complex, is an associative mechanism. The former 
mechanism, almost without exception, has the highest activation energy for 
platinum(II) complexes, making them energetically more difficult. It is known that 
increased ligand stereochemistry (more bulky ligands), leads to slower kinetics, 
mainly because it forces an SN1 mechanism. ZD0473 or JM473 also known as 
picoplatin, has illustrated this effect as explained previously. Recall, this complex 
has an alkyl substituent crowding the nitrogen donor of the ligand, thus slowing 
down the exchange rate by providing screening, and in this way limiting the 
formation of the activated complex, but at the same time inducing a barrier, 
preventing the donation of sulphur atoms, which are present in biological 
macromolecules, which could render the anticancer agent detoxified and lead to 
other toxic side-effects. This mechanism has also been applied to palladium(II) 
complexes where the normal ligand exchange rate is 1005 times faster than their 
platinum(II) analogues.  
The above point would imply that decreased stereochemical crowding, would lead 
to decreased anticancer activity and vice versa. However, there have also been 
studies8 which indicated that, as substitution on the nitrogen-donor atoms of the 
coordinated amines in platinum(II) complexes increased, the anticancer activity of 
the resulting complex tended to decrease. This made sense in light of the popular 
school of thought which taught that there should be at least one hydrogen present 
on the coordinating amine in order to facilitate stabilization through hydrogen-
bonding in the formation of Pt-DNA adducts. This does, however, seem to 
contradict the previous point, as made in the case of JM473. Upon closer 
inspection of JM473, however, we see that the crowding alkyl group is not on the 
coordinating nitrogen but rather on the carbon atom adjacent to it.  Thus, it seems 
reasonable to assume that the use of bulky ligands is acceptable, if the crowding 
part is positioned away from the coordinating (nitrogen) donor atom of the ligand, 
in order to avoid steric interaction with DNA which could hamper adduct 
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formation.28 
Steric hindrance, as a result of using bulky ligands, may also play a role in 
overcoming tolerance of “conventional” cisplatin-DNA adducts. In comparing the 
DNA-adducts formed by cisplatin and oxaliplatin, we note that the major difference 
was the insertion of the DACH part into the major groove of the DNA as opposed 
to the ammonia in cisplatin.29  Cisplatin is said to depend on the proteins of the 
mismatch repair pathway (MMR) to bring about toxicity. These proteins recognise 
the cisplatin-DNA adducts and then bind to them30. These proteins then contribute 
to the “futile cycle” of continuous damage removal from the newly synthesized 
strand and DNA resynthesis, ending in strand break production and ultimate cell 
death toxicity.31 Certain cell lines, which are deficient in MMR, are resistant to 
cisplatin and, as they are able to replicate DNA uninterrupted past the cisplatin-
DNA adducts, they may as a result not undergo apoptosis.32,33 Cell lines such as 
these are often not resistant to oxaliplatin, this is assumed to be due to the 
presence of the DACH ring, which prevents recognition by and thus binding to, the 
MMR proteins.34,31,35,32 
1.2.3.1 Hydrophobicity 
This property could play a contributing role in the cellular toxicity of the drug. 
Again, using the example of cisplatin vs oxaliplatin and the difference in protrusion 
of the non-leaving groups into the major groove in the formation of the resulting 
DNA-adducts; it was noted that the DACH part protrudes more into the major 
groove in the case of the latter. This was thought to contribute to further narrowing 
of the major groove in the case of oxaliplatin (relative to cisplatin). It has been 
shown34,36 that Pt-DNA adducts with the DACH ligand were more effective 
inhibitors of replication and transcription as opposed to the Pt-DNA adducts 
formed with the cis-diammine ligand. This effect is attributed to the bulkier, more 
hydrophobic adduct formed in the case of oxaliplatin31. 
1.2.3.2 Lipophilicity 
For a potential anticancer agent to enter a cell, it has to pass through the cell 
membrane. The cell membrane is a selectively permeable phospholipid bilayer. 
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This lipid bilayer (hydrophilic head and hydrophobic tail), prevents polar solutes 
(e.g. amino acids) from diffusing across the membrane, but generally allows the 
passive diffusion of hydrophobic molecules. Thus lipophilicity related to 
stereochemistry can be an important determinant of activity, since passive uptake 
across the lipid bilayer is facilitated by a higher degree of lipophilicity37.  
Platinum(IV) complexes, in particular, are interesting in this way, in that the axial 
sites allow for modification of lipophilicity through the use of a variety of 
carboxylate groups.  An increase in the aliphatic chain length of the attached axial 
carboxylato groups, as well as an increase in the size of the alicyclic ring attached 
to the equatorial donor  atoms in selected platinum(IV) complexes, resulted in an 
increase in their cytoxicity38,39. The increased cytoxicity is reported to be partly 
due to their increased intracellular accumulation as a result of their lipophilicity39.  
1.2.4  NATURE OF ANION 
This is an important parameter in as far as ligand exchange rate is concerned. For 
example, monodentate oxygen donor anionic species such as perchlorate (ClO4-), 
and other ligands such as fluoride(F-), which have very weak covalent capabilities, 
are poorly coordinated to platinum(II) and as a result ionize very readily. The other 
halide ions have increased covalent character in the direction viz. Cl-, Br-, I-, and 
consequently lower ionization in the same direction, for example, iodocomplexes 
have very low aqueous solubility and low ionization. 
1.2.4.1 Chelation 
Dianionic oxygen donor anions like oxalate and malonate, which form 5 and 6-
membered chelate rings with platinum(II), behave very differently to their 
monodentate analogues (ionization is limited). The behaviour of the dicarboxylato 
species as compared to chloro species is clearly illustrated by the difference in 
ionization of cisplatin to that of oxaliplatin or carboplatin (one hundred times less 
ionization) 
1.2.5  NATURE OF THE NON-LEAVING GROUP 
A known factor influencing the anticancer action of a complex is the non-leaving 
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groups. Take for instance the effect of ligands like DACH (1R,2R 
diamminocyclohexane), with its Pt-DNA adducts, allowing for better penetration into 
the major groove of DNA (as discussed earlier) and thus better anticancer action. 
Another aspect of non-leaving groups is their hydrophobic character, already 
discussed earlier. 
1.2.6  PLATINUM BIOMOLECULE INTERACTION 
The target of platinum drugs is DNA, but en route to this nucleophile, the platinum 
drug may encounter other nucleophiles in the cell. These biomolecules, which 
contain ‘class B’ nucleophiles, such as sulphur atoms, are particularly important since 
they have the ability to detoxify the complex and contribute to toxic side-effects as a 
result of protein binding. Due to this “interfering” interaction of S-containing 
biomolecules, it has become important to administer so-called “rescue” agents shortly 
after the platinum drugs have been administered, in order to minimize this effect. 
These “rescue” agents, usually sulphur containing molecules, are believed to 
minimize binding to the detoxifying sulphur molecules in the body, and may also 
revert platinum-protein binding, thus diminishing toxic side effects.40 
Next, follows a brief discussion on the interaction of platinum complexes with the 
two more significant groups of biomolecules in the body, viz. DNA nucleobases 
and sulphur-containing biomolecules. 
1.2.6.1 Platinum and DNA - Nucleobase Interaction 
The aim of cisplatin, as well as other platinum containing drugs, is to reach the 
target DNA. The active aquated platinum species is a bifunctional electrophilic 
agent, able to bind to any site present on the DNA. A basic discussion  of the 
structure of DNA will follow, in order to place all this in perspective.  
DNA resides in the nucleus of all eukaryotic cells, it consists of two strands and 
each strand is made up of a chain of nucleotide bases.  
17 
 
Figure 1-6 A schematic representation of the DNA double helix (left) and the “opened” 
DNA-nucleobases with sugar-phosphate scaffold (right).41 
There are four types of nitrogenous bases on each strand, namely Adenine(A); 
Thymine(T); Cytosine(C) and Guanine(G); each attached to a sugar-phosphate  
backbone (see Figure 1-6). The two strands are joined together by weak bonds, 
these bonds always form in the same way, A attached to T and G attached to C. 
Thus, one strand on the DNA is a mirror image of the other and the paired bases 
are described as being complementary. The paired bases are like the rungs of a 
flexible ladder, if you were to take hold of the two ends of the ladder and twist 
them in opposite directions, you would end up with a spiral structure; termed a 
double helix. 
Closer inspection of each nucleobase reveals numerous nucleophilic atoms with 
which cisplatin (in its aquated form) can bind (see Figure 1-7).  
Metal binding to a nucleobase is influenced by a variety of factors, such as the 
basicity of the donor, steric fitting and inter-ligand interaction, to name a few. 
Basicity of the donor itself, though important, is not solely a good indicator of the 
metal being able to bind under physiological conditions.  In Table 1-1 therefore a 
list of factors are given so as to explain which sites are more favoured by the 
platinum metal to bind at.  
18 
                             
 
N
1
N
3N
9
8
N
7
NH2
3'
2'
1'O
4'
H
O
H
H
H
5'
H
P
O
O
HO
O
NH1
N
3
N
7
O
NH2N
3'
O
H
H
H
H
5'
H
O
PO
O
O
N3
NH2
O
N
1
3'
O
H
O
HH
H
5'
H
P
O
O O
5
NH3
O
O
CH3
N
1
3'
O
HO
H
H H
5'
H
P
O
-O O-
Adenine
Guanine
Cytosine
Thymine
= Pt binding only after
   deprotonation
= common Pt
   binding sites
 
Figure 1-7 Possible binding sites for platinum(II) coordination compounds on the 
bases of single-stranded DNA.42 In double-stranded DNA only G-N7 and A-N7 are 
accessible from the solvent.  
 
Table 1-1 Factors favouring / disfavouring platinum(II) coordination through various 
purine (A and G) and pyrimidine (T and C) nucleobase N-donor sites in double 
stranded DNA. 43 
 
Nucleoside Site pKa Commentsb 
N1 9.2 
I. Protonated at physiological pH 
II. Involved in H-bonding within DNA helix 
III. Steric hindrance by exocyclic amine at C2 
N2c   
N3  I. Observed only with excess platinum
44 
II. Site is sterically hindered45 
Guanine 
N7 2.2 I. Potential steric hindrance by 6-oxo group 
N1 3.6 I. Involved in H-bonding within DNA helix II. Steric hindrance by exocyclic amine N6 
N3  I. Site is sterically hindered45 
N7 -1.6 I. Steric hindrance by exocyclic amine N6 
Adenine 
N6c  I. Platinum adducts rarely observed44 
N3 4.3 I. Involved in H-bonding within DNA helix 
Cytidine 
N4 16.7 I. Only observed in a N3-N4 chelate with Pt(IV)44 
Thymidine N3 9.6 I. Protonated at physiological pH II. Involved in H-bonding within DNA helix 
 
a pKa values were taken from Martin46,47 
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b Comments adapted from Martin48 unless otherwise indicated 
c Exocyclic amine 
The above table then reveals that the sites of the N7 atoms of guanine and 
adenine are the only ones relatively available for platinum coordination. They are 
“available” because they are unprotonated, exposed to solvent, uninvolved in 
Watson-Crick hydrogen bonding and sustain the least possible steric hindrance. 
A comparison of these two favoured N7 donors necessitated the acquisition of 
space-filling models and charge distribution values of the two nucleobases (see 
Figure 1-8). 
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Figure 1-8 The attained space-filling models and charge-distribution models of 
guanine and adenine. 
 Immediately, the space-filling models reveal that the N7 atom in guanine is 
a lot less crowded (stereochemically), than in the case of its adenine 
complement.  
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 The charge distribution diagram indicates that the charges on the two 
atoms adjacent to the N7 atom in guanine are a lot more negative than in 
its adenine equivalent. This implies that the N7 site in guanine has a 
greater potential for electron transfer by platinum(II). 
 The higher pKa value of guanine (pKa = 2.2) reveals that it is more basic 
than adenine and thus this would make for a stronger platinum-nitrogen 
bond than in the case of adenine. 
 Also, the presence of an oxygen atom on the C6-atom of guanine, allows 
for hydrogen boding with the activated platinum species, which leads to 
further stabilization (chelation)45. There is no such oxygen atom present in 
the C6-atom of adenine, instead repulsion will rather be experienced (see 
Figure 1-9). 
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Figure 1-9 A comparison of the bonding of guanine with platinum(II) (A) as opposed to 
adenine with platinum(II) (B). 
Figure 1-9 also illustrates the preference of platinum(II) for the N7 atom of 
guanine. Furthermore ligand - exchange studies performed on platinum(II) 
anticancer agents in vivo revealed the order of replacement to be: 
Thiols (glutathione) > G-N7 > thioethers (methione) > A-N7.49    
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This effect will become apparent in section 1.2.7 
1.2.7  ROLE OF S-DONORS 
The order of the trans-effect of ligands already indicates the dominant role of S-
donors. A variety of S-donor biomolecules are found in the biological system and 
the platinum drugs can interact with them instead of the target DNA. These 
sulphur containing biomolecules can be classified in terms of their thermodynamic 
and kinetic abilities. Literature studies indicated that they can be divided into two 
classes. Firstly, the σ-donor -donor ligands like thiols and thiourea and secondly, 
the σ-donor -acceptor ligands like thioethers and dimethylsulphoxide.  
The former class form thermodynamically and kinetically more stable complexes 
with platinum(II). These ligands cannot be replaced by aromatic N-donors like the 
N7 atom of guanine. Thus these are irreversibly bound and the platinum drug is 
said to be detoxified. They can, however, be reversed by lowering the pH, in 
which case their protonation competes with their platinum-binding ability. 
Unfortunately, this is not likely to occur in the relevant buffered biological system.  
Thioethers on the other hand, are kinetically faster in terms of bonding to the 
platinum(II), but thermodynamically more unstable than the N7 atom of guanine. 
Thus these can, as a function of time, be replaced by the N7 atom of guanine. 
Such complexes have been referred to as potential platinum-reservoirs.40,50 
Thus, is seems as though the presence of sulphur containing biomolecules may 
pose at times to be a conflicting interest for platinum binding. Space-filling models 
of the sulphur containing biomolecules were derived to elucidate this effect, in an 
attempt to rationalise it.  
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Figure 1-10 Spacefilling and charge distribution model of the biomolecule cysteine. 
In the case of cysteine (thiol), the spacefilling model reveals that the sulphur atom 
is much larger than the competing N7 atom of guanine (seeFigure 1-8) . As 
mentioned previously, the ligand exchange of platinum(II) complexes takes place 
via a SN2 mechanism through the formation of a trigonal bipyramidal intermediate. 
It could be argued that the larger/bulkier S-biomolecule would make ligand 
exchange more difficult as a result of stereochemical crowding as opposed to the 
uncrowded N7 atom of guanine. 
Thus far, we’ve looked at all the negative attributes of sulphur containing 
biomolecules. They do however possess a positive side. In the case of 
platinum(IV) complexes like JM216, which need to be reduced to their more active 
platinum(II) counterparts, the S-containing biomolecules like glutathione and 
cysteine, facilitate this requirement by acting as biological reducing agents51,52,53. 
Furthermore, thioether binding, due to its lesser thermodynamic ability can act as 
“protector” in preventing the platinum-complexes from binding with the more 
thermodynamically stable thiols which would result in irreversible deactivation of 
the anticancer agent, hence they are referred to as drug reservoirs, as mentioned 
above. 
1.2.8  SOME BIOCHEMICAL ASPECTS OF ANTICANCER ACTION 
A large volume of knowledge has been assembled in connection with aspects of 
anticancer action, which can be described as essentially biochemical. Since the 
main objective of this thesis was the development and study of platinum 
anticancer agents, in which case their structure, thermodynamic and kinetic 
properties were directly correlated with their anticancer action, as measured by 
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their efficacy to lead to cell death of three different cancer cells. As a first order 
monitor, the main aspects will only be briefly mentioned in the next paragraph.  
The mode of bonding in DNA has been studied extensively54. It has been 
indicated that platinum anticancer agents, like cisplatin, act according to a scheme 
given in Figure 1-11. The most important mechanism of binding to DNA, seems to 
result in the formation of about 90% 1,2 intrastrand crosslinks of which 65% 
involve two adjacent N7 guanine sites (1,2-GpG) and about 25% involves a N7 
guanine site with a N7 adenine site (1,2-ApG). The remainder (10%), can be 
ascribed to other intra- and interstrand crosslinks, monofunctional adducts and 
protein-DNA crosslinks.55 
 
 
  Figure 1-11 Types of cisplatin-DNA adducts.56 
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The formation of these DNA adducts is seen as distortions in DNA and lead to cell 
death in various ways: 
A. Conformational changes in DNA 
B. Inhibition of DNA Replication 
C. Inhibition of DNA Transcription 
D. Poor repair of Pt-DNA adducts 
The above processes do seem to be interrelated and somewhat complicated, to 
say the least. What can be said, however, is that cell death is usually a 
combination of effects, with its roots firmly bound in DNA-adduct formation.  
1.2.9  CELL RESISTANCE 
As mentioned earlier, concerning cisplatin, a major stumbling block for an 
anticancer agent is the occurrence of cancer cell resistance. This resistance 
occurs in mainly two ways; either acquired or intrinsic. In the former, the drug is 
initially beneficial, but becomes ineffective overtime. In the latter, the drug is 
ineffective from the onset. This greatly limits the efficacy of the drugs’s operation. 
The mere fact that colon cancer cells do not become resistant to oxaliplatin, 
relates to its optimal usage as anticancer agent. 
There are at least three different ways that a cell can become resistant to the 
action of platinum agents31: 
 A decrease in cellular uptake and/or an increase in drug efflux will both 
reduce the actual amount of the intracellular drug available for cytotoxic 
action. 
 On the other hand, while accumulating into the cell, the compound 
undergoes side reactions which may result in its inactivation/trapping (e.g. 
reaction with the sulphydril group of glutathione) before cytotoxic action can 
be expressed.  
 Finally resistance to cisplatin may arise from increased repair of drug-DNA 
adducts (through NER, nucleotide excision repair) and/or increased 
tolerance to platinated DNA. The latter situation can be observed through 
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the increase in the replication bypass process past the DNA–platinum 
adducts and/or a defective MMR, as mentioned previously. 
Inhibition of STAT function 
The mode of action of anticancer agents such as cisplatin, has mostly been 
attributed to their DNA alkylating effect. However, recently the effects on DNA, as 
well as possible interactions with proteins, were thought to be part of a series of 
molecular events induced by platinum complexes,57 which influence their overall 
therapeutic outcome. Thus, the potential for platinum compounds to modulate 
signal transduction events, which may contribute to their overall therapeutic effect, 
is a recent avenue of study which is fairly unexplored. Although these signalling 
mechanisms involved are complicated and beyond the scope of this work, a brief 
consideration of the fundamental aspects involved is necessary, in order to make 
plain the action of platinum compounds in this course of events.  
What are STATs? 
Signal transducers and activators of transcription (STATs), are a family of seven 
latent cytoplasmic transcription factors, that transmit signals, usually at cell 
surface receptors, to the nucleus, where these STATs then bind to specific DNA 
promoter sequences and thereby regulate gene expression58. 
How are they activated? 
They are activated in response to cytokines and growth factors. The binding of 
cytokines to their receptors leads to the activation of receptor-associated tyrosine 
kinase (e.g.JAKs), which phosphorylate the receptor cytoplasmic portion and the 
binding of growth factors (e.g. EGF), autophosphyrylate the receptor cytoplasmic 
tail. Sometimes, non-receptor tyrosine kinase (e.g. oncogenic and Abl Src) also 
participate in STAT activation. To phosphorylate the cytoplasmic tail, makes for a 
docking site for the recruitment of monomeric STATs. Once recruited, STATs 
themselves can become substrates for tyrosine phosphorylation.  These 
phosphorylated STATs dimerise and translocate to the nucleus where dimers bind 
to specific STAT DNA-response elements and directly regulate gene expression.  
STATs are proposed to participate in oncogenesis through up-regulation of genes 
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encoding apoptosis inhibitors (Bcl-xl), cell cycle regulators (Cyclins D1/D2) and 
inducers of angiogenesis (VEGF).  
 
 
Figure 1-12 Illustration of normal and onconogenic STAT signalling pathways.59 
Why are STATS important?   
A number of oncogenic signalling pathways all seem to converge on a limiting set 
of nuclear transcription factors. These factors act as final ‘switches’ that activate 
gene-expression patterns which ultimately lead to malignancy.  Thus, transcription 
factors are logical choices as anticancer targets60.  
Such an ideal transcription target should60: 
- Be overactive in a large percentage of cells in different tumour types. This 
overactivity should be the cause of gene-expression patterns that not only 
promote cancer cell survival and proliferation, but also promote other 
malignant properties, such as tumour angiogenesis. 
- Be susceptible to specific inhibition of small molecule drugs. 
- Have tumour cells more dependent on their activity, when compared to 
normal cells. 
Such ideal transcription targets has been found in STAT3 and STAT5.60 
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 In normal cells, STAT3 phosphyrylation is transient, lasting from minutes to 
hours. However, in numerous cancer cell lines or primary tumours, STAT3 is 
persistently phosphyrylated, which appears to disrupt normal physiological control 
and lead to malignancy. As STATs are involved in regulating many genes in 
normal cells that control fundamental biological processes - such as cell 
proliferation, apoptosis, angiogenesis and immune responses - the permanent 
alteration of the genetic programme present in tumour cells should have a 
profound biological impact. Thus far, research has shown that blocking STAT3 
signalling in tumour cells; induces apoptosis, inhibits proliferation, suppresses 
angiogenesis and stimulates immune responses.60 
Platinum STAT interaction 
A platinum(IV) complex, IS3 295, reportedly61 acts as a STAT3 inhibitor by direct 
interaction with the protein itself. Evidence indicates that IS3 295 interacts with 
STAT3, both the inactive monomer and the activated dimer, and represses 
STAT3 phosphotyrosine levels, DNA binding affinity and transcription regulation. 
The treatment of activated STAT3 with IS3 295 induced an apparent change in 
the binding affinity of the protein for the consensus DNA sequence. This could 
imply that either both IS3 295 and the consensus DNA sequence bind to the same 
region of STAT3 in the DNA-binding domain, or that STAT3 undergoes 
conformational changes upon binding to the DNA sequence that restricts access 
to the key amino acid residue(s) and thus prevent interaction with IS3 295.  
Thus the effect of IS3 295 is that it inhibits STAT3 mediated induction of critical 
genes, these include: 
 the cell cycle arrest regulator cyclin D1; 
 anti-apoptotic bcl-xl; and 
 pro-angiogenic VEGF. 
which are important for tumour processes. 
A further report by Turkson et al.57 says the platinum compounds, CPA-1 
Pt(en)Cl3(NO), CPA-7 Pt(NH3)2Cl3(NO) and platinum(IV)tetrachloride, block 
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STAT3 activity in vitro at low micromolar levels.  The biological effects of CPA1, 
CPA7 and Pt(IV)Cl4 in this study include:growth inhibition and apoptosis of 
malignant cells that harbour constitutively active STAT3. These effects are 
reported to be stronger and more selective against malignant cells that contain 
persistently active STAT3 than those that do not, reflecting in part the inhibition of 
constitutive activation of STAT3 signalling and providing further support for a 
critical role for abnormal STAT3 activity in the growth, control and survival of 
transformed cells. Moreover, CPA7 reportedly induces the regression of mouse 
CT26 colon tumour, which correlates with the abrogation of persistent STAT3 
activity in tumours. 
1.3 AN OVERVIEW OF PRESENT PROGRESS IN ANTICANCER AGENTS 
The discovery of the anticancer action of cisplatin1,2 in 1967 was mentioned 
earlier. This triggered increased study of the amine complexes of platinum(II) by 
research laboratories worldwide. Almost all of this, however, dealt with the so-
called cisplatin analogues. For almost two decades, little progress was made. In 
the early 1980’s carboplatin, (cis-diammine-[1,1-
cyclobutanedicarboxylato]platinum(II)) was produced and studied. Although this 
was still a cis-diammine-species, the introduction of a substituted malonato 
leaving group produced an improved species in so far as that toxic side-effects 
were greatly limited. This was later proved to be related to the slower degree of 
ionization. The action pattern of carboplatin was, however, very similar to that of 
cisplatin. The next advance came with the development of oxaliplatin in the early 
1990’s. The dicarboxylato leaving group again resulted in slower ligand exchange, 
in combination with the DACH non-leaving group. It provided an anticancer agent, 
which for the first time can be regarded as a non-cisplatin analogue with respect 
to its behaviour as an anticancer agent. Parallel to the development of oxaliplatin 
was the development of stereochemically crowded platinum(II) complexes, of 
which picoplatin, ZO473/JM473 (see Figure 1-5), is a good example of this. This 
complex has the capability of slowing down the interaction of S-donor ligands. 
This was followed by the digression which led to the discovery of a platinum(IV) 
complex, Satraplatin, JM216 (see Figure 1-13). This, however, is still under study. 
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Figure 1-13 The platinum(IV) complex, JM216 (satraplatin), was until very recently still 
undergoing clinical trials. 
A new development in the platinum(IV) field is the synthesis and characterization 
of trichloronitroplatinum(IV)ammine complexes. The most important of these 
appears to be CPA7 (cis-diamminedichloro-trans-nitrochloroplatinum(IV)). The 
synthesis of this complex, however, especially on even as little as a gram scale, 
has not been clarified and seems to be insurmountable.  
In this thesis, attention was given to the development of novel synthetic methods 
for some existing successful anticancer agents, as well as the development of 
novel improved anticancer-agents.  
In light of the importance of oxaliplatin as a novel non-cisplatin analogue coupled 
with its slower ligand exchange rate of the dicarboxylato leaving group, efforts 
were directed to develop non-silver synthetic methods for this important 
anticancer agent, which is the leading pharmaceutical for colon cancer at present. 
This work will be described in Chapter 3. 
Although numerous amine complexes of platinum(II) have been studied, efforts 
were directed to reinvestigate some aspects of these; applying novel variations 
to alter those factors which lead to inefficiency. For example, by far the bulk of the 
previously studied complexes were chloro complexes, of which the ligand 
exchange rates are too fast, leading to enhanced toxicity. Leaving groups were 
therefore changed in an attempt to slow down ionization rates. Stereochemistry 
of the non-leaving group will be altered to improve efficiency as well, in view of the 
success obtained by the usage of DACH as a non-leaving group, this research will 
be described in detail in Chapter 4.  
The apparent success achieved with mononitroplatinum(IV) complexes as 
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illustrated by CPA7 (cis-diamminedichloro-trans-nitrochloroplatinum(IV)) indicated 
potential for this modus operandi. Although the potential of CPA7 was shown, at 
present, it is not much more than that, since the product could not be synthesized 
in any significant yield and high degree of purity, even on a gram scale. 
Investigation will be directed towards the major improvement of this method, 
employing a variety of leaving groups including dicarboxalato groups. This work 
will be described in Chapter 5, where improved synthetic methods of efficient 
compounds will be described. 
In all of these complexes studied, the accent was on the development of improved 
synthetic methods. In all cases mass-spectral and other spectral methods, 
thermogravimetric measurements and, where possible, x-ray crystal structural 
measurements were employed for full characterization. Ligand-exchange and 
anticancer efficiency studies were finally applied. 
The various analytical methods applied and the routine synthetic methods will be 
described in Chapter 2. 
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CHAPTER 2 
EXPERIMENTAL 
2.1 INTRODUCTION 
The experimental procedures described in this chapter, were those used to 
prepare coordination complexes in this dissertation. Details concerning the 
instrumentation and supplier of the reagents used, are also included herein. 
2.2  PREPARATION OF COMPLEXES 
Potassium tetrachloroplatinate(II); K2PtCl4 was used as the precursor for all 
platinum complexes. Its synthesis, from platinum metal, consisted of three distinct 
steps, which will be described as such. The method used was an adaptation of 
that provided by Keller.62 
2.2.1  SYNTHESIS OF K2PtCl4 
Step 1: Preparation of Hexachloroplatinic(IV) Acid (H2PtCl6) Solution 
Powdered platinum metal powder (99.99% Pt) was dissolved in aqua regia 
(3:1 hydrochloric acid : nitric acid) with heating. The stirred solution was 
evaporated by heating, until a silvery paste was obtained. The paste was then 
redissolved in concentrated hydrochloric acid, in order to remove any species 
other than the chloro complex. The solution was once again boiled down to a 
silvery paste and the hydrochloric acid treatment repeated. The final paste 
obtained was dissolved in 1 M HCl. 
Step 2: Preparation of Potassium Hexachloroplatinate(IV) (K2PtCl6) 
A 250 cm3 aliquot of a 3.65 M KCl solution (0.91 mol, 68 g) was added dropwise 
to 250 cm3 aliquot of a stirred 0.82 M hexachloroplatinic acid solution (0.21 mol). 
A bright yellow precipitate of K2PtCl6 formed almost instantaneously and 
continued throughout the addition of KCl. Thereafter, the resulting mixture was 
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diluted with an equal volume of 95% ethanol and left to stand in an ice bath for 1-
2 hours. After the supernatant liquor had been decanted through a suction filter, 
the potassium salt was thoroughly washed by decantation with two 400 cm3 
portions of 50% ethanol and thereafter transferred to the filter with the aid of 95% 
ethanol. The yellow solid was finally washed with 3  100 cm3 portions of diethyl 
ether and dried in an oven at 50C overnight.  
Yield : 99%. 
Step 3: Preparation of Potassium Tetrachloroplatinate(II) (K2PtCl4) 
Solid K2PtCl6 (0.067 mol, 30 g) was suspended in 300 cm3 water in a 1000 cm3 
wide-necked flask and reduced with a freshly prepared SO2 solution (the SO2 
solution was prepared by bubbling SO2 gas through distilled water for ~20min).  
The flask was placed in a water bath maintained at 85-90C during the reduction 
process and the mixture stirred constantly with a magnetic stirrer. Not more than 
5 cm3 of the reducing solution was added at a time, and sufficient time was 
allowed between additions (approx. 10 minutes), for the SO2 odour to disappear. 
The solution became red as the reduction proceeded. Towards the end of the 
reaction, smaller quantities of SO2 solution were added and larger intervals 
allowed between additions. The reduction process was continued until only a 
trace of the solid hexachloroplatinate(IV) remained. This was filtered off and 5 cm3 
concentrated hydrochloric acid added to the red solution, which was subsequently 
concentrated by heating on a hot plate. Often, more of the yellow 
hexachloroplatinate(IV) precipitated, as the solution volume was reduced. This 
was filtered off and the concentration continued. Heating was discontinued at the 
first sign of crystallization of the product (approx. 180 cm3). The solution was 
cooled in an ice bath and red needles of K2PtCl4 were recovered on a suction 
filter. The filtrate was concentrated further, to obtain subsequent batches of 
crystals. Crystals were washed with dry acetone and dried at 50C overnight.  
Yield: 70-80%. 
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SYNTHESIS OF CISPLATIN 
This method is an adaptation from Dhara63. This synthesis required 2 steps, a 
description of which will now follow. 
Step 1: Preparation of Diamminediiodoplatinate(II) PtI2(NH3)2   
Potassium tetrachloroplatinate(II) (6.0 g, 14.5 mmol), was dissolved in 60 cm3 
water to which was added a 20 cm3 solution containing 10 equivalents KI (24 g, 
145 mmol). The solution was stirred for 40 min at room temperature. While stirring 
4 cm3 of concentrated NH3 was added dropwise. The solution was parafilmed and 
stirred at room temperature for 4 hours. The yellow precipitate was filtered and 
washed with 15 cm3 portions of water, ethanol and diethyl ether respectively. The 
PtI2(NH3)2 was dried in the oven at 50°C.   
Yield: 95%   
Step 2: Preparation of Diamminedichloroplatinate(II) [PtCl2(NH3)2]   
AgNO3, 1.95 equivalents (4.53 g, 26.7 mmol) was dissolved in 20 cm3 water and 
added to a suspension of PtI2(NH3)2 (6.6 g, 13.7 mmol) in 20 cm3 water. The 
mixture was stirred overnight at room temperature in the dark. The mixture was 
centrifuged until the supernatant liquid was clear.  This was decanted and filtered 
to remove any remaining AgI.  A solution containing 10 equivalents of LiCl 
(5.8 g, 137 mmol) in 15 cm3 water was added.  The solution was stirred overnight 
at room temperature, after which it was cooled at 5ºC for 2 hours.  The yellow 
precipitate was filtered and washed with 15 cm3 ethanol and diethyl ether 
respectively.  The PtCl2(NH3)2 was dried at 50ºC in an oven.   
Yield: 85%   
2.2.3 SYNTHESIS OF POTASSIUM BIS-OXALATOPLATINUM(II) K2Pt(C2O4)2 
This procedure was adapted from Krogman64. 
Potassium tetrachloroplatinate(II) (2.08 g, 5.0 mmol) and 16 equivalents of 
potassium oxalate monohydate (14.77 g, 79.9 mmol), was dissolved in 30 cm3 
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distilled water at 90C and stirred for 1 hour, maintaining the temperature at 90C, 
after which the reaction mixture was left at 5C for two hours.  The resultant 
K2Pt(C2O4)2·2H2O precipitate which formed, was filtered, washed 5 times with 
15 cm3 distilled water, once with 10 cm acetone and dried in a oven at 50C.   
Yield: 95%. 
2.2.4  SYNTHESIS OF OXALIPLATIN 
The preparation of this complex involves four separate steps, as will be described 
here. It is an improvement on the method by Kidani65. 
Step 1: Preparation of Reagents/Solvents 
Deoxygenated water 
The above was prepared by vigorously bubbling a high-pressure stream of 
nitrogen gas through hot (90ºC) distilled water for at least 30 minutes. 
Deoxygenated dimethylformamide (dmf) 
The above was prepared by vigorously bubbling a high-pressure stream of 
nitrogen gas through hot (120ºC) dmf for at least 30 minutes. 
Step1: Preparation of Pt((1R,2R)-(-)-1,2-diaminocyclohexane)Cl2 (Pt(dach)Cl2) 
0.85 g dach (7.44 mmol) was dissolved in approximately 3.5 cm3 water and added 
in portions to a solution of K2PtCl4, prepared by dissolving 3.1 g (7.47 mmol) in 62 
cm3 water, over a period of 30 minutes. The mixture was stirred at 30 C for 18-
24 hr, or until the supernatant liquor was visibly decolourized (pale yellow). The 
solid yellow Pt(dach)Cl2 was collected by suction filtration, washed with water, 
ethanol and ether, in that order, and dried at 50 C overnight.  
Yield: 90% 
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Step2: Preparation of Tetrabutylammonium Oxalate Solution  
Oxalic acid (5 g, 39.6 mmol) was dissolved in a 1.5 M aqueous solution of 
tetrabutylammonium hydroxide (~52 cm3, 79.2 mmol). The pH of the solution was 
adjusted to 7 via the addition of measured quantities of oxalic acid and 
tetrabutylammonium hydroxide. The solution was evaporated to dryness at 
reduced pressure at 50ºC, whereupon it was dissolved in 55 cm3 dry, 
deoxygenated DMF. The solution was dried over 3 Å molecular sieves for 24 hr.  
Step 3: Preparation of Oxaliplatin 
Pt(dach)Cl2 (5 g,13.2 mmol) was dissolved in a solvent mixture of 650 cm3 
deoxygenated dmf and 45 cm3 deoxygenated water at 65-70ºC. Thereafter, 
1.5 molar equivalents of a dmf solution of tetrabutylammonium oxalate (45 cm3, 
38.9 mol) was added and the mixture stirred at 65-70ºC for 4 hr in a closed 
reaction vessel flushed with nitrogen. A second portion of Pt(dach)Cl2 
(5 g,13.2 mmol), dissolved in 650 cm3 deoxygenated dmf : 45 cm3 deoxygenated 
water, was then added and the mixture stirred for a further 20 hr at 65-70ºC. The 
solvent was removed under vacuum (30-50 mTorr) at 50ºC, where after the dark 
brown residue was vigorously stirred in 450 cm3 of deoxygenated water at 70ºC 
for 20 minutes. Following filtration through a porosity 3 sintered glass filter, the 
yellow-orange filtrate was evaporated to dryness under vacuum (10-20 mTorr) at 
50ºC.  
The resulting residue was suspended in dry ethanol (70 cm3) and stirred 
vigorously for 5 minutes, where-after the suspension was centrifuged at 2000-
2500 rpm for 15 minutes. The yellow-orange supernatant was decanted and 
tested for the presence of oxalate by taking a small aliquot of the supernatant 
liquid and adding an aliquot of barium nitrate solution to it. The ethanol-washings 
were repeated, until the supernatant was colourless and free of oxalate (usually 
four). The sedimented residue was then suspended in dmf (8 cm3) and vigorously 
stirred for 5 minutes, following which it was centrifuged for 10 minutes at 
2500 rpm. The yellow supernatant was decanted and the procedure repeated until 
no or very little yellow colouration was observed in the supernatant or sediment 
(usually three or four). The white sediment was then treated analogously with 
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ethanol (10 cm3-one wash) and dry acetone (10 cm3-one wash). All residues were 
subsequently dried at 50ºC under vacuum.  
Yield: 50% 
Purification of oxaliplatin 
If need be, the oxaliplatin was purified by recrystallization from deoxygenated 
water (70-80 cm3 per gram crude oxaliplatin) at 70ºC under nitrogen. Typically the 
water was preheated to the desired temperature (preheating would reduce the 
volume of dissolved oxygen) and the crude oxaliplatin added in portion and stirred 
vigorously. Stirring at the elevated temperature was continued until 90-95% of the 
material dissolved, where after the solution was filtered rapidly via suction filtration 
to remove the undissolved solids. The filtrate was flushed with nitrogen and 
cooled to 4ºC overnight. The white crystals were filtered off and the volume of the 
filtrate reduced by a third under vacuum at 45C. The filtrate was cooled for a 
further 15 hr and the precipitated crystals filtered off, washed with acetone and 
dried at 50C.  
Yield: 25% 
To make up for the loss of product, further crops were collected by reducing the 
volume of mother liquor under vacuum at 70C. These crops were often slightly 
yellow, due to the coprecipitation of Pt(dach)Cl2. The latter was conveniently 
removed by washing with very small quantities of dmf, until the yellow colouration 
was visibly reduced. 
2.2.5  IODOPLATINUM(II) COMPLEXES 
These complexes were prepared for their use as precursors in preparation of 
either bromo, oxalato or in some case the chloro complexes. Thus a general brief 
description will be given. Unless stated otherwise, all reactions were performed at 
room temperature (20-23C). 
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Preparation of PtLI2  
To a 20 cm3 solution of K2PtCl4 (7.79 mmol; 3.2 g) was added KI (78 mmol; 
12.9 g) dissolved in 10 cm3 water. The mixture was allowed to stir for 30 min in a 
covered beaker during which time the colour of the reaction mixture darkened 
noticeably due to the formation of K2PtI4.  
At this point in the reaction the ligand was added. If the ligand was a 
dihydrochloride salt (ligand 25), then 1 molar equivalent of the ligand (9.43 mmol;) 
was dissolved in 5 cm3 water to which was added Na2CO3 (9.39 mmol; 0.99 g) 
dissolved in 5 cm3 water. Once the effervescence had subsided, the solution was 
added in portions to the K2PtI4 solution over a 1 hour period. If the ligand was not 
a dihydrochloride salt, then the ligand (9.43 mmol) was dissolved in 3 cm3 water 
and added in the same manner. Precipitation occurred without any difficulty, as 
was seen in the mustard suspension that became apparent soon after the initial 
addition of ligand. The reaction mixture was allowed to stir covered overnight, 
where after it was filtered and the mustard/yellow precipitate washed with 3 small 
aliquots of water, followed by 2 small aliquots of ethanol and a final wash with 
ether. The solid was dried in an oven at 50C for a few hours. The yield was 84-
93% (with respect to platinum) and the product of relatively good purity. 
Table 2-1 Yields and colouration of iodoplatinum(II) complexes* 
 
Complex Yield Colour 
Pt(L-hme)I2 86% Mustard-yellow 
Pt(2-aba)I2 84% Darker yellow 
Pt(2-aeae)I2 89% Bright yellow 
Pt(N-beda)I2 93% Yellow 
Pt(N-chpd)I2 90% Mustard-yellow 
                                            
* Please see list of abbreviations (pg xviii) for abbreviations of ligands. 
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2.2.6  CHLOROPLATINUM(II) COMPLEXES 
Complexes of platinum(II)chloride were prepared by use of each of the 
aforementioned diamine ligands. As the methods used were similar, only a 
generalized procedure will be given and unless otherwise stated, all reactions 
were performed at room temperature (20-23C). 
Preparation of PtLCl2 
Method 1 (Direct method) 
The respective ligand (1.63 mmol) was dissolved in 1 cm3 water and added in 
small aliquots to 5 cm3 of a stirred solution of K2PtCl4 (1.32 mmol; 0.54 g). The 
addition took place over a 60 minute period. Precipitation proceeds gradually after 
the initial drops of ligand soluion were added. The reaction mixture was allowed to 
stir overnight for 20-24 hr. Thereafter the reaction mixture was filtered through a 
porosity 3 suction filter and washed with water. The complexes were allowed to 
dry at 50C for a few hours. 
(In the case where the ligand is a dihydrochloride salt, it (1.63 mmol) was 
dissolved in 1.5 cm3 water and added to Na2CO3 (1.63 mmol) which was 
dissolved in 1.5 cm3 water. The reaction mixture was allowed to stir until fizzing 
subsided. The rest of the procedure is as described). 
Table 2-2 Yields and colouration of chloroplatinum(II) complexes 
 
Complex Yield Colour 
Pt(L-hme)Cl2 50% Light peach 
Pt(2-aeae)Cl2 71% Light yellow 
Pt(N-beda)Cl2 92% Light yellow 
Pt(N-chpd)Cl2 95% Peach 
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Method 2 (Silver method) 
In an attempt to improve yields, it was decided to attempt synthesis of the some of 
the aforementioned chloroplatinum(II) complexes via the use of the respective 
iodoplatinum(II) complex. In the case of the synthesis of Pt(2-aba)Cl2 which 
proved to be problematic via the direct method, this method of synthesis was 
adopted. 
The PtLI2 complex (0.94 mmol) was suspended in a mixture consisting of 10 cm3 
acetone and 2 cm3 water (83% acetone:17% water). To this suspension was 
added AgNO3 (1.8-1.9 molar equivalents) dissolved in 1 cm3 water. The reaction 
mixture was covered and allowed to stir in the dark overnight. Thereafter, the 
yellowish suspension was centrifuged and filtered to remove any traces of AgI. To 
the resulting light yellow supernatant liquor, was added solid LiCl (9.53 mmol; 10 
molar equivalents) dissolved in 1 cm3 water. In some cases, immediate 
precipitation occurred, but in others the reaction mixture had to be heated slightly 
over a 45-50°C water bath for about 50 minutes to aid complexation. Thereafter 
the reaction mixture was allowed to cool down to room temperature and 
proceeded to stir overnight. In the event that the resultant precipitate seemed very 
soluble in the solution, the product was placed at 4°C overnight to assist with 
precipitation. The resultant product was recovered by filtration through a porosity 
3 suction filter, washed with water and allowed to dry at 50°C for a few hours. 
Table 2-3 Yields and colouration of chloroplatinum(II) complexes 
 
Complex Yield Colour 
Pt(L-hme)Cl2 25% Light yellow 
Pt(2-aba)Cl2 52% Pinkish 
Pt(2-aeae)Cl2 69% Light yellow 
Pt(N-beda)Cl2 28% Lime-yellow 
Pt(N-chpda)Cl2 64% yellow 
 
In the case of Pt(L-hme)Cl2 and Pt(2-aba)Cl2, a deficiency of LiCl was used which 
could account for the low yields in these two cases, but does not account for the 
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much lower yield in the case of Pt(N-beda)Cl2. This method, in general, did not 
improve the yields. 
2.2.7  BROMOPLATINUM(II) COMPLEXES 
Complexes of platinum(II)bromide were prepared at room temperature for each of 
the ligands used. The method employed for each ligand was very similar and 
involved the use of the respective platinum(II)iodo complex . A brief generalized 
description will now follow. 
Preparation of PtLBr2 
The PtLI2 complex (0.94 mmol) was suspended in a mixture consisting of 10 cm3 
acetone and 2 cm3 water (83% acetone:17% water). To this suspension was 
added AgNO3 (~1.80 mmol; 1.8-1.9 molar equivalents) dissolved in 1 cm3 water. 
The reaction mixture was covered and allowed to stir in the dark overnight. 
Thereafter, the yellowish suspension was centrifuged and filtered to remove any 
traces of AgI. To the resulting light yellow supernatant liquor were added 10 molar 
equivalents NaBr or KBr (9.40 mmol) which were dissolved in 1-2 cm3 water. In 
cases where precipitation did not occur soon after addition of the NaBr solution, 
the reaction mixture was slightly heated at 45-50°C for 50 minutes, to aid with 
complexation. The reaction mixture was then cooled to room temperature, while 
stirring and continued to stir overnight. In the event that the resultant precipitate 
seemed very soluble in the solution, the product was placed at 4°C overnight to 
assist with precipitation. The resultant product was recovered by filtration through 
a porosity 3 suction filter, washed with water and acetone and allowed to dry at 
50°C for a few hours. 
Table 2-4 Yields and colouration of bromoplatinum(II) complexes 
 
Complex Yield Colour 
Pt(L-hme)Br2 51% Bright yellow 
Pt(2-aba)Br2 47% Light brown 
Pt(2-aeae)Br2 70% Yellow 
Pt(N-beda)Br2 31% Yellow 
Pt(N-chpd)Br2 49% Light yellow 
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2.2.8  OXALATOPLATINUM(II) COMPLEXES 
Complexes of platinum(II) oxalates were synthesized for each of the 
aforementioned ligands. The method used in each case was very similar and 
included the use of the respective PtLI2 complex and thus a generalized 
description will be given here.  
Preparation of PtL(C2O4) 
The PtLI2 complex (1.38 mmol) was suspended in a mixture consisting of 10 cm3 
acetone and 2 cm3 water (83% acetone:17% water). To this suspension was added 
1.8-1.9 molar equivalents of AgNO3 (~2.48 mmol) dissolved in 1 cm3 water. The 
reaction mixture was covered and allowed to stir in the dark overnight. Thereafter the 
yellowish suspension was centrifuged and filtered to remove any traces of AgI. To the 
resulting light yellow supernatant liquor was added 3 molar equivalents of 
K2C2O4·H2O (4.14 mmol), which was dissolved in 4-5 cm3 water. In some cases the 
complex proceeded to precipitate out gradually but in other cases the reaction 
mixture had to be heated slightly over a 45-50°C water bath for about 90 min. This 
was done, not only to aid complexation, but also to prevent the K2C2O4·H2O from 
precipitating out. The reaction mixture was then cooled down to room temperature 
while stirring. The reaction mixture was allowed to stir overnight at RT. The resulting 
precipitate was then recovered by filtering through a porosity 3 filter, washed with 
water and acetone, and placed in oven at 50°C to dry for a few hours.  
Table 2-5 Yields and colouration of oxalatoplatinum(II) complexes 
 
Complex Yield Colour 
Pt(L-hme)C2O4 53% Cream 
Pt(2-aba)C2O4 22% Light brown 
Pt(2-aeae)C2O4 8.38% White 
Pt(N-beda)C2O4 49% Cream 
Pt(N-chpd)C2O4 37% White 
 
In the case of Pt(L-hme)C2O4 (yol25.1), this complex was also prepared via the use 
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of K2PtC2O4·2H2O prepared in this laboratory. Due to the insolubility of 
K2PtC2O4·2H2O, it had to be dissolved over a 80-90°C water bath. Thereafter the 
reaction mixture had to be kept at 45-50°C, while the neutralized ligand addition was 
made over a 60 min period.  The reaction mixture was allowed to cool down to room 
temperature while stirring and continued to stir overnight. Recovery of the cream 
product was made in a similar manner as described above. The yield was now only 
22-29% though. Due to much lower yields this method of synthesis was terminated. 
2.2.9  PLATINUM(IV) COMPLEXES 
Preparation of Mar4.1.4 (Pt(dach)(C2O4)(NO2)Cl)  
(3.24 g, 8.15 mmol) oxaliplatin (trans-(1R,2R)-(-)-1,2-Diaminocyclohexane-
oxalatoplatinum(II)), was suspended in a mixture of 60 cm3 distilled water and 
140 cm3 acetone; (30% water:70% acetone mixture). To this reaction mixture was 
added 1 molar equivalent of NaCl (8.16 mmo) which was dissolved in 2 cm3 water 
(making up part of the aforementioned 30% water used). A light cream 
suspension was formed which was immediately reacted with NO2 gas. The NO2 
gas was produced and controlled by the dropwise addition of concentrated nitric 
acid into a three-necked round-bottomed flask which contained approximately 4.5  
g of pure copper metal. The gas was then passed through an empty wash bottle 
into the two-necked round-bottomed flask containing the reaction mixture, through 
the use of a slow flux of N2 carrier gas. This process continued for 30 minutes, 
until a clear bottle green solution was obtained, after which NO2 gas flow was 
terminated (see Figure 2-1 for set-up). The reaction mixture was then covered 
with foil and allowed to stir overnight whilst undergoing further oxidation by 
atmospheric oxygen. After about 20 hours, the reaction mixture appeared as a 
yellow suspension, of which the volume had reduced considerably. Further 
precipitation was facilitated by blowing air over the reaction mixture. The 
precipitate was then recovered by filtration through a porosity 3 or 4 filter and 
washed with 3 small aliquots of distilled water. The product was allowed to dry at 
50°C for few hours. 
As a variation on this method NaBr was used in lieu of NaCl and these complexes 
are denoted Mar4.1.4.3 for instance. Oxidation of a select few other platinum(II) 
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complexes was performed in an analogous manner as that described for 
Mar4.1.4.  
Table 2-6   Yields and colouration of platinum(IV) complexes 
 
Complex Yield Colour 
Pt(dach)(C2O4)(NO2)Cl 75-86% Creamish 
Pt(dach)(C2O4)(NO2)Br 74-84% Lime/Yellow 
Pt(L-hme)(C2O4)(NO2)Cl 37-50% Peach 
Pt(L-hme)(C2O4)(NO2)Br 80% Brown/orange 
Pt(N-chpd)(C2O4)(NO2)Cl 55% Lime/yellow 
Pt(N-chpd)(C2O4)(NO2)Cl 69% Light yellow 
 
N2 Gas
Cu Metal
NO2 Gas
Reaction Vessel
Concentrated 
        HNO3
 
 
Figure 2-1   An illustration of the experimental set-up used in the NO2 oxidation 
reactions 
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2.3  ANALYSIS TECHNIQUES 
2.3.1  ELEMENTAL ANALYSIS 
Microanalysis for C, H and N was performed at the University of Cape Town. The 
samples were analysed by a Fisons Elemental Analyser 1108 CHNS-O. 
2.3.2  SPECTROMETRIC ANALYSIS 
Infrared spectroscopy 
Infrared spectra were recorded on an Excalibur HE FTS3100 spectrophotometer 
in the range of 3800-300 cm-1 using the single beam mode. Through use of dried 
potassium bromide, solid samples were compressed into discs and scanned with 
nitrogen gas as reference. Liquid samples were spread as a thin film between two 
sodium chloride plates and scanned using the empty plates as reference. 
 
Electronspray Ionization Mass Spectrometry 
Electronspray mass spectra were obtained from Shimoda Biotech.  
Measurements were carried out on an LCQ Deca instrument (Finnigan, San Jose, 
CA, USA) in either positive or negative ionization mode.  For infusion studies, the 
samples, in appropriate solvent, were directly infused at a flow rate of 10 µl/min 
using a 500 µl Unimetrics HPLC syringe and the instrument’s own syringe pump.  
A 50% MeCN/ 10 mM ammonium formate/ 0.06% formic acid solution was used 
as sheath liquid, at a flow rate of 150 µl/min.  The tip of the fused silica capillary 
(i.d. 100 µm, o.d. 190 µm) was positioned 0.5 to 1.0 mm inside the tip of the 
stainless steel sprayer capillary, allowing direct contact with the analysis solution.  
The parameters of the instrument were tuned utilising an infusion solution of 
Pt(dach)Cl2 in MeCN (10 µM at 10 µl/min). 
 Positive ion mode instrument settings 
The instrument parameters were tuned using the ammonium adduct [M+NH4]+ 
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with the following values: nitrogen sheath gas flow rate 80 arbitrary units, nitrogen 
auxiliary gas flow rate 20 arbitrary units, sprayer voltage 3.5 kV, capillary voltage 
46.0 V, tube lens offset 55.0 V, multipole 1 offset -5.75 V, lens voltage -28.0 V, 
multipole 2 offset -10.00 V, multipole RF amplitude (V p-p) 400 V, entrance lens -
62.0 V and 100 ms maximum injection time using automatic gain control.   
 Negative ion mode instrument settings 
The parameters of the instrument were tuned using the formate adduct 
[M+HCOO]- to the following values: nitrogen sheath gas flow rate 80 arbitrary 
units, nitrogen auxiliary gas flow rate 20 arbitrary units, sprayer voltage 5.0 kV, 
capillary voltage -12.0 V, tube lens offset 5.0 V, multipole 1 offset 5.25 V, lens 49 
voltage 46.0 V, multipole 2 offset 10.00 V, multipole RF amplitude (V p-p) 400 V, 
entrance lens 38.0 V and 100 ms maximum injection time using automatic gain 
control.   
HPLC-MS 
Due to the compatibility of ESI with the solvents used for HPLC (water, methanol 
and acetonitrile), it is also possible to use the mass spectrometer as a very 
specific detector for HPLC. This enables mass-selective characterisation of 
individual species present in a solution. By performing a typical gradient HPLC 
separation (1 to 70% acetonitrile), utilising a reverse phase column (C8 or C18) 
and detecting the eluting compounds in positive and negative ion mode, an 
enormous amount of relevant data can be obtained in a relatively short space of 
time. 
LC-MS 
The LCQ Deca mass spectrometer was connected to a Thermo Surveyor HPLC 
system consisting of a quaternary gradient pump and auto-sampler. For LC-MS, 
varying solvents were utilised, but in each case the solvents and modifiers 
complied with the overriding requirements of ESI-MS, in that all components had 
to be volatile.  
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HPLC-UV 
LC separations were performed on a Waters HPLC system, consisting of a WISP 
717 auto-sampler, 600E quaternary gradient pump and 484 variable wavelength 
UV-Vis detector. 
Column separations 
Various HPLC separation columns were used during this study. The specifications 
of each are listed in Table 2-7 below. 
Table 2-7   HPLC separation columns employed. 
 
Supplier Phase  Dimension 
YMC Hydrosphere C18 120 Å 5µm 250 x 4.6 mm 
Phenomex  Curosil PFP 5µm 250 x 4.6 mm 
Water Novapak C18 120 Å 5µm 150 x 3.9 mm 
SGE  Nucleosil C4 300 Å 5 µm  150 x 2.0mm 
 
Analytical methods pertaining to Chapter 3 – Micro Analysis 
Standardisation of TBAOx in dmf 
Prior to monitoring the reaction of Pt(dach)Cl2 with TBAOx to produce oxaliplatin, 
a method was required to standardise the TBAOx which had been prepared (See 
section 2.2.4) 
The developed method was based on the method used for the determination of 
oxalate (Impurity A) in oxaliplatin, according to the European Pharmacopoeia.66 
However, due to the sample being in dmf and not water, the method had to be 
adjusted.  
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The wavelength was changed from 205 to 260 nm and the sample injection 
volume was decreased from 20 µl to 5 µl. At the shorter wavelength, the 
absorbance due to dmf made accurate quantitation of oxalate ions impossible and 
the smaller injection volume decreased the effect of peak tailing.  
HPLC  
System Waters 600E pump Water 717 WISP autosampler wavelength 
UV detector 
Mobile phase 3.2ml TBAOH (40%) 
0.544g KH2PO4 
400cm3 water 
Adjust pH to 6 with 8.5% H3PO4 
Add 100cm3 acetonitrile 
Column  Waters Novapak C18 150 x 3.9mm (5µm) 
Detection wavelength 260nm 
Flow rate 1.5ml/min 
Injection volume  5µl 
 
 Preparation of standards and control samples 
Two oxalate stock solutions were prepared by weighing oxalic acid (3.5 mg) into a 
4 cm3 vial and adding enough 90% dmf (10% water) to produce a 1.00 mg/cm3 
oxalic acid (11.11 mM oxalate) solution.  One solution was used to prepare the 
standard solutions, while the other was used to prepare control standards.  The 
preparation of these solutions is stipulated in Table 2-8. 
Table 2-8 An indication of how the standard and control samples for the determination of 
oxalate concentration in dmf were prepared. 
 
Standard Oxalate stock 11.11 mM (µl) dmf (cm
3) water (µl) [oxalate] (µg/ml) 
Std1 200 3.42 380 48.9 
Std2 400 3.24 360 97.8 
Std3 600 3.06 340 146.7 
Std4 800 2.88 320 195.6 
Crl1 400 3.24 360 97.8 
Crl2 400 3.24 360 97.8 
 
 Triplicate sample preparation 
The sample solution (ca. 1 M TBAOx) in dmf (42.1 µl), was diluted to 4.0 cm3 with 
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dmf (10.52 mM). This solution was further diluted (648 µl) to 4.0 cm3 with dmf to 
yield an oxalate concentration of (150 µg/ml). 
A sample concentration of 150 ug/ml oxalate thus reflects an original 
TBAOx solution of 1.00 M. 
Degradation of oxalate in 95% dmf 
This method was fashioned specifically to monitor the degradation of oxalate 
during typical reaction conditions. To determine the degradation of TBAOx in 95% 
dmf at 3 molar ratios of Pt(dach)Cl2: TBAOx  viz. 1:1.5; 1:2.5; 1:5 and 4 different 
temperatures (70; 75; 80 and  85°C). 
For each reaction parameter (e.g. 1:1.5 at 70°), 10 samples were taken over a 7.5 
hour period. As dissociation of the TBAOx into TBA+ and Ox2- takes place upon 
injection into the flow path of the HPLC (80% water), it was decided to monitor the 
concentration of the oxalate anions as opposed to the expected more stable 
tetrabutylammonium cations. (See HPLC conditions outlined above). 
 Sample preparation 
A 1M TBAOx solution was prepared (dmf) and diluted to 10.52 mM using dmf. 
This diluted TBAOx stock solution was then used to prepare the sample solutions 
as depicted in Table 2-9. 
Table 2-9  Indication of the preparation of samples used to observe the degradation of 
TBAOx in 95% dmf.  
 
Ratio Pt(dach)Cl2: 
TBAOx 
Volume   
10.52 mM 
TBAOx (µl) 
Volume 
dmf (µl) 
Volume 
water (µl) 
dmf 
(%) 
No. of samples   
Prepared 
1:1.5 150 1370 80 95 10 
1:2.5 250 1270 80 95 10 
1:5.0 500 1020 80 95 10 
 
 Degradation 
The vials (vial racks) were placed in ovens at the specified temperature. Two 
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ovens were used. The first was a GC oven (70ºC on day 1 and 80ºC on day 2). 
The second oven was a standard lab oven which had been calibrated (75ºC on 
day 1 and 85ºC on day 2).  At the appropriate time the oven door was opened and 
the specific vials were removed. The oven door was not opened for more than 
30 s at a time. The removed vials were placed in a freezer at  -18ºC 
On the day of the analysis (15 days later), the samples were removed from 
the freezer and allowed to reach RT. A subset of selected samples was done 
first [T0 (time 0:00), T5 (time 02:30) and T9 (07:30)]. It was quickly noticed 
that very little drop, if any, in the oxalate level had occurred. Consequently 
only these three time intervals were analysed (36 samples in total). [4 
temperature levels x 3 concentration levels x 3 time intervals = 36]. 
 Calibration 
To produce the standard solutions, sequential dilutions of the stock 10.52 mM 
TBAOx had to be performed (see Table 2-10). 
Table 2-10   Indication of how standards were prepared for the analysis of oxalate 
concentration in 95% dmf. 
 
Standard Volume TBAOx [10.52 mM] (µl) 
Volume dmf 
(µl) 
Volume water 
(µl) 
[oxalate] 
(µg/ml) 
1 37.5 1482.5 80 21.7 
2 75 1445 80 43.4 
3 150 1370 80 86.8 
4 250 1270 80 145 
5 500 1020 80 289 
 
The determination of the concentrations of Pt(dach)Cl2 and oxaliplatin in 95% dmf 
Experiments of this nature were performed to observe the decrease in Pt(dach)Cl2 
concentration as reagent and the increase in oxaliplatin concentration as product 
in 95% dmf over a 20 hour period under the following conditions: Molar ratios of 
Pt(dach)Cl2:TBAOx of 1:1.5; 1:2.5; 1:5 and temperatures of 70; 75; 80 and 85°C. 
The reaction species (Pt(dach)Cl2 and oxaliplatin) were quantified using LC-MS 
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(negative ion mode). Simultaneously, a set of experiments were performed to 
observe the degradation of Pt(dach)Cl2 and oxaliplatin under the same conditions. 
 Preparation of stock solution in 95% dmf 
Pt(dach)Cl2 in dmf  
A mass of Pt(dach)Cl2 (50.23 mg ) was weighed into a 25 cm3 volumetric flask 
and the flask filled to the mark with dmf. (Actual concentration 5.287 mM/2009.2 
ppm). 
TBAOx in dmf 
As described earlier in this section, a standard solution of TBAOx in dmf was 
prepared. The concentration of the TBAOx solution was determined to be 
0.577 M. An appropriate dilution was then made to prepare a 10.52 mM solution. 
 
Oxaliplatin in dmf 
A 0.657 mM/261 ppm oxaliplatin stock solution was prepared by weighing 
13.0 mg oxaliplatin into a 50 cm3 volumetric flask. The flask was made to the mark 
with a solution of 10% water in dmf. (Actual concentration 0.654 mM/260 ppm) 
Internal standard in dmf 
A series of dilutions were performed to establish the linear region for Y14.2 under 
the analytical conditions used for this study. It was determined that addition of 100 
µl of 500 ppm Y14.2 solution (dmf) to 400 µl of the reaction mixture, yielded an 
internal standard concentration of 100 ppm which was well within the linear region 
for Y14.2. A 500 ppm stock solution of Y14.2 was prepared by weighing 27.3 mg 
Y14.2 into a 50 cm3 volumetric flask. The flask was made to the mark with dmf. 
(Actual concentration 545 ppm) 
Sample preparations 
All reactions were performed in 2 cm3 glass autosampler vials with Teflon lined 
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septa. The reaction solutions were transferred to each vial using a calibrated auto 
pipette with the appropriate sized plastic tip. The volume of each of the stock 
solutions used is depicted in Table 2-11.  
 
Table 2-11 An indication of how the samples were prepared prior to incubation and analysis 
in 95% dmf. 
 
  
TBAOx 
(10.52 mM) 
(µl) 
Pt(dach)Cl2 
(5.263 mM) 
(µl) 
dmf 
 
(µl) 
water 
 
(µl) 
oxaliplatin 
(0.657 mM) 
(µl) 
Total 
 
(µl) 
 Pt(dach)Cl2:  TBAOx       
1 1 :1.5 37.5 50 292.5 20 - 400 
2 1 :2.5 62.5 50 267.5 20 - 400 
3 1 :5.0 125 50 205 20 - 400 
4 Pt(dach)Cl2 degradation  50 330 20 - 400 
5 oxaliplatin degradation  - - - 400 400 
In each case (Reactions 1-5), 16 vials were similarly filled (T0 to T15), for each 
temperature level (70, 75, 80 and 85ºC). The total number of reaction vials used 
for this portion of the experiment was thus:  
5 x 16 x 4 = 320 
Standard preparations 
 Oxaliplatin  
Table 2-12  Preparation of oxaliplatin calibration standards in dmf 
 
 
Volume oxaliplatin stock 
(0.654 mM/260 ppm) 
(µl) 
Volume 10% water 
90% dmf 
(µl) 
[oxaliplatin] 
(µg/ml) 
Std1 80 320 52 
Std2 160 240 104 
Std3 240 160 156 
Std4 320 80 208 
Std5 400 - 260 
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 Pt(dach)Cl2 
A diluted stock solution (250 µg/ml) was prepared by taking 250 µl of the 2000 
ug/ml stock to 2.0 ml (dmf). 
 
Table 2-13  Preparation of Pt(dach)Cl2 calibration standards in dmf 
 
 
Volume Pt(dach)Cl2 stock 
( 250 ppm) 
(µl) 
Volume dmf 
(µl) 
[Pt(dach)Cl2] 
(µg/ml) 
Std1 80 320 50 
Std2 160 240 100 
Std3 240 160 150 
Std4 320 80 200 
Std5 400 - 250 
 
 Sample reactions 
As only 2 calibrated ovens were available and the period monitored was 20 hours, 
the experiment was conducted over 2 days. On day 1, temperature levels 70 and 
75ºC were evaluated, while temperature levels 80 and 85ºC were evaluated on 
day 2. In all cases (except for the oxaliplatin degradation samples), the solution 
containing the Pt(dach)Cl2 was added just before the start of the experiment. The 
vials were well shaken and transferred to Perspex vial racks which were placed in 
the equilibrated ovens. Care was taken to ensure that no fluid had collected under 
the lid. The T0 samples were removed and placed in the freezer. At the 
designated time the oven door was opened and the specific vials were removed. 
The oven door was not opened for more than 30 s at a time. The removed vials 
were placed in a freezer at -18ºC. 
The time intervals utilised for this study are given in Table 2-14. 
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Table 2-14   Display of sample times utilised for monitoring the reactions in 95% dmf. 
 
 Time (min) 
Time 
(h) 
Time 
(h:min) 
70 ºC and 75ºC 
Day 1 
80 ºC and 85ºC 
Day 2 
T0 0 0.00 0 10:45 07:50 
T1 10 0.17 00:10 10:55 08:00 
T2 30 0.50 00:30 11:15 08:20 
T3 60 1.00 01:00 11:45 08:50 
T4 100 1.67 01:40 12:25 09:30 
T5 150 2.50 02:30 13:15 10:20 
T6 210 3.50 03:30 14:15 11:20 
T7 280 4.67 04:40 15:25 12:30 
T8 360 6.00 06:00 16:45 13:50 
T9 450 7.50 07:30 18:15 15:20 
T10 550 9.17 09:10 19:55 17:00 
T11 660 11.00 11:00 21:45 18:50 
T12 780 13.00 13:00 23:45 20:50 
T13 910 15.17 15:10 01:55 23:00 
T14 1050 17.50 17:30 04:15 01:20 
T15 1200 20.00 20:00 06:45 03:50 
 
After completion of all the reactions, the reaction vials together with the standard 
vials were removed from the freezer and allowed to equilibrate. To each of the 
vials was added 100 µl of the internal standard solution (Y14.2/500 ppm). All vials 
were thoroughly shaken prior to analysis. The analysis sequence followed is 
detailed in Table 2-15. 
Table 2-15  Stipulation of the sample analysis sequence followed during the 95% dmf 
investigation. 
 
Run 
# Sample 
Run 
# Sample 
Run 
# Sample 
Run 
# Sample 
1 Pt(dach)Cl2 std1 91 
Pt(dach)Cl2  
std1 181 
Pt(dach)Cl2  
std1 271 
Pt(dach)Cl2  
std1 
2 Pt(dach)Cl2 std2 92 
Pt(dach)Cl2  
std2 182 
Pt(dach)Cl2  
std2 272 
Pt(dach)Cl2  
std2 
3 Pt(dach)2Cl2 std3 93 
Pt(dach)Cl2  
std3 183 
Pt(dach)Cl2  
std3 273 
Pt(dach)Cl2  
std3 
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Run 
# Sample 
Run 
# Sample 
Run 
# Sample 
Run 
# Sample 
4 Pt(dach)Cl2  std4 94 
Pt(dach)Cl2  
std4 184 
Pt(dach)Cl2  
std4 274 
Pt(dach)Cl2  
std4 
5 Pt(dach)Cl2  std5 95 
Pt(dach)Cl2  
std5 185 
Pt(dach)Cl2  
std5 275 
Pt(dach)Cl2  
std5 
6 oxaliplatin std1 96 oxaliplatin std1 186 oxaliplatin std1 276 oxaliplatin std1 
7 oxaliplatin std2 97 oxaliplatin std2 187 oxaliplatin std2 277 oxaliplatin std2 
8 oxaliplatin std3 98 oxaliplatin std3 188 oxaliplatin std3 278 oxaliplatin std3 
9 oxaliplatin std4 99 oxaliplatin std4 189 oxaliplatin std4 279 oxaliplatin std4 
10 oxaliplatin std5 100 oxaliplatin std5 190 oxaliplatin std5 280 oxaliplatin std5 
11 70115T00 101 75115T00 191 80115T00 281 85115T00 
12 70125T00 102 75125T00 192 80125T00 282 85125T00 
13 70150T00 103 75150T00 193 80150T00 283 85150T00 
14 70P00 104 75P00 194 80P00 284 85P00 
15 70O00 105 75O00 195 80O00 285 85O00 
16 70115T01 106 75115T01 196 80115T01 286 85115T01 
17 70125T01 107 75125T01 197 80125T01 287 85125T01 
18 70150T01 108 75150T01 198 80150T01 288 85150T01 
19 70P01 109 75P01 199 80P01 289 85P01 
20 70O01 110 75O01 200 80O01 290 85O01 
21 70115T02 111 75115T02 201 80115T02 291 85115T02 
22 70125T02 112 75125T02 202 80125T02 292 85125T02 
23 70150T02 113 75150T02 203 80150T02 293 85150T02 
24 70P02 114 75P02 204 80P02 294 85P02 
25 70O02 115 75O02 205 80O02 295 85O02 
        
        
        
        
86 70115T15 176 75115T15 266 80115T15 356 85115T15 
87 70125T15 177 75125T15 267 80125T15 357 85125T15 
88 70150T15 178 75150T15 268 80150T15 358 85150T15 
89 70P15 179 75P15 269 80P15 359 85P15 
90 70O15 180 75O15 270 80O15 360 85O15 
 
All samples were analysed by LC-MS using a Thermo Surveyor quaternary HPLC 
and LCQ Deca quadruple ion trap mass spectrometer operating in the negative 
ion mode and utilising an electrospray API source. 
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Details 
System Thermo Surveyor autosampler and quaternary HPLC LCQ  
Deca quadropole ion trap mass spectrometer utilizing an 
Electrospray API Source 
Mode Negative ion mode 
Mass range m/z 300-600 
Tune file Pt(dach)Cl2 neg 050517 
Capillary temperature 200°C 
Capillary voltage 5.0kV 
Probe position 4 
Flow rate  400µl/min 
Column SGE GL Nucleosil C4 2.0 x 150 mm (5µm) 
Mobile phase 45% acetonitrile containing 20 mM ammonium formate 
Injection volume 2µl 
Run time 6 min (Divert to MS from 1 to 3.2 min) 
Analytes monitored 
The MS was set up to quantify negative ions related to the reactants (m/z 300 – 
600). These ions include: 
Pt
Cl
Cl
H2
N
N
H2
CHO2-
Pt
O
O
C
C
O
O
H2
N
N
H2
CHO2-
N
NH
Pt
Pt(dach)Cl2    m/z 423- Oxaliplatin m/z 441-
N
H3C
O
O
O
O
Y14.2  m/z 494-
CHO2-
 
Inductively-coupled plasma emission spectroscopy 
A Perkin Elmer SCIEX Elan-6100 ICP-MS Spectrometer was used to analyse the 
platinum content of samples prepared for solubility studies. The ICP setting used 
are given below in Table 2-16.  
The isotopes used for optimal analysis were 194Pt and 195Pt . The standards 
ranging from 5-1000 µg/l were prepared in an aqueous medium containing 0.1M 
HCl. Samples for analysis were therefore diluted appropriately and prepared in a 
0.1M HCl matrix. 
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Table 2-16 General ICP settings used 
 
Control feature Setting 
RF Power 1.4 kW 
Coolant gas 15 L/min 
Nebulizer gas flow 0.7 L/min 
Dwell time per AMU 50ms 
Sweeps/reading 10 
Readings/replicate 2 
Replicate 10 
 
2.3.3  OTHER ANALYSIS 
Thermal gravimetric analysis (TGA) 
The TGA was performed on a TGA 2050 Thermogravimetric Analyser using TA 
Instrument – Advantage software for Thermal Analysis. The data obtained was 
analysed on TA Universal Analysis 2000. All samples were heated at a rate of 
5°C/min in a nitrogen atmosphere.  
Cyclic voltammetry 
Cyclic voltammetric experiments were performed on a BAS100-Epsilon instrument 
at 25C with a scan rate of 100 mV/s. Each platinum(IV) complex was dissolved in 
0.1 M KCl solution to a final concentration of 1 mM (unless stated otherwise). 
Nitrogen was bubbled through the solution to remove oxygen. A glassy carbon 
electrode was used as the working electrode, Ag/AgCl was used as the reference 
electrode, and a platinum wire was used as the auxiliary electrode. 
2.3.4  CRYSTALLOGRAPHIC ANALYSIS 
Full X-ray structure determinations were attempted on two platinum complexes.  
The diffraction data was collected at the University of the Witwatersrand using a 
Bruker SMART 1K CCD area detector diffractometer with graphite 
monochromated MoKα radiation (50 kV, 30 mA).  The collection method involved 
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ω-scans of width 0.3°.  Data reduction was carried out using SAINT+ (Bruker, 
1999)67 and absorption corrections were made using the program SADABS 
(Sheldrick,1996).68 
The WinGX 1.64.0269 suite of programs was used to solve the crystal structures 
using either direct methods or the Patterson approach. Refinement was done 
using SHELXS-9770. Non-hydrogen atoms were first refined isotropically, followed 
by anisotropic refinement by full matrix least-squares calculation based on F2. 
Hydrogen atoms were positioned geometrically and allowed to ride on their 
respective parent atoms. Torsional angles and least squares planes of selected 
atoms were calculated using PARST71. Diagrams were generated using 
ORTEP72. 
2.3.5  SOLUBILITY STUDIES 
The solubility of the complexes was determined as follows: A small quantity of the 
complex was suspended in 2 cm3 water and stirred vigorously at 25°C for 30 
minutes. Thereafter the mixture was centrifuged for 10 minutes, filtered through 
Whatman 510 filter paper and the resulting supernatant liquid adequately diluted 
for the total platinum analyses via inductively coupled plasma mass spectroscopy 
(ICP-MS). 
2.3.6 IONIZATION STUDIES 
2-4 mg of the platinum complex was weighed out into 2 cm3 glass vials. Sufficient 
methanol was added to each flask to give a final concentration of approximately 
10 mg/cm3 of the complex. An 80 µl aliquot was taken from each flask and diluted 
to 4 cm3 with water. The time that the aliquot was added to the water was taken 
as time zero (t0) for that sample. The samples were thereafter shaken and 
transferred to the HPLC autosampler for analysis. Typical delay periods of 2-3 
minutes were obtained between t0 and the first injection. 
LC-UV parameters: Hydrosphere C18 column was used together with a mobile 
phase containing 30% acetonitrile in distilled water. A flowrate of 1 cm3/minute 
was used, with a detector wavelength of 210 nm and an injection volume of 
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20 cm3. Run times of between 8 and 12 minutes were used depending on the 
hydrophobicity of the complex. 
2.3.7  CYTOTOXIC EVALUATION 
All novel complexes prepared in this dissertation were tested for anticancer action 
according to known literature methods73,74  by the Biochemistry department of the 
Nelson Mandela Metropolitan University under the supervision of Dr. M. van de 
Venter.  The compounds were tested on 3 cancer cell lines viz.  a colon cancer 
cell line (HT29), a breast cancer cell line (MCF7) and cervical cancer  cell line 
(Hela).  Cisplatin, and in some cases oxaliplatin, was used as reference. A 
summary of the general method is given below. 
Preparation of assay 
Cytotoxicity in cell lines was determined by a modified MTT assay (Sigma). Cells 
in exponential growth will be trypsinized, counted using a haemocytometer and 
diluted to a density of 30 000 cells per ml.  Aliquots (200 L) of cell suspensions 
will be added to each well of a 96-well microtiter plate and incubated for 24 hours.  
The novel platinum containing compounds will be screened for cytotoxicity using  
approximately 10, 50 and 100 M concentrations.  Cisplatin (approximately 10, 50 
and 100 M concentrations) will serve as a positive control.  The spent medium 
will be removed from the 96-well plate and aliquots (200 L) of the treatments will 
be added to the wells in quadruplicate. The plate will be incubated in a 37C-5% 
CO2 humidified incubator for 48 hours. A 5 mg/mL stock solution of MTT will be 
prepared in PBSA and used to prepare a 1 mg/mL solution of MTT in growth 
medium, to be applied to wells in 200 L aliquots.  The plate will be incubated for 
3 hours before the MTT will be removed and replaced by 200 L of DMSO to 
dissolve MTT formazan.  The plates will be agitated on a shaker for 5 minutes, 
before the absorbance will be read at 540 nm on a multiwell scanning 
spectrophotometer.  The values obtained will be used to determine the 
percentage inhibition of cell growth that these drugs cause (Hagopian et al. 1999 
and Huq et al. 2004). 
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Preparation of platinum complexes to be tested 
The treatment solutions (100 M) will be made up in pre-warmed (37C) RPMI 
1640 medium containing 10% foetal calf serum.  The samples will be vortexed for 
approximately 1 minute, sonicated for 10 minutes and then briefly vortexed again 
before it will be ready for use.  The 100 M solutions will be filter sterilized using 
0.22 M syringe filter units.  Appropriate dilutions were made to make up the 100, 50 
and 10 µM solutions.  These solutions will be applied to cells in 200 L aliquots for 48 
hours. 
Table 2-17  Chemicals used 
 
Chemical Supplier 
L-histidine methyl ester (98%) Fluka 
2-aminobenzylamine (98%) Aldrich 
2-aminoethylaminoethanol (98%) Aldrich 
N-benzylethylenediamine (97%) Aldrich 
N-cyclohexane-1,3-propane diamine (99%) Aldrich 
Sodium Chloride (99% min) Saarchem 
Sodium Bromide (99%) ACE 
Sodium Iodide (>99%) Fluka 
Sodium Cyanide (98%) Saarchem 
Sodium Carbonate (anhydrous) (98% min) Saarchem 
Sodium Perchlorate monohydrate (98%) Fluka 
Silver Nitrate (99%) Saarchem  
Copper metal (99%) Sigma-Aldrich 
Oxalic acid dihydrate (99.5 min%) Riedel-de Haën 
Potassium oxalate monohydrate (99.5%) Riedel-de Haën 
Acetone (99%) SMM Chemicals 
Platinum metal (99.99%) Impala platinum  
Potassium bromide  AR ACE 
Potassium Iodide (99%min) Saarchem 
Potassium Chloride (99-100.5%) Saarchem 
Hydrochloric Acid (32%) Saarchem  
Nitric Acid (69%) Riedel-de Haën 
SO2 gas (99.9%) Chemical Initiatives 
Tetrabutylammonium hydroxide 40%in water Fluka 
R,R-1,2 diamonicyclohexane(99%) Aldrich 
Ethanol (95%) Merck 
Diethylether(99%) Saarchem 
Dimethylformamide(99%) Saarchem 
Concentrated Ammonia (30-33%) Saarchem 
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Chemical Supplier 
1,2 Dichloroethane (99.5%) Merck 
Ethylacetate (99.5%) Saarchem 
Methylacetate (>99%) Fluka 
Methanol (99.9+%) Burdick and Jackson 
Ammonium formate (99%) Fluka 
Formic Acid Aldrich 
Acetonitrile (99.9+%) Burdick and Jackson 
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CHAPTER 3   
NON–AQUEOUS PREPARATIVE METHOD FOR 
OXALIPLATIN 
3.1 INTRODUCTION 
The discovery of oxaliplatin and its pharmaceutical properties, made in 1976 by 
Kidani et al.65,75 and its subsequent clinical success, spurred interest in the 
synthesis of various other oxalatoplatinum complexes in search of antineoplastics. 
 For the past three decades, the synthesis of these complexes has proceeded via 
an established65,75 and largely uncontested method, which employs the use of the 
heavy metal ion, silver (Ag). A major drawback associated with the use of silver is 
that it is toxic, but not only that - it is fairly expensive too. It is, however, its toxicity 
which makes it especially important to ensure the removal of any unreacted silver 
and its halides from the product, thus additional steps are required.  
In light of this, it was of our intention to develop a synthetic route which excludes 
the use of Ag completely. 
3.2 THE SILVER METHODS 
3.2.1 THE SOLUBLE SILVER METHOD 
Platinum based pharmaceuticals are always synthesized using either K2PtCl6 or 
K2PtCl4 as starting material.  In the instances where monodentate neutral ligands 
are used, such as NH3, and a cisplatinum(II) product is required, as in the 
preparation of cisplatin, it is necessary to prepare K2PtI4, prior to reacting it with 
the neutral ligand, (NH3 in the above instance).  This requirement is necessitated 
by the fact that a mixture of cis, trans and auto ionized products are obtained by 
using K2PtCl4 directly.  Iodide has a larger trans directing capability than chloride.  
Two moles of neutral ligand are then reacted upon K2PtI4, resulting in the 
formation of the cis- diammine di-iodoplatinum(II) complex.   
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The traditional method65,75 of achieving ligand exchange is through the use of a 
silver salt like AgNO3 or Ag2SO4, which then slowly leads to the precipitation of 
silver iodide and the formation of the diaquoplatinum(II) complex, viz. 
[Pt(NH3)2(H2O)2]2+ and nitrate (or sulphate) as counter ions.  After filtration, upon 
which the AgI is removed, this solution is reacted with two moles of a monoanionic 
species, such as Cl-, or one mole of a dianionic species such as a dicarboxylate.  The 
required product gradually precipitates from the aqueous system.  Due to the 
metastability of the diaquoplatinum(II) species and the light sensitivity of the silver 
halide, the entire operation is performed at room temperature and in the dark.  
The reactions are thus as follows: 
K2PtCl4   +   4I- K2PtI4
red brown
K2PtI4    +   2NH3 cis-Pt(NH3)2I2   +   2KI
yellow
cis-Pt(NH3)2I2   +   2Ag+  +   2NO3- H2O Pt(NH3)2(H2O)22+   +    2NO3-   +   2 AgI
white/cream
Pt(NH3)2(H2O)22+   +    2NO3-   +   2Na+   +   2Cl-
cis-Pt(NH3)2Cl2   +   2Na+   +2NO3-
yellow
 
e.g. Pt(NH3)2Cl2 or Pt(NH3)2(dicarboxylate) 
When a bidentate non-leaving group is used, such as DACH, as in the synthesis 
of oxaliplatin, the ligand could be directly reacted by addition to K2PtCl4.  This can 
be followed by a similar silver method, in which AgCl precipitates76.  In more 
recent methods, the iodide intermediate step has been included; even in thís 
synthesis, in light of the greater insolubility of AgI (Ksp  1X10-16) as compared to 
AgCl (Ksp  1X10-10).  The result is a smaller chance for contamination of toxic Ag+ 
in the final product.  The aqueous solution of the diaquoplatinum(II) complex, 
before addition of oxalic acid or oxalate, is strongly acidic due to hydrolysis.  
[Pt(dach)(H2O)2]2+    +   H2O [Pt(dach)(H2O)(OH)]+   +   H3O+  
At this low pH (~1), oxalic acid or oxalate is partially protonated, due to its low 
second ionization constant, thus ligand exchange of OH with oxalate is fractional.  
63 
The pH needs to be increased by controlled addition of NaOH to reach a pH value 
between 3 and 6, ideally, between 4 and 5.  Above a pH value of 6, a 
dioxodiaminocyclohexane platinum(II) dimer can form, which will result in an 
impure product.  (See structure below). 
N
H2
Pt
H2
N
N
H2
Pt
H2
NO
O
di--oxobis[1R,2R-cyclohexane-1,2-diamine]platinum(II)
 
3.2.2 THE SILVER OXALATE METHOD 
Instead of using a soluble silver salt (NO3- or SO42-) the usage of Ag2C2O4 was 
also patented77. Both the Pt(dach)Cl4 and Pt(dach)Cl2 compounds were refluxed 
in aqueous solution, with excess Ag2C2O4 in the former case and the 
stoichiometric amount in the latter case.  In another, more recent patent78, a 
Ag2C2O4 solution at a pH between 4.5 and 5 was used in combination with a 
suspension of Pt(dach)I2 and heated to 55-60°C for 3 hours.  
The reaction sequences in the above instances are as follows:  
K2PtCl6   +   dach
10hr
reflux
Pt(dach)Cl4
Pt(dach)Cl4    +   excess Ag2C2O4
1hr
reflux
Pt(dach)(C2O4)
or
Pt(dach)Cl2   +   Ag2C2O4 Pt(dach)(C2O4)



 
Pt(dach)I2   +   AgC2O4

3hr
Pt(dach)(C2O4)
 
3.2.3 SILVER CARBONATE METHOD 
A similar carbonate method was also proposed for the synthesis of platinum(II) 
dicarboxylate salts, e.g. by synthesizing Pt(dach)(CO3) in a 50% yield from 
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Pt(dach)Cl2 and Ag2CO3 and subsequent reaction with the parent acid (e.g. 
malonic acid)79. 
Pt(dach)Cl2     +    Ag2CO3
24hr stir in dark Pt(dach)(CO3)    +     2AgCl
1.2mmol 3.6mmol 50% yield
Pt(dach)(CO3).2H2O   +   CO2CH2CO2
Stir 30min
room temperature
N2 atm room temp
Pt(dach)(CO2CH2CO2)   +   CO2(g) +   H2O
68% yield
 
3.3 NON-SILVER METHODS 
As illucidated in the introduction, there are a number of negative factors 
associated with the application of the silver method for the synthesis of oxaliplatin. 
These include; the multistep nature, the possibility of contamination with Ag+, the 
expense of using silver salts and the labour intensive nature.  In light of these 
factors, our efforts were directed to improving the synthetic procedure. 
3.3.1 AQUEOUS DIRECT LIGAND EXCHANGE 
The possibility of direct ligand exchange was therefore investigated viz.  
Pt(dach)Cl2  +  C2O42-
2Cat+
Pt(dach)(C2O4)   +   2Cl-
2Cat+  
The fact that one dianionic species, is replacing two monoanionic species, will be 
favoured by the “entropy effect”.  This should produce an additional driving force 
for the reaction.  However, elevated temperatures will be required to drive the 
reaction in a relatively short time.  Oxalate is a reducing agent, due to the C-C 
single bond and the two oxygen atoms on both sides withdrawing electrons out of 
it. 
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O
O-
O
-O
Oxalate anion  
When direct ligand exchange is used in the formation of [Pt(C2O4)2]2- from [PtCl4]2- 
through heating the chloro complex in the presence of a mild excess of oxalate, 
some black colloidal platinum is formed. It was shown that this does not occur 
when a large excess of oxalate is used81. 
Preliminary experiments were performed in which Pt(dach)Cl2 was heated with 
excess sodium and potassium oxalate.  Some replacement occurred, but the 
separation of the product from the salts of both chlorides formed (sodium and 
potassium) and excess oxalate, was virtually impossible, due to the similarity of 
the solubilities of oxaliplatin and the sodium and potassium salts.  All these were 
only soluble in water and with similar solubilities. 
Experiments were then performed using caesium oxalate and 
tetrabutylammonium oxalate.  These salts were chosen because of their 
solubilities in non-aqueous solvents, like for example alcohols.  It was however 
found that these solvents could not remove these salts by extraction from  
aqueous solutions. Thus, we were still without a solution to solve the separation 
problem we were faced with. 
3.3.2 DIRECT LIGAND EXCHANGE FROM K2PtOx2 
It is known that PdL2Ox complexes can readily be prepared from K2PdOx2 80 (L = 
monodentate neutral ligand).  A similar reaction has not been recorded for the 
analogous platinum complex.  This reaction was thus also considered, as a 
possibility for the synthesis of oxaliplatin.  
From the reaction of diamines, such as en with K2PtCl4, it was learned that a 
number of simultaneous equilibria exist, of which the following are the most 
important: 
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2K+   +    PtCl42-   +   en Pt(en)Cl2   +   2KCl                        (1)
2K2 PtCl4   +   2en [Pt(en)2
2+][PtCl42]-   +   4K+  +  4Cl -       (2)  
When en is directly added to a solution of [PtCl4]2-, the product in equation 2 is the 
major one.  However, if a buffered solution of en (pH 6) is added, the product in 
eq. 1 can be formed in larger amounts. 
When the free amine, DACH, was slowly added to an aqueous solution of 
K2PtOx2 at 90°C, a yellow product readily precipitated.  This product contains 
almost purely [Pt(dach)2]2+[PtOx2]2-.  Oxaliplatin could not be recovered from this 
product.  If, however, the DACH solution was buffered with glacial acetic acid, to 
between pH 6 and 7.5 and then added to the hot K2PtOx2 solution half hourly, in 
eight increments at 90°C, a relatively large amount of the monomolecular species, 
oxaliplatin is formed.  From this solution, it was possible to produce pure 
recrystallized oxaliplatin in a 20% yield. This method was successfully patented.81 
3.4 LIGAND EXCHANGE IN AN ESSENTIALLY NON-AQUEOUS SOLVENT 
SYSTEM 
In light of the disadvantages of an aqueous solution in the use of oxalate, which is 
known to reduce platinum(II) to platinum black at elevated temperatures64,82, and 
the rapid hydrolysis rate of platinum(II) chloro complexes in water, it was decided 
to investigate the use of a different solvent system.  
The purpose is to exchange two chloro ions for one oxalate ion in the square 
planar platinum(II) complex. 
Cl
Cl
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Pt
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3.4.1 REQUIREMENTS FOR THE SOLVENT SYSTEM  
(i) A solvent system, in which both of the reagents are soluble enough to 
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allow for reaction.  Preferably, the oxalate salt must have greatly different 
solubility properties to the product, (oxaliplatin).  This will facilitate the 
isolation of the oxaliplatin. 
(ii) A dielectric constant (εm), which will allow enough ionization to enable 
ligand exchange, (part of the driving force for the reaction is the 
replacement of a monodentate ligand (Cl-) with a bidentate one (C2O42-),  
thus an entropy driven reaction). 
(iii) A solvent system, in which solvation can occur, but preferably not 
solvolysis. The anation of a neutral oxygen donor ligand (replacement by 
an anion) from the coordination sphere of the platinum(II), e.g. anation of 
[Pt(OH2)] species will occur readily, since negatively charged donor 
ligands are normally stronger donors than neutral ones.  In the case of a 
solvolyzed species, e.g. replacement of the [Pt-OH] species will not occur 
readily at a neutral pH. 
(iv) A solvent system, in which the product (oxaliplatin) is insoluble and all the 
other species soluble will be very useful, since it will provide additional 
driving force to the reaction and minimize decomposition of the oxaliplatin.  
Dmf as non-aqueous solvent 
In terms of the above criteria, dmf appeared to have the most acceptable 
properties to be used as non-aqueous solvent.  Its εM (dielectric constant) value is 
36.1 and its DN (donor number) is 26.6.  Thus, ionization of the oxalate salt should 
occur readily and adduct formation (solvation) of the cationic platinum(II) species 
can be expected.   
Both oxaliplatin and Pt(dach)Cl2 are somewhat soluble in dmf.  Inorganic oxalate 
salts, however, are hardly soluble in dmf as solvent, with Cs2C2O4 being the most 
soluble, especially if dmf contains a small amount of water.  Since a large excess 
of oxalate was required to drive the reaction and the ready separation of it from 
the product (oxaliplatin) a requirement, an oxalate salt which is very compatible 
with the non-aqueous solvent was necessary.  This is particularly true when the 
high charge density (hard nature) of the oxalate ion, with its resulting low 
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polarizability, is borne in mind. To this end, bulky alkylated ammonium ions could 
be considered suitable, provided that they are of the quaternary type, since the 
presence of free amines is possible in tertiary or secondary ones.  For non-
aqueous compatibility, cations of low charge density - thus high polarizability (i.e. 
high molar refractivity RD) - will be required.   
The relationship between charge density of a number of cations, as expressed in 
terms of the inverse of their radii or thermal radii, is illustrated with reference to their 
polarizability parameter, RD, and is plotted in Figure 3-1.  See also the data in Table 
3-1.  It is also of interest to investigate the relationship between polarizability and 
softness (σ), as defined by Marcus.83  The latter is a measure of the tendency of an 
ion to engage in covalent bonding.  The relationship between normalized 
polarizability of cations and their softness (σ) is given in Figure 3-2 and Table 3-2.  
The rapidly increasing polarizability of the quaternary ammonium cations, with 
increasing size of the alkyl groups and thus increasing softness, is also reflected in 
their reaction with water.  The hydration number (hi) of Nme4+ is only 1.8 and those of 
the larger ones Net4+ – Nbut+ are all zero.84  This behaviour can also be interpreted as 
their increase in compatibility with non-aqueous solvents. 
In light of the above information, we obtained the oxalates of TEA, TPA and TBA 
cations, and determined their non-aqueous compatibility. In these ion pairs the 
cations are very soft, but the counteranion is very hard.  The oxalate ion is very polar 
with a large charge density.  The ΔGhydr of similar ions containing dianionic oxygen, 
are high, e.g. SO42- and CO32- are -930 and -1315 kJ/mole respectively as compared 
to -340 for Cl-.  Such an anion will thus be incompatible with a non-aqueous aprotic 
solvent.  We, therefore, used a solvent with a small percentage of water (dmf 95% 
water 5%).  The charge density of the oxalate is thus greatly reduced by it being 
partly hydrated. However, only the TBA salt was freely soluble in such a medium of 
dmf (95%) and water (5%).  It can be seen that the relatively small amount of water 
partially hydrates the oxalate ions, thus lowering its charge density resulting in 
greater organic compatibility.  
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Figure 3-1  Plot of polarizability (RD) vs 1/r for bulky cations. 
 
Table 3-1 Polarizability (RD) and inverse radii (1/r) of some large cations. 
 
Ion RD 1/r 
As(C6H5)4+ 115 2.34 
Nbut4+ 79 2.42 
Nprop4+ 61 2.63 
Net4+ 39 2.96 
Nme4+ 23 3.57 
Cs+ 6.71 5.92 
NH4+ 4.7 7.81 
K+ 2.71 7.52 
 
Table 3-2 Softness (σ) and Normalised polarizability (RD/10) of some large cations 
 
Ion Softness(σ) RD/10 
Li+ 115 2.34 
Na+ 79 2.42 
NH4+ 61 2.63 
K+ 39 2.96 
Cs+ 23 3.57 
Rb+ 6.71 5.92 
(CH3)4N+ 4.7 7.81 
(C6H5)4As+ 2.71 7.52 
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Figure 3-2 The relationship between polarizability of cations (RD/10) are their 
softness(σ). 
3.4.2 DIRECT LIGAND EXCHANGE FROM Pt(dach)Cl2 
Ligand exchange using metal oxalates 
The logical source of oxalate for the above purpose, would be metal oxalates.  
The common ones viz. Na2C2O4 and K2C2O4, are insoluble in dmf.  The heavier 
alkali metal oxalates, are much more soluble in water, e.g.  283g of Cs2C2O4 
dissolve in 100 ml of cold water! 
Experiments were subsequently performed using Cs2C2O4 as source of oxalate 
The main disadvantage of this system however, was the scarcity and expense of 
Cs2C2O4 and thus this method was not pursued. 
Tetrabutylammonium as source of oxalate 
The greater organic character endowed by the organic cation and its relatively 
weak ion-pairing with oxalate would enable adequate solubility in the non-
aqueous reaction medium, as well as allowing its subsequent removal from the 
hydrophilic oxalatoplatinum(II) product.  Furthermore, the disparity in size between 
cation and anion was not excessively large to render the salt terribly thermally 
unstable.  Tetrabutylammonium oxalate was chosen, since the oxalates of the 
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smaller tetraalkyl analogues were not soluble enough in dmf.  This salt was not 
commercially available.  Thus it was synthesized by reacting the 
tetrabutylammonium hydroxide solution with pure oxalic acid in a 2:1 mole ratio. 
The salt is extremely hygroscopic.  Upon heating the solid to 80°C it gradually 
darkens.In light of the previous observation, a temperature of 65°C and a solvent 
mixture of ~90% dmf and 10% water was initially used.   
The next question was whether or not to use an excess of oxalate.  Chemical 
potential is an important factor in direct ligand exchange reactions and indeed an 
excess of oxalate would be expected to enhance the forward reaction.  However, 
as mentioned earlier, oxalate is a reducing agent and its ability to reduce 
platinum(II) to platinum(0) is known64,82.  Thus, from a chemical point of view, it 
would make no sense to react an excess of a reducing agent with platinum(II) at 
elevated temperatures.  Indeed, this could very well have been the reason why 
such reactions have been poorly studied.  However, our work on the synthesis of 
bisoxalato complexes of platinum(II), as patented81, indicated that a large excess 
of oxalate, under appropriate conditions, can actually enhance the formation of 
the oxalate product and stabilize it, thus overcoming its reducing power.  On this 
basis, we decided to experiment with various oxalate to Pt(dach)Cl2 ratios, viz. 
1:1.5, 1:2.5 and 1:5.  
Temperature range 
Ligand exchange in the silver method is performed at room temperature, since the 
driving force in that case is the affinity of Ag+ for halide and the insolubility of the 
silver halides.  In the case of direct ligand exchange of Cl- with oxalate, the driving 
force is only enhanced chemical potential of oxalate by using an excess and the 
bidentate nature of oxalate, thus resulting in a “chelate effect”.  Higher 
temperatures are therefore required to achieve exchange in a reasonable time. 
3.4.3 KINETIC DATA 
At this stage, it was realized that kinetic data was required to improve insight into 
the intricacies of this reaction.  The effects of temperature, varied between 70°-
85°C, and oxalate concentration (varied from 1.5 - 5.0 mol equivalents) were thus 
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investigated.  Use was made of LC-MS in which the concentrations of Pt(dach)Cl2 
and oxaliplatin were monitored as a function of time. All experiments were 
performed in 95% dmf (as will be explained later). 
In Figure 3-3 to Figure 3-6, the normalized concentrations of the molecular forms 
of both Pt(dach)Cl2 and oxaliplatin are plotted as a function of time during their 
reactions for each of the temperatures: 70°C (Figure 3-3); 75°C (Figure 3-4), 80°C 
(Figure 3-5) and 85°C (Figure 3-6).  In each figure, the data is plotted for three 
different Pt(dach)Cl2:TBAOx ratios (1.5, 2.5 and 5.0).  
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Figure 3-3 Normalised concentrations of oxaliplatin and Pt(dach)Cl2 measured over a 
period of time during a reaction performed at 70C and at 3 Pt(dach)Cl2:TBAOx molar 
ratios. 
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Figure 3-4   Normalised concentrations of oxaliplatin and Pt(dach)Cl2 measured over a 
period of time during a reaction performed at 75C and 3 Pt(dach)Cl2:TBAOx molar 
ratios. 
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Figure 3-5   Normalised concentrations of oxaliplatin and Pt(dach)Cl2 measured over a 
period of time during a reaction performed at 80C and 3 Pt(dach)Cl2:TBAOx molar 
ratios. 
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Figure 3-6   Normalised concentrations of oxaliplatin and Pt(dach)Cl2 measured over a 
period of time during a reaction performed at 85C and 3 Pt(dach)Cl2:TBAOx molar 
ratios. 
 
The pronounced increase in reaction rate, with increase of temperature, is reflected 
by these curves.  The times taken for the formation of ~33% of oxaliplatin 
theoretically is: 11.5 hr (70°C); 7 hr (75°C), 5 hr (80°C) and 3.5 hr (85°C).  From 
Figure 3-3 to Figure 3-6 it can be seen that the increase in the oxalate concentration 
has a relatively small effect on the formation of the oxaliplatin.   
In Figure 3-7, the rate curves for 70°C are compared with those of 85°C, to enable a 
more direct observation of the effect of temperature under the same conditions of 
excess oxalate (1:5.0).  
It is also noticeable that the formation of oxaliplatin levels off at ~65% after ~7 hr 
at 85°C. The most obvious explanation for the observation would be that due to 
limited solubility, oxaliplatin has reached a maximum concentration in the reaction 
mixture (95% dmf). 
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Figure 3-7 A display of the formation of oxaliplatin and the decrease in Pt(dach)Cl2 in  
reactions performed at 70C vs. 85C at a molar ratio of Pt(dach)Cl2:TBAOx of 1:5 
measured over a set period of time. 
 
To test this hypothesis, an experiment was performed in which the reactions were 
repeated at the same ratios of PtLCl2 to TBAOx (1:5.0 at 80C in 95% dmf), but 
the absolute concentration of the reactants were diluted to 75, 50 and 25% of the 
concentration used in the study depicted above. The findings showed that the 
observed decrease in expected oxaliplatin concentration was not due to solubility 
limitations. 
The levelling off of the oxaliplatin concentration can be interpreted in terms of the 
equilibrium reached for the formation in equation (1), since this reaction is reversible. 
Pt(dach)Cl2   +   Ox2- Pt(dach)Ox   +   2Cl-                                        (1)  
It is also noticeable that the Pt(dach)Cl2 concentration in the 85°C case continues 
to decrease to ~zero after 20 hr.  If this is due to the reaction in equation (1), then 
the oxaliplatin formation curve should correspond with the top curve in Figure 3-8 
(a replot of the 85°C Figure 3-7).   
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In Figure 3-8 is also plotted the oxaliplatin formation curve for the ratio of 1:1.5.  
This clearly suggests some degradation of Pt(dach)Cl2 upon prolonged heating.  
The oxaliplatin formation curve for the ratio of 1:1.5 indicates that some 
decomposition of oxaliplatin also occurs.  These results will be put into 
perspective after the thermal degradation studies.   
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Figure 3-8   Depiction of the difference between the expected and actual 
concentrations of Pt(dach)Cl2 and oxaliplatin  for reactions performed at 85C and 
molar ratios 1:1.5 and 1:5 Pt(dach)Cl2:TBAOx 
3.4.4 THERMAL DEGRADATION STUDIES ON Pt(dach)Cl2  
As a function of solvent 
This study was performed using the following solvents.  
A mixture of : 5% dmf 95% water 
  50% dmf 50% water 
  pure dmf 
All of these were done at 70°C, while measuring the concentration of the neutral 
Pt(dach)Cl2 intermittently for up to 15 minutes.  
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Figure 3-9   Degradation of Pt(dach)Cl2 at 70C in the presence of varying dmf:water 
mixtures. 
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Figure 3-10  Display of the formation of [Pt(dach)Cl2-Cl+MeCN] upon degradation of 
Pt(dach)Cl2 at 70C in the presence of varying dmf:water mixtures. 
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Figure 3-11  Display of the formation of [Pt(dach)Cl2-Cl+dmf] upon degradation of 
Pt(dach)Cl2 at 70C in the presence of varying dmf:water mixtures. 
 
In Figure 3-9 the “disappearance” of the Pt(dach)Cl2 molecular species is plotted 
against time in each of the three solvent systems at 70°C.  Rapid destruction 
occurs in the 5% dmf:95% H2O system. The concentration at T0 is already much 
lower than the starting concentration, since the reading could not be taken quickly 
enough.  The 50% dmf solvent system has an intermediate degradation rate, 
whereas no reaction occurs in the 100% dmf.  
In Figure 3-10 the formation of the most prominent solvated product viz. [M-
Cl+MeCN] + was plotted as a function of time and solvent system.  Once again no 
reaction occurred in pure dmf. The decomposition rate of Pt(dach)Cl2 increases 
very significantly with water content.  The mass spectral data revealed that three 
solvated species are present, viz. the mono aqua, mono acetonitrile and mono 
dmf species.  In this figure the acetonitrile adduct reaches the highest 
concentration in the 5% dmf system.  In Figure 3-11 the dmf adduct reaches the 
highest concentration in the 50% dmf system - both this concentration and that of 
the MeCN adduct, reaches a plateau after ~10 min. 
Interpretation of data 
The first noticeable fact is that no solvation occurs in pure dmf, even at 70°C.  In 
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pure water, solvation occurs very rapidly (See Figure 3-12).   
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Figure 3-12   Degradation of Pt(dach)Cl2 at 70C in the presence of varying dmf:water 
mixtures as well as in 100% water. 
 
In these dmf/H2O mixtures, the mono aquated species always has a low 
concentration.  This can only be interpreted that the coordinated water is very 
readily replaced by both MeCN and dmf.  This could explain why no solvation 
occurs in pure dmf as solvent.  The concentration level of the mono aqua complex 
is kept low by its replacement by the other donor solvents.  The ionization of 
chloride occurs much more readily in a protic solvent such as water, which can 
solvate both cation and anion as compared to the aprotic MeCN and dmf.   
Coordinated water in platinum(II) can thus very rapidly be replaced by the MeCN 
and dmf, the latter two are in competition.  At low dmf concentration (5% dmf) the 
CH3CN dominates.  At high dmf concentration (50%), the dmf adduct dominates.  
This is demonstrated in Figure 3-13 and Figure3-14. Ions at m/z361, m/z386 and 
m/z418 can be ascribed to the monosolvates viz. aqua, methylcyanide and dmf 
respectively.  
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Figure 3-13 Time lapse mass spectra showing the decrease in Pt(dach)Cl2 concentration 
together with the increase in concentration of both monosolvates, [Pt(dach)Cl-Cl+dmf] and 
[Pt(dach)Cl-Cl+MeCN] in 5% dmf. 
 
 
 
 
 
 
 
 
 
Figure3-14 Time lapse mass spectra showing the decrease in Pt(dach)Cl2 
concentration together with the increase in concentration of both monosolvates, 
[Pt(dach)Cl-Cl+dmf] and  [Pt(dach)Cl-Cl+MeCN]in 50% dmf. 
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Degradation of Pt(dach)Cl2 in pure water at 70°C 
The curve in Figure 3-12, shows the decrease in concentration of the molecular 
species.  The simultaneous formation of three different detectable species occurs, 
viz. [M-Cl+H2O]+, [M-2Cl+2H2O]+ and a suspected dimeric species, with the 
former being the most important over 20 min.  The degradation at 70°C in a 95% 
dmf / 5% H2O solvent system over the same time is only marginal. Under these 
conditions, only small amounts of the mono aqua species are detectable.  
The previous investigation illustrated the stabilizing effect that dmf has as part of 
the mixed solvent system on the stability of Pt(dach)Cl2.  It was also possible to 
obtain information of the solvated species present.  
Degradation as a function of extended time 
It is now necessary to investigate how Pt(dach)Cl2 degrades over the full time of 
the synthetic reaction.  
 In Figure 3-15 the decrease in the concentration of Pt(dach)Cl2 in a 95% dmf / 
5% H2O solvent system, over a 20hr period, is  presented as a function of 
temperatures, ranging from 70°C to 85°C (5°C steps).  The drastic influence of 
elevated temperatures is clearly illustrated.  However, if the decrease of the 
Pt(dach)Cl2 concentration in a reaction at 85°C, having a 1:5 fold excess of 
oxalate is plotted (lined curve), then it indicates how much faster the ligand 
exchange reaction occurs; as compared to the degradation of Pt(dach)Cl2 alone.  
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Figure 3-15 Degradation of Pt(dach)Cl2 over an extended period of time at 70, 75, 80, 
85C versus the decrease in concentration of Pt(dach)Cl2 at 85C in a reaction of a 
molar ratio of Pt(dach)Cl2:TBAOx of 1:5 in 95% dmf 
 
3.3.5 THERMAL DEGRADATION STUDIES ON OXALIPLATIN 
It is also necessary to determine the thermal degradation of oxaliplatin in the 
solvent system employed for the ligand exchange reaction. 
The degradation of oxaliplatin in a solution of 95% dmf / 5% H2O is plotted against 
time up to 20 hours at temperatures of 70, 75, 80 and 85°C, respectively.  The 
effect of temperature is clearly illustrated in Figure 3-16.   
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Figure 3-16  Degradation of oxaliplatin over an extended time period at 70, 75, 80 and 
85C in 95% dmf. 
 
It is also noticeable that oxaliplatin degrades to a lesser extent than Pt(dach)Cl2.  
This is to be expected, in view of the slower kinetics experienced for the 
dicarboxylate as compared to the chlorides and the greater stability of the 
complex of the bidentate anionic ligand.  
Experiments were conducted to determine how the degradation of oxaliplatin in 
the presence of excess TBAOx behaves.  
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Figure 3-17  A display of the effect that TBAOx has on the degradation of oxaliplatin in 
the presence of varying ratios of TBAOx. 
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The results of this study are depicted in Figure 3-17.  It was found that at 80°C 
(15 hr) pure oxaliplatin degrades by 45% in 88% dmf.  In the presence of excess 
TBAOx, for a ratio of 1:5, only 13% degradation occurs.  It was also found that the 
amount of excess TBAOx has little influence, providing it is more than 1, i.e. a 
ratio of 1:2 platinum to oxalate.  This can readily be visualized if the degradation 
reaction is assumed to be: 
Pt(dach)Ox   +    H2O [Pt(dach)(H2O)2]2+  +   Ox2-  
3.4 CLARIFICATION OF SOME EARLIER RESULTS 
A reconsideration of the curves in Figure 3-7, paying particular attention to points 
A, B and C, indicates that a mol % formation of oxaliplatin of 43.8% at 85C, is 
attained approximately 10 hours earlier than in the case of the same reaction 
performed at 70C.  However, despite this difference in time (3.2 hr at 85C and 
13.3hr at 70C), it was found that the concentration ratios of oxaliplatin to 
Pt(dach)Cl2 are the same in this solvent systems. This is interesting, since it 
indicates that up to those points in each case, no significant destructive 
degradation of oxaliplatin and Pt(dach)Cl2 occurred, in spite of the 10hr difference 
in reaching that stage.  Although the formation reaction is much slower at 70°C, 
the same applies to the destructive degradation of Pt(dach)Cl2.  Excess oxalate in 
the solution protects against the degradation of oxaliplatin.  These facts thus also 
suggests that the decrease in Pt(dach)Cl2 concentration, up to that stage, is 
partially only due to progress of the reaction to the right hand side. 
Pt(dach)Cl2   +   TBAOx Pt(dach)Ox   +   2TBACl  
The levelling off of the oxaliplatin concentration at ~65% formation must be due to 
the attainment of the equilibrium (ratio of 1:5.0 / 85°C).  The further rapid 
decrease in Pt(dach)Cl2 concentration can certainly be accounted for by the 
destructive thermal degradation of Pt(dach)Cl2, i.e. after equilibrium has been 
reached.  The formation curve of oxaliplatin, for the ratio of 1:5.0, shows little 
decomposition of oxaliplatin due to the large excess of TBAOx.  The case for the 
ratio of 1:1.5 does show decomposition, since the excess of TBAOx is too small to 
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stabilize it.   
When all the above facts are borne in mind, we are confident that equilibrium of 
the above reaction is reached at 65% formation of oxaliplatin under these 
conditions.  
Thus taking all this into accoumt, the reaction was performed at a mole ratio of 
Pt(dach)Cl2:TBAOx of 1:1.5 at a temperature of 65-70C for approximately 20 
hours in a 95%dmf / 5%H2O solvent system. Under these conditions, the crude 
product was recoved in 98% purity, as seen in the chromatogram below, and 50% 
yield. Loss of product can be ascribed to oxaliplatin being slightly soluble in dmf. 
This method has been successfully patented85. 
 
 
Figure 3-18  LC-UV separation of a crude sample of oxaliplatin obtained using a YMC 
C18 Hydrosphere (250x4.6mm; 5m) and an eluent consisting of 1%MeCN/0.06% 
H3PO4  at 1ml/min detected at 210nm 
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CHAPTER 4 
NEW ASPECTS OF DIAMINE PLATINUM COMPLEXES 
4.1 INTRODUCTION 
As mentioned in Chapter 1, since the discovery of cis-diaminedichloroplatinum(II), 
[cis-(NH3)2PtCl2], Figure 4-1, clinically called cisplatin, thousands of platinum 
complexes, mainly amine chloro complexes, have been synthesized and 
evaluated for their anticancer activity.   
 
Pt
H3N Cl
ClH3N  
Figure 4-1   A representation of cis- diaminedichloroplatinum(II). 
However, only a few of these complexes have entered clinical trials.  Worldwide, 
only two of these viz. cisplatin and carboplatin are in use, and recently oxaliplatin 
(see Figure 4-2) in Europe and the USA.  
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Figure 4-2  In this figure “a” refers to carboplatin and “b” refers to oxaliplatin. 
The limitations of cisplatin have stimulated research in the field of platinum 
antitumour chemistry by giving specific goals.  These include - reduction in toxicity 
associated with cisplatin (nausea, ear damage, vomiting, loss of sensation in 
hands and kidney toxicity); overcoming circumstances of the acquired drug 
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resistance observed in certain tumours and an increased spectrum of activity - 
since cisplatin is inefficient against some of the commonest tumours (e.g. colon 
and breast).  
Enormous efforts have been directed to understand the mechanism of the 
cytotoxic activity of cisplatin, as well as additional parameters which can promote 
the efficiency of the action. Some of these factors, which were recently realised to 
have important bearing on antitumour activity, will now be investigated, with 
emphasis on their fundamental nature. Some of these have already been 
discussed in Chapter 1, but for completeness, will be touched on briefly here. 
4.1.1  LIGAND EXCHANGE RATE 
Halide ions 
(i) Chloro species  
It was soon realized that the extent of ionization of cisplatin (see reaction 1) can 
be related to the large number of its negative effects.  
(NH3)2Pt(H2O)Cl+   +    Cl-
H2OH2O
(NH3)2PtCl2 (NH3)2Pt(H2O)2
2+   +    Cl- (1)  
These aqua complexes are very reactive and react with donor biomolecules having N 
and/or S donor atoms such as guanine’s nitrogen atoms and gluthione’s S atoms  
The most likely mechanism for ligand exchange is through the formation of a trigonal 
bipyramidal (tbp) coordination expanded intermediate complex.  Such a mechanism 
requires less activation energy under normal conditions when compared to bond-
breaking, i.e. an SN1 mechanism, as discussed in the introduction.  It is also known 
that one way of slowing down the rate is to use stereochemical blocking to 
demotivate the formation of the tbp intermediate.   
A typical example of this behaviour is found for [cis-(2-
methylpyridine)amineplatinumdichloride], i.e. the stereochemically crowded        
picoplatin, indicated in Figure 1-5.  This compound has a slower ionization rate 
than cisplatin and cancer cells had lower resistance to ZDO473.25  It is known that 
detoxification by elevated glutathione levels is one of the resistance mechanisms.  
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This complex thus, although slower to ionize, reaches the same level of 
platination and lesser detoxification by S-containing biomolecules.  Another 
advantage of slower ionization is that lesser negative effects occur in the blood 
where the Cl- concentration is 100 µM.  This allows the complex more time to 
reach the cancer cell - which has a much lower Cl- concentration (~40µM) - and 
thus more rapid formation of the active aqua species is formed intracellularly.  
(ii) Bromo species 
Since the platinum-bromide bonds have somewhat higher covalent character than 
those of their chloro-analogues, it could be expected that the resulting increase in 
kinetic stability will result in a lesser degree of ionization and thus lower 
concentrations of the platinum aqua-complexes.  Although this is only one 
parameter involved in anticancer action, it could result in some improved 
behaviour.  Although bromocomplexes have hardly been studied, there are some 
cases in which these have superior anticancer action when compared to their 
chloro analogues. 
(iii) Iodo species 
The increase in covalent character from bromo to iodo platinum, is so large and 
the increase in their kinetic stability to such an extent, that these have virtually no 
anticancer action.  These complexes also have very low aqueous solubilities.  
This, however, is a useful property for exploitation in synthetic processes, since 
the iodocomplexes can be isolated in a high degree of purity and in a high yield 
(see application later in this chapter).  
(iii) Dicarboxylates 
The extent of ionization can also be limited through using dianionic leaving 
groups such as dicarboxylates.  The malonato species, (cis-diamine-1,1’-
cyclobutanedicarboxylateplatinum(II) (carboplatin), is a good example of this.  
Ionization in this compound is a hundred fold reduced as compared to 
cisplatin27.  Carboplatin was readily accepted due to the equivalence of its 
efficacy as compared to that of cisplatin, but also owing to its significantly reduced 
non-haematological toxicity (emesis, nephrotoxicity and ototoxicity), as observed 
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in a large number of patients. 
4.1.2  STRUCTURE OF THE NON-LEAVING GROUP / LIGAND 
In a prior paragraph, it was already indicated how stereochemical crowding by the 
non-leaving group of a platinum(II) complex can influence its anticancer action by 
slowing down the extent of ionization.  In addition to this, it was also shown that if 
a non-leaving ligand has a “planar” group at an angle with the platinum(II) 
coordination plane, it could assist in the platination of the DNA.  The DACH ligand 
in oxalato(trans-ℓ-1,2-diaminocyclohexane)platinum(II) i.e. oxaliplatin, is thought to 
penetrate the major groove in the DNA31 , thus assisting in its binding to DNA.  
There are also suggestions in the literature, that a bulky planar group as the non-
leaving ligand has a similar effect as described for the dach ligand. 
Ideally speaking, a suitable platinum anticancer compound should have a 
considerable hydrophobic part to facilitate cell wall transport. This however, 
restricts its aqueous solubility.  In order to achieve this, it was found preferable to 
introduce an oxygen containing group, such as OH, as part of the the non-leaving 
group part or otherwise to use an oxygen containing leaving group, such as 
carboxylate or dicarboxylate, e.g. oxalate or malonate.  
The factors discussed above were considered in this study of platinum amine 
complexes and the results will be described in paragraphs in which the common 
factor will be the leaving group.  All of these are bidentate ligands which interact 
with the platinum in the form of chelate rings, enhancing the stability of the 
complexes.  The general synthetic methods were described in Chapter 2 and will 
only be referred to in case of significant differences. The cationic form of all the 
complexes following will, for simplicity reasons, be defined as Yolx, where x = a 
number relating to the non-leaving groups, whereas the associated different 
leaving groups will be referred to by .2 for Cl-; .3 for Br-; .5 for I- and .1 for C2O42-.  
For example, yol25.2 is the platinum(II) chloro complex of ligand 25; L-hme. See 
Appendix for common names and chemical formulas used throughout this 
thesis when referring to complexes. 
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4.1.3  NON-LEAVING GROUPS INTRODUCED 
The ligands to be described in the following paragraphs were employed as non-
leaving groups in the synthesis of the complexes in this thesis. 
 L-histidine methyl ester (ligand 25, see Figure 4-3), the methyl ester form of this 
ligand was selected, since it can act as a neutral diamine ligand which is 
biocompatible. The effects of amino acids on anticancer action have been well 
studied, however the presence of the anionic group in the form of the carboxylate, 
greatly influences their behaviour as anticancer agents. The affect of the anionic 
part has been cancelled by the esterification, although the presence of the oxygen 
atoms should enhance the aqueous solubility of the platinum(II) complex. It was 
also hoped that the aromatic nitrogen of the imidazole constituent would make for 
a small enough cone-angle which would enable a close metal-ligand approach 
and therefore a strong bond. In addition, the polar nature of the ring and the 
presence of another nitrogen, would impart some degree of water solubility. 
Furthermore, an aromatic N-donor involved in platinum bonding would allow a 
more thermodynamically stable bond due to its  - backbonding capability. 
The selection of 2-aminobenzylamine (ligand 29, see Figure 4-4), was based on 
the premise that the benzyl structure would provide a potential of an angular plane 
of the ligand in terms of the coordination plane of the platinum(II). This 
phenomenon was thought to assist in the platination of the complex86.  
The ligand 2-aminoethylaminoethanol is a derivative of ethylenediamine, 
containing CH2CH2OH attached to one of the nitrogens of the diamine. The choice 
of  2-aminoethylaminoethanol (ligand 31, see Figure 4-5), was largely due to the 
presence of the hydroxide group and its implied capability to render the diamine 
complex more water soluble, which is normally a problem with this type of 
complex. It was also thought that the presence of the CH2CH2OH group would 
further stabilise the platinated DNA-adduct by hydrogen bonding. This supposition 
was based on the structure of the cisplatin-DNA adduct, in which the major 
interaction is a 1,2d(GpG) intrastrand cross-link, formed by platination of the N(7) 
sites of the guanine bases87. 
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On the other hand, the choice of N-benzylethylenediamine (ligand 33, see Figure 
4-6) was based on the possibility of having an angular plane with respect to the 
coordination plane of the platinum(II) (such as in the case of 2-
aminobenzylamine), but with the presence of a longer alkyl chain and the absence 
of any hydroxyl group (unlike 2-aminoethylaminoethanol), improving its 
hydrophobicity.  
The selection of N-cyclohexyl-1,3-propanediamine (ligand 35, see Figure 4-7), 
was a dual one. Firstly, it provided a comparison of a propylene diamine with an 
ethylenediamine, and secondly, to investigate the influence of a cyclohexyl group 
(non-planar). Another motivation would be its comparison to the DACH (1,2- 
diaminocyclohexane) ligand, in that it too contains a relatively large hydrophobic 
group. In the case of DACH, it is believed that the presence of the hydrophobic 
group is related to the apparent efficacy of its platinum complexes.88,89 
These bidentate ligands would each form either a 5-membered or 6-membered 
ring with the platinum(II) metal centre, which would supply the eventual complex 
with additional stability and an immunity to ligand substitution as a result of the 
chelate effect. The preference for platinum to form thermodynamically stable 
bonds with nitrogen donors has also been exploited here.  
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Figure 4-3  On the left, a ball and stick 3D representation of L-histidine methyl ester, 
while on the right you have a 2D representation of the same ligand. (Ligand 25) 
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Figure 4-4   On the left, a ball and stick 3D representation of 2-aminobenzylamine, 
while on the right you have a 2D representation of the same ligand. (Ligand 29) 
 
 
H
N
NH2HO  
Figure 4-5   On the left, a ball and stick 3D representation of 2-aminoethylamino 
ethanol, while on the right you have a 2D representation of the same ligand. (Ligand 
31). 
 
 
H
N
H2N  
Figure 4-6   On the left, a ball and stick 3D representation of N-benzylethylenediamine, 
while on the right you have a 2D representation of the same ligand. (Ligand 33). 
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Figure 4-7   On the left, a ball and stick 3D representation of N-cyclohexyl-1,3-
propanediamine, while on the right you have a 2D representation of the same ligand. 
(Ligand 35) 
4.2  COMPLEXES 
4.2.1  CHEMICAL ASPECTS RELEVANT TO SYNTHESIS 
It is worth mentioning that the chemical properties of platinum largely determine 
the procedures and types of reactions that are feasible. As already mentioned, 
dominant features include the slow rate of ligand exchange and the associated 
dominance of the trans-effect and the preference for soft donor atoms in ligands 
such as nitrogen, sulfur and phosphorous. The fact that a single starting material 
(viz. K2PtCl4) is extensively applied in the syntheses of most platinum complexes 
in the literature is important, and thus deserves some attention. 
The general reaction types are given in equations 2 - 4 
PtX42- (aq)   +   L PtLX2(aq)  +   2X-
PtLX2(aq) PtLX2(s)
2PtLX2(aq) PtL2
2+(aq)  +  PtX42-(aq)
PtL22+(aq)  +  PtX42-(aq) PtL2PtX4(s)
PtLX2(aq)  +  L PtL22+(aq)  +  2X-(aq)
PtL22+(aq)  +  PtOx22- PtL2PtX2(s)
(2)
(2a)
(3)
(3a)
(4)
(4a)
 
Where reactions 2 & 2a refer to molecule formation; reactions 3&3a refer to auto-
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ionization and reaction 4 refers to ionization. Furthermore X = monoanionic 
leaving group; L= bidentate leaving group (or two monodentate leaving groups) 
and Ox = oxalate; to illustrate that similar equilibriums are applicable for dianionic 
leaving groups as well. 
The reactions represented by equations 2 and 2a are very important since the 
molecular form of the complex possesses the greatest promise as anticancer 
agents. Cisplatin is a typical example of this.  
In contrast to the molecular species, very few, if any, auto-ionized species - 
represented by equations 3 and 3a - are of beneficial relevance in anticancer action. 
The same can be said about the ionized species represented by equation 4. The 
occurrence of auto-ionization is of relevance, since this reduces the yield of the much 
sought after monomeric species. It is this particular incident that has restrained the 
synthesis of cisplatin to the extent that direct addition of ammonia to K2PtCl4 is not an 
option - due to the formation of the so-called Magnus green salt, [Pt(NH3)4][PtCl4]90. A 
similar event takes place upon the addition of an unbuffered solution of 
ethylenediammine, a bidentate nitrogen donor ligand, to K2PtCl4.91  This occurs as 
the result of the high lattice stabilization of the dianionic species, PtCl42- and the 
dicationic species, Pt(en)22+, which coexist during ligand addition, resulting in the 
precipitation of the undesired insoluble [Pt(en)2Pt(Cl4)]. 
Thus it is understandable that certain precautions have to be taken so as to avoid 
unwanted side-reactions. These included; adherence to stoichiometric ratios, 
temperature control and slow addition of the ligand. 
4.2.2  IODOPLATINUM(II) COMPLEXES 
The iodocomplexes of the amine ligands were prepared in spite of their known 
inertness as anticancer agents.  These are useful for the preparation of 
complexes with other leaving groups such as bromides, oxalates, etc. where the 
“silver method” needs to be used.  The iodocomplexes are very water insoluble, 
due to their high covalent character and can thus be produced in high yields from 
aqueous solutions.  Silver iodide is very insoluble (Ksp ~1x10-16), thus resulting in 
the very effective removal of iodide and Ag+. This method is even required for the 
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synthesis of chloro complexes, in cases where the direct interaction of the ligand 
with K2PtCl4 results in the formation of auto-ionized species, e.g. en91 as 
mentioned earlier.  
 
 
 
 
 
 
 
Figure 4-8 Mass-spectra of Pt(N-beda)I2 m/z 598.1 (yol33.5) in the positive (top) and 
negative (bottom) ion modes with structural assignments. 
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Where M  =
 
As a prototype, the mass-spectrum of the iodoplatinum(II) complex, formed when N-
benzylethylenediamine is used an non-leaving group, is given in Figure 4-8.  This 
complex could be prepared through the general method discussed in Chapter 2 in a 
93% yield.   The possible species present indicates that some ionization occurred in 
the water/acetonitrile solvent mixture used in the analysis. However, the fractions 
indicated can all be derived as fractions from the molecular species. Similar mass-
spectra could be obtained for the rest of the ligands used to produce complexes of 
the form, PtLI2.  
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Figure 4-9   Mass-spectra of Pt(N-chpd)I2 (yol35.5) m/z 604.1 indicating the presence of 
some auto-ionised species and other tentative structural assignments. Positive ion 
mode (top) and negative ion mode (bottom). 
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It must be mentioned though that, some auto-ionization did occur in the case of 
yol35.5. However, upon washing the product with cold ethanol, the monomeric 
species, which was more soluble in ethanol could, with some unavoidable loss, be 
recovered by vacuum evaporation at 50°C. The presence of the significant 
amount of auto-ionized species could indicate that its formation is dependant on 
the nature of the non-leaving group. (To a much lesser extent auto-ionization was 
also detected in the case of yol29.5) 
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4.2.3  CHLOROPLATINUM(II) COMPLEXES 
Synthesis 
As already described in Chapter 2, the chlorocomplex was prepared by either the 
direct slow addition of the ligand (in slight excess) to the K2PtCl4 solution or via 
the silver method, involving the use of the respective PtLI2 complex. The resulting 
complex was either light peach or light yellow in colour and of reasonable purity. 
Characterization 
Electronspray Ionization Mass Spectroscopy 
The occurrence of auto-ionization among complexes of platinum(II) can have 
undesirable effects on the anticancer action of  the platinum(II) complex. Since the 
empirical ratio of atoms of the monomeric compound and its auto-ionized form is 
the same, elemental analysis (C,H,N analysis, see Appendix) cannot distinguish 
between these two types of species. To a reasonable extent, Mass-spectra 
analysis is more useful in this regard, with its ability to reveal the molecular mass 
of a complex.  
 
 
 
 
 
 
 
Figure 4-10 Mass-spectra of one of the chloroplatinum(II) complexes prepared via the 
silver method, namely the peach coloured Pt(Nchpd)Cl2(yol35.2);m/z 420.8.Positive ion 
mode (top) and negative ion mode(bottom). 
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Figure 4-11   Mass-spectra of one of the chloroplatinum(II) complexes prepared 
namely Pt(N-chpd)Cl2 (yol35.2), a yellow coloured complex prepared via the direct 
addition of K2PtCl4 m/z 420.8. Positive ion mode(top) and negative ion mode(bottom).  
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N Cl
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From the mass-spectra, it can be seen that all the abundant peaks can be 
accounted for. Furthermore, in the case of this ligand, it was mentioned that its 
PtLI2 complex (yol35.5) exhibited the presence of some auto-ionised species. This 
apparent exception suggests that not only the non-leaving group is a parameter in 
the formation of the auto-ionized species, but also the size of the halo atom in the 
PtLX2 complex, since this could stabilize the ion-paring of the cationic and 
dianionic species.   This resulted in a marked decrease in the yield of yol35.2 
indicated by M in mass-spectra, (K2PtCl4 95% vs silver method 64%), but as is 
evident in the mass-spectra above, had very little effect on the purity of the 
complex. 
Due to the rapid ionization of the chloroplatinum(II) complexes in general, 
chromatograms of each complex could not be obtained. In the case of yol25.2 
though, the mass-spectra and the chromatogram (RT=3.53 yol25.1; RT=4.03 [M-
Cl+I]) indicated the presence of the monomolecular species. The mass-spectra 
[M]NH4+ 
[M]CHO2- 
[M-2Cl]+ 
[M-Cl]+ 
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also show the presence of solvated species formed upon dissolution.  
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Figure 4-12 LC-UV separation of Pt(L-hme)Cl2 (yol25.2) prepared via the silver method, 
obtained by utilizing a YMC C18 Hydrosphere column with 50%MeCN as eluent at flow 
rate of 1ml/min detected at 210nm. 
 
 
 
 
 
 
 
Figure 4-13  Mass-spectra of Pt(L-hme)Cl2 m/z  434.6 (yol25.2) prepaired via the silver 
method. Positive ion mode(top) and negative ion mode(bottom). 
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Similar mass-spectra could be obtained for the rest of the complexes prepared 
(see Appendix). 
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Table 4-1 Compilation of the m/z values and the relative ion abundances(%) of 
molecular ion peaks observed in the EI-MS mass spectra of the five chloroplatinum(II) 
complexes in both the positive and  negative ion modes. 
 
m/z 
Complex Mw (g/mol) *[M]NH4+ [M]CHO2- [M-H]- 
[M-Cl]+ 
/-2Cl- [M-Cl+H2O]
+ [M-Cl+MeCN]+ 
yol25.2 434.6 100 - 100 - 30 35 
yol29.2 387.6 100 - 100 15 - 50 
yol31.2 369.6 100 100 - 70 - - 
yol33.2 415.7 100 100 - 40 - - 
yol35.2 421.7 100 100 - 20/20 - - 
*The [M]NH4+ peak is used as reference peak 
 
Table 4-1 represents the mass-spectra data for all the chloroplatinum(II) 
complexes which were prepared. Thus, the mass-spectra data indicates the 
presence of the monomeric species in each case, either associated with a cation 
or an anion, as well as some of its other ionized forms. Furthermore, this data 
confirmed the absence of any auto-ionized species; at the very least it is safe to 
assume that if it were present, it was only in very negligible amounts.  
Thermal Analysis 
Each of the solid chloroplatinum(II) complexes were subjected to an analysis of 
their thermal behaviour. Thus their thermal conduct was observed up to 400°C 
(and in some cases 700°C) by thermogravimetry (TG). In each case the 
experiments were conducted at a heating rate of 5°C/min in a nitrogen 
atmosphere. The TG curves are displayed in Figure 4-14. 
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Figure 4-14  Thermogravimetric curves for chloroplatinum(II) complexes 
 
Investigation of these curves reveal that these complexes are stable up to 
~200°C, soon thereafter a clear mass loss transition was observed which 
continued with a gradual mass loss until the end of the temperature range 
selected. A TG of K2PtCl4 (used as precursor for most of these complexes) 
revealed no significant mass loss transitions before a temperature of 500°C was 
reached. For the chlorocomplexes in question, this could imply that the observed 
mass losses were due to thermal degradation of the coordinated nitrogen donor 
ligands.  
Table 4-2 Temperatures at which decomposition of the chloroplatinum(II) complexes 
were initiated. 
 
Complex Onset point (°C) N-donor Ligand 
yol25.2 259 L-histidine methyl ester 
yol29.2 233 2-aminobenzylamine 
yol31.2 245 2-aminoethylaminoethanol 
yol33.2 302 N-benzylethylenediammine 
yol35.2 211 N-cyclohexyl-1,3propanediamine 
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These solid state complexes start their decomposition in the range from 211°C -
302°C. In the most unstable one (Yol35.2), the non-leaving group has a bulky 
group attached to one of the N atoms. In general, six membered rings are 
thermodynamically less stable than five-membered rings, but since yol 35.2 is one 
of three other six-membered rings present in the complexes prepared (yol25.2 
and yol29.2) it could be that steric bulky group makes it even more unstable in the 
solid state.  After 211°C a very rapid mass loss of ~50% occurs. This can 
theoretically be attributed the loss of the ligand together with the two chloro ions 
which together makes up about 53% of the complex theoretically. The other 
complexes gradually degrade at higher temperatures except Yol33.2, which also 
has a sudden mass loss of ~36% at 302°C which theoretically can be related to 
the loss of the amine ligand (36%).  
Kinetics 
Due to the extent of ionization playing an influential role in anticancer action of the 
complex, as in the case of cisplatin, it was considered important to study the rate 
of ionization of each of these complexes as described in Chapter 2. The results 
are depicted in Figure 4-15. 
The ionization curves (Figure 4-15) do not differ significantly after 5 hours. The 
initial period is more important from an anticancer viewpoint. It is of interest that 
Yol33.2 of which its solid state shows greater stability, also has a greater kinetic 
stability over the initial five hour period. This behaviour can possibly be related to 
a screening effect of the phenyl ring of the benzyl group. The lower ionization rate 
leads in some cases to increased anticancer behaviour. Later results in this 
chapter show that this is not the case for Yol33.2, thus emphasizing the 
complexicity of anticancer action. The other complexes are similar in their 
ionization behaviour. Yol25.2 is of specific interest in view of its very 
recommendable anticancer action (see later). It was therefore of interest to 
compare its ionization behaviour with that of cisplatin and Pt(dach)Cl2. The plot in 
Figure 4-16 show its slower ionization rate determined at 37°C. 
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Figure 4-15  An overlay of the ionization curves of the chloroplatinum(II) complexes 
with different non-leaving groups obtained at room temperature. 
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Figure 4-16   A comparative overall hydrolysis rate representation which includes 
yol25.2, Pt(dach)Cl2 and Cisplatin in water at 37C. 
 
The experimental results given in Figure 4-16 suggest that the ionization of 
yol25.2 is somewhat slower than the other two complexes.  
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Table 4-3  Resultant solubility of each of the chloroplatinum(II) complexes 
 
 
 
 
 
These solubilities can be regarded as comparable to that of cisplatin (3.33mM),  
except for those cases where the non-leaving groups contain benzyl groups (as in 
the case of yol29.2 and yol33.2). The complex containing an alcohol group in the 
leaving group, however, displayed slightly higher solubility, yol31.2. 
4.2.4  BROMOPLATINUM(II) COMPLEXES 
Synthesis 
The bromoplatinum(II) complexes were prepared via the so-called silver-method 
(see Chapter2), and resulted in the formation of a yellow complex in almost each 
instance. 
Characterization 
 Electronspray Ionization Mass Spectroscopy 
As mentioned earlier, one of the motivations for synthesizing bromoplatinum(II) 
complexes was the assumption that ionization in these complexes would be less 
than in the case of their chloro counterparts. Nonetheless, since the probability of 
the formation of auto-ionized species still exists, mass-spectral analysis of each 
complex was employed in order to verify that the monomeric species implied (but 
not distinguished from its auto-ionized form) by the C,H,N analysis, was indeed 
justified.  
Complex Solubility ( mM) 
Yol25.2 3.17 
Yol29.2 0.64 
Yol31.2 4.45 
Yol33.2 0.17 
Yol35.2 1.55 
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An inspection of the mass-spectra revealed that the monomeric species in the 
case of each complex was indeed present. As prototypes in this regard, the mass-
spectra of yol29.3 and yol35.3 will be given, since as mentioned before, it was 
only their iodo complexes - which were used as precursors in the formation of the 
bromoplatinum(II) complexes - which displayed some evidence of the auto-ionized 
species. 
 
 
 
 
 
 
 
 
Figure 4-17 Mass-spectra of Pt(2-aba)Br2 m/z 476.5 (yol29.3) indicating the presence of 
the the bromoplatinum(II) species, some unreacted iodo species, as well as some 
auto-ionozed species. Postive ion mode(top) and negative ion mode(bottom). 
 
HN
NHPt
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Br
Where M  =
 
 
Due to the slower ionization of the bromoplatinum(II) species compared to their 
chloro analogues, some of their chromatograms could also be obtained, indicating 
an 80% purity as indicated by the major peak at 6.43min. 
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Figure 4-18  LC-UV separation of Pt(2-aba)Br2 (yol29.3) obtained utilizing a YMC 
Hydrosphere C18 column using 20%MeCN as eluent at a flow rate of 1.0ml/min 
detected at 210nm. 
 
The mass-spectra for yol35.3, indicated in Figure 4-19, does not indicate any 
auto-ionized species to be present, despite the fact that a small amount was 
present in its iodo precursor.  
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Figure 4-19   Mass-spectra of Pt(N-chpd)Br2 m/z 510.6 (yol35.3) indicating the 
presence of the bromo species and some unreacted iodo species. Positive ion mode 
(top) and negative ion mode(bottom). 
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Similar mass-spectra could be obtained for the rest of the bromoplatinum(II) 
complexes. Table 4-4 gives a summary of the molecular ion peaks accounted for 
in each of these complexes. 
Table 4-4   Compilation of the m/z values and the relative ion abundances(%) of 
molecular ion peaks observed in the EI-MS mass spectra of the five 
platinum(II)bromocomplexes in both the positive and negative ion modes 
 
m/z 
Complex Mw (g/mol) *[M]NH4+ [M]CHO2- [M-H]- 
[M]-Br+ 
/-2Br [M-Br+H2O]
+ [M-Br+MeCN]+ 
yol25.3 523.5 100 30 100 - 70 90 
yol29.3 476.5 100 - 100 - - - 
yol31.3 458.5 100 110  110 - - 
yol33.3 504.5 100 100 - 90 - 60 
yol35.3 510.6 100 100 - 30/20 - - 
*The [M]NH4+ peak is used as reference peak 
 
As reflected in Table 4-4, the mass-spectra data for each complex indicates the 
monomeric species or one of its ionized forms to be in abundance. (In the case of 
yol29.3, however, the presence of some auto-ionized species was indicated in the 
positive ion mode (PtL22+, relative ion abundance 30%) and in the negative ion 
mode (PtBr42-, relative ion abundance 20%), see Figure 4-17). 
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Thermal Analysis 
As in the case of the chloroplatinum(II) complexes each of the bromo counterparts 
was subjected to an analysis of their thermal behaviour up to 500°C. 
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Figure 4-20  Thermogravimetric curves for the bromoplatinum(II) complexes. 
 
A study of these curves reveal that the bromoplatinum(II) complexes, like their 
chloro counterparts, are stable up to about ~200°C.  Soon thereafter, thermal 
degradation becomes evident for most of them.  
As in the case of the chlorides, a trend in thermal degradation is not obvious, what 
can be said though is that just as in the case of the chloroplatinum(II) complexes, 
the complex containing N-cyclohexyl-1,3-propanediamine as ligand (yol35.3) 
seems to be the least stable, while the complex with N-benzylethylenediamine  as 
non-leaving group (yol33.3) seems to be the most stable. 
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Table 4-5 Temperatures at which decomposition of the bromoplatinum(II) complexes 
were initiated. 
 
Complex Onset point (°C) N-donor Ligand 
yol25.3 228 L-histidine methyl ester 
yol29.3 263 2-aminobenzylamine 
yol31.3 213 2-aminoethylaminoethanol 
yol33.3 276 N-benzylethylenediammine 
yol35.3 214 N-cyclohexyl-1,3-propanediamine 
 
A comparison of the temperatures reported in Table 4-2 vs. Table 4-5 above, 
indicates that the bromoplatinum(II) complexes are less stable in the solid state 
than their chloroplatinum(II) equivalents. In most cases the onset temperatures 
are 28-33°C lower in the case of the bromoplatinum(II) complexes. The exception 
being complexes which contain the N-cyclohexyl-1,3-propanediamine ligand, 
which share virtually the same onset temperature (211°C vs. 214°C) in both its 
chloro (yol35.2) and bromo (yol35.3) forms.  
Also, as in the case of the chlorocomplex, the bromocomplex, yol35.3, undergoes 
a distinct mass loss of 57%, which in this instance can approximately be attributed 
to the theoretical loss of the ligand together with both the bromo ions (61%). In the 
case of its chloro counterpart the distinct mass loss was related to loss of the 
ligand and its two chloro ions. Again, this displays the instability of this sterically 
hindered 6-membered ring complex. 
Solubility 
The solubility of each of the bromoplatinum(II) complexes was determined as 
described in Chapter 2. 
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Table 4-6   Solubility of the bromoplatinum(II) complexes in water at 25°C  
 
 
 
 
 
A comparison of the values reported in Table 4-3 vs. Table 4-6 indicates that 
chloroplatinum(II) complexes, are much more soluble than their bromo 
counterparts, except for yol33.3 which is more soluble than yol33.2.  
Kinetics 
At this point, a study of the ionization of the bromoplatinum(II) complexes proved 
to be of obvious interest, especially in comparison to their chloro counterparts. 
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Figure 4-21   An overlay of the ionization curves of the bromoplatinum(II) complexes 
with different non-leaving groups obtained at room temperature. 
Complex Solubility ( mM) 
yol25.3 1.91 
yol29.3 0.11 
yol31.3 1.76 
yol33.3 0.53 
yol35.3 0.18 
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The lower aqueous solubility of the bromocomplexes can be ascribed to the 
somewhat higher covalent character in the Pt-Br bond. This same behaviour was 
found, to a much larger extent, for the iodocomplexes. The result was that the 
comparable ionization studies could not be made between chloro and bromo 
species in a purely aqueous solution. The complexes were dissolved in methanol 
and some water gradually added to obtain comparable concentrations. The 
ionization curves for the bromocomplexes are shown in Figure 4-22. Instead of 
the expected slower ionization, these were found to be faster and to a somewhat 
greater extent. It was found that when mixtures of water and polar non-aqueous 
solvents are used to dissolve the halocomplexes, solvation of the cationic species 
by CH3CN or CH3OH increases in the direction Cl-, Br-, to I-.  This does not reflect, 
therefore, the true situation in pure water which will be a closer approximation to   
serum. In spite of this problem, the cytotoxic studies showed that the bromo 
analogues compare well and, in a particular case, even better than the chloro 
species (see later). The ionization of the complexes yol31.2 and yol31.3 was not 
included, but it can be inferred that it will display a similar ionization pattern as the 
complexes which were studied. 
4.4.3  OXALATOPLATINUM(II) COMPLEXES 
Synthesis 
As already described in Chapter 2, the oxalato complexes were prepared in most 
cases via the silver method, employing the use of the corresponding iodoplatinum(II) 
complex.  The resulting complex was either white/cream and in the case of yol29.1, 
light brown.  In the case of the chloroplatinum(II) complexes, direct addition of the 
ligand to K2PtCl4 resulted in the formation of the desired product. However, the use of 
K2Pt(C2O4)2 in an analogous manner, did not work as effectively due to relatively high 
aqueous insolubility of K2Pt(C2O4)2  which required higher reaction temperatures 
while running the risk of forming some of the unwanted auto-ionised species. Thus, 
the silver method, pioneered by Dhara92, was employed.  
[PtCl4]2- [PtI4]2- PtLI2
[PtL(H2O)2]2+  +  NO32-  +  2AgI PtL(C2O4)
I- L 1.9 AgNO3
excess
C2O42- (5)  
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Characterization 
Electronspray Ionization Mass Spectroscopy 
As mentioned in the introduction, the implementation of dicarboxylato leaving 
groups can limit the ionization of the complex. Again, as in the case of the 
platinum(II) chloro and bromo species, this method of analysis was employed to 
confirm the results implied by C,H,N analysis and to ensure the lack of any 
possible auto-ionized species.  As prototypes of the analysis of these complexes 
the mass-spectra of yol25.1 and yol35.1 will be given. Due to the comparably 
limited ionization in the case of these complexes, both their mass-spectra and 
chromatograms (indicating the purity) could be obtained for each complex.  
 
 
 
 
 
 
 
Figure 4-22 Mass spectra of Pt(L-hme)C2O4 m/z451.7 (yol25.1) prepared via the silver 
method in positive (top) and negative (bottom) ion modes. 
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Figure 4-23   LC-UV sepation of yol25.1 (Figure4-22) utilizing a YMC Hydrosphere C18 
column with 20%MeCN as eluent at a flow rate of 1.0ml/min detected at 210nm. 
 
 
 
 
 
 
 
Figure 4-24  Mass-spectra of Pt(L-hme)C2O4 m/z451.7 (yol25.1) prepared via 
K2PtC2O4·2H2O in positive (top) and negative (bottom) ion modes. 
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Figure 4-25 LC-UV sepation of yol25.1 (Figure4-24) utilizing a YMC Hydrosphere C18 
column with 10%MeCN as eluent at a flow rate of 1.2ml/min detected at 210nm. 
 
The mass-spectra obtained from both methods display mass-fragments which can 
all be accounted for. In the case of Figure 4-24, [M]Na+ relates to the sodium 
(Na2CO3) used in the neutralization of the acidic form of the ligand, which is now 
associated with the target product. In the case of Figure 4-23 and Figure 4-25, the 
chromatograms indicate purities of 97% and 94% respectively. This reveals that 
although none of the anticipated auto-ionised species were formed in the case of 
yol25.1 via the use of K2Pt(Ox)2 – and that no disparity in purity was evident – one 
drawback is the considerable decrease in yield of the product.  
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Figure 4-26 Mass-spectra of Pt(N-chpd)C2O4 m/z438.7 (yol35.1 prepared) via the silver 
method. Positive ion mode (top) and negative ion mode (bottom). 
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Thus the latter point, together with the risk associated with the formation of auto-
ionised species at elevated temperatures, was sufficient reason for us to abandon 
this preparative method.  
 
The mass-spectra of yol35.1 (Figure 4-26) indicates no trace of the auto-ionized 
species which was present in its iodo-complex, which in turn was used as starting 
material in the formation of its oxalatoplatinum(II) complex. The chromatogram 
(see Figure 4-28) indicates a product of 100% purity. Similar mass-spectra and 
chromatograms could be obtained for the rest of the oxalatoplatinum(II) 
complexes. Table 4-7 gives an indication of the relevant peaks observed and 
accounted for. 
Table 4-7 Compilation of the m/z values and the relative ion abundances (%) of 
molecular ion peaks observed in the EI-MS mass spectra of the five 
oxalatoplatinum(II) complexes in both the positive and negative ion modes prepared 
via the silver method 
 
m/z 
Complex 
Mw 
(g/mol) *[M]NH4
+ [M]CHO2- [M-H]- *[M]H+ 
[M-C2O4]/ 
+MeCN 
[M]-C2O4 
+MeCN 
yol25.1 451.7 100 - 100 - - - 
yol29.1 404.7 - - 100 100 - - 
yol31.1 386.7 12 100 8 100   
yol33.1 432.7 - 100 - 100 - 25 
yol35.1 438.8  100  100 20  
*The [M]NH4+ peak is used as reference peak in the case of yol25.1, whereas for 
the rest of the complexes the [M]H+ peak is used instead.  
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Table 4-7 confirms the presence of the sought after monomeric spesies and 
eliminates the presence of any auto-ioniozed species in each case. Table 4-8 
relates the approximate purity of each of the complexes as derived from their 
respective chromatograms, a further attestment to the absence of any auto-
ionized species. 
Table 4-8 The purity of each of the oxalatoplatinum(II) complexes prepared 
 
Complex % Purity 
yol25.1 97 
yol29.1 92 
yol31.1 94 
yol33.1 100 
yol35.1 100 
 
Thermal Analysis 
As in the case of platinum(II) - chloro and bromo complexes, so too were the 
oxalatoplatinum(II) complexes subjected to an inspection of their thermal 
behaviour. Figure 4-27 gives an indication of their thermal behaviour.  
 
Table 4-9 Onset temperatures of the platinum(II)oxalato complexes 
 
Complex Onset Temperature (°C) Approximate Mass losses 
75.7 2H2O K2PtC2O4·2H2O 224.1 2CO2+O2 
Oxaliplatin 258 L+CO+O2 
143.4 CO yol25.1 
233.4 L+CO2 
yol29.1 219.1 L 
79.8 H2O yol31.1 
251.9 CO2 
yol33.1 239.7 L 
yol35.1 267.9 L+CO2 
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Figure 4-27   Thermogram of the various oxalatoplatinum(II) complexes with onset 
temperatures. 
 
Solubility 
Table 4-10 Displays the solubility of the oxalatoplatinum(II) complexes in water at 
25°C 
 
 
 
 
 
4.4.4  DISCUSSION 
In the solid state, the chloroplatinum(II) complexes are more stable than their 
bromo analogues.  Both the platinum(II) halo complexes are more stable in 
general than their oxalato counterparts. In the case of the latter, the oxalato group 
Complex Solubility (mM) 
yol25.1 0.31 
yol29.1 2.85 
yol31.1 50.40 
yol33.1 0.41 
yol35.1 2.30 
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is the most unstable part. 
In the solid state, complexes having N-cyclohexyl-1,3- propanediamine (yol35.2 
and yol35.3) as ligand display the least stability as far as chloro and bromo 
complexes are concerned. As mentioned, this can possibly be related to the 
lesser stability of the six-membered chelate ring and/or steric hinderance. 
Complexes having N-benzylethylenediamine (yol33.2 and yol33.3) as ligand 
display the most stability in these cases.  As far as the oxalato species are 
concerned, the complex with N-cyclohexyl-1,3-propanediamine (yol35.1) as ligand 
now displays the most stability - it could be that the effect of the oxalate forming 
another chelate ring with respect to platinum(II) induces some stability into the 
complex. 
As far as aqueous solubility is concerned, the chloroplatinum(II) species display a 
greater solubility than the bromo analogues as expected, except for yol 33.3 
which is more soluble than yol33.2. The oxalatoplatinum(II) complexes are more 
soluble than their chloro counterparts, this too is expected due to the oxygen 
atoms present in the oxalates, however yol25.1 is much less soluble than yol25.2 
( or yol25.3). Thus establishing a trend in stability is not that obvious. 
The effect of the OH group in the non-leaving part of the complex is pronounced 
in the case of the oxalato complex (yol31.1). 
As stated earlier, the ionization studies of the chloro and bromo species cannot 
readily be used to decide what will occur in a pure aqueous solution, like serum, 
due to the low solubility of the bromo complex and thus the usuage of non-
aqueous solvents to provide enough solubility. Inspite of this, however, the 
cytotoxic studies indicated that in one particular case, the bromo complex 
displayed a higher efficiency than its chloro analogue. 
4.4.5  CYTOTOXIC EVALUATION 
The cytotoxic capability of each of the platinum(II) – chloro, bromo and oxalato 
complexes was determined via testing on available colon (HT29), breast (MCF7) 
and cervical cancer (Hela) cell lines. These results are displayed in the tables and 
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figures that will follow. 
The effect of the histidine ester as a non-leaving group is exceptional, since it is 
very rare that the non-leaving group is so dominant in the anticancer action. All of 
its complexes, halo and oxalato, are good anticancer agents, varying only in 
effect. In the cases of cervical and breast cancer, the chloro and oxalato 
compounds compare well with cisplatin (see Table 4-11; Table 4-13 and Figure 
4-28; Figure 4-30). The former is also comparable to cisplatin towards colon 
cancer. The bromo complex is even somewhat better than cisplatin on breast 
cancer cells. See Table 4-12 and Table 4-11. 
The chloro complex of 2-aminobenzylamine (yol29.2) displays a comparable 
behaviour to cisplatin in two of the cancer cell lines (Hela, MCF7) (see Table 
4-11.and Figure 4-28). Whether this behaviour can be related to the previously 
mentioned “angular planar” effect is difficult to determine, since the other benzyl 
containing non-leaving group, N-benzylethylenediamine, does not behave 
similarly. Only the chloroplatinum(II) complex of N-cyclohexyl-1,3-propanediamine 
displayed some anticancer action in Hela and HT29 cells, (see see Table 
4-11.and Figure 4-28). 
  
Table 4-11  A tabular representation of the effect of each of the chloroplatinum(II) compounds synthesized on all three cancer cell lines 
with reference to Cisplatin as displayed in figures below. 
 
Cell lines                   Hela HT29 MCF7 Concentration (µM) 
Cisplatin 78±1 85±0 84±0.6 62±2 63±3 64±1 81±1 78±3 80±1 12.3 61.4 122.8 
yol25.2 64±4 85±0 84±0 24±2 49±2 61±2 69±5 78±1 79±2 10.1 50.7 101.4 
yol29.2 52±2 79±1 84±1 24±4 40±3 59±1 62±7 77±1 76±2 8.2 40.9 81.9 
yol31.2 12±2 44±2 66±1 19±1 39±3 59±1 28±3 58±3 69±1 8.3 41.6 83.2 
yol33.2 7±4 11±3 7±1 14±4 8±6 6±7 31±3 33±2 28±2 0.67 3.5 6.7 
yol35.2 22±8 52±5 68±1 24±3 56±2 62±1 33±3 59±6 65±3 7.9 39.8 79.7 
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Figure 4-28 Graphical representation of the effect of each of the chloroplatinum(II) compounds synthesized on all three cancer cell 
lines with reference to Cisplatin. 
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Table 4-12  A tabular representation of the effect of each of the bromoplatinum(II) compounds synthesized on all three cancer cell lines 
with reference to Cisplatin as displayed in figures below. 
 
Cell lines Hela HT29 MCF7  
Concentration (µM) 
Cisplatin 63±4 77±1 78±1 65±1 69±0 68±2 56±4 61±2 68±0 10.4 52.2 101.4 
yol25.3 44±5 70±1 75±1 19±3 33±1 51±2 42±2 71±2 71±2 8.3 41.6 83.2 
yol29.3 22±5 31±2 40±8 10±4 19±1 20±4 22±3 27±3 32±6 4.7 23.5 47.0 
yol31.3 16±5 37±2 54±2 11±6 34±3 52±4 9±4 31±3 45±2 9.9 49.9 99.8 
yol33.3 6±1 3±3 7±3 2±2 1±3 0±3 10±4 0±7 0±6 2.0 10.2 20.4 
yol35.3 6±9 15±9 31±3 7±7 27±1 36±2 2±2 13±4 18±2 1.9 9.8 19.6 
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Figure 4-29  A representation of the effect of each of the bromoplatinum(II) compounds synthesized on all three cancer cell lines with 
reference to Cisplatin. 
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Table 4-13 A tabular representation of the effect of the rest of the oxalatoplatinum(II) complexes on all three cancer cell lines with 
reference to Cisplatin as displayed in figures below 
 
Cell lines Hela HT29 MCF7 Concentration (µM) 
Cisplatin 65±6 78±1 78±1 59±6 67±1 67±3 55±2 61±1 69±1 10.4 52.2 104.4 
Yol25.1 43±2 75±2 84±1 16±3 34±4 45±3 36±6 74±3 83±1 9.2 45.3 90.1 
yol29.1 1±7 21±5 45±2 4±10 13±8 26±3 10±1 31±6 46±2 6.6 32.9 65.8 
yol31.1 14±7 17±6 32±21 7±4 8±5 11±5 12±5 10±4 13±3 5.3 26.4 52.7 
yol33.1 9±3 14±4 22±4 6±9 16±6 14±4 19±4 22±2 22±1 11.4 56.7 113.4 
yol35.1 15±4 30±4 58±1 5±3 20±5 39±2 15±7 31±4 41±2 8.4 41.7 83.4 
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Figure 4-30 A graphical representation of the effect of the oxalatoplatinum(II) complexes on all three cancer cell lines with reference to 
Cisplatin.  
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CHAPTER 5   
MONONITROPLATINUM(IV) COMPLEXES 
5.1 INTRODUCTION 
As mentioned earlier in the introduction, platinum(IV) complexes are kinetically 
more inert than their platinum(II) counterparts.  This inertness would imply that 
such complexes would have both high activity and low toxicity. The potential 
advantage of platinum(IV) complexes that remain in this higher oxidation state in 
the bloodstream, are that their lower reactivity would diminish loss of active drug 
and thus lower the incidence of unwanted side reactions which lead to toxic side-
effects. In addition, the higher lipophilicity of some platinum(IV) complexes would 
be retained, leading to potential improvements in cellular uptake93.  
Recently it was shown that some mononitroplatinum(IV) complexes have 
particularly promising anticancer potential in that they inhibit Stat3 binding to DNA 
and induce apoptosis with little effect on normal tissue. This could possibly be 
ascribed to the tumour cells having become irreversibly dependent on Stat3 
signalling to sustain their growth and survival, while normal ones may be able to 
use alternate pathways to compensate for Stat3 loss60.  Futhermore, it has also 
been postulated that nitric oxide, produced by macrophages in the body, can kill or 
stop the proliferation of tumor cells. It appears that nitric oxide attacks by bonding 
to the metal enzymes that are involved in respiration, which prevents them from 
functioning. The cells then actually starve to death94.   
Thus the exploration of synthesizing platinum(IV) complexes with NO2 in at least 
one of the axial positions was so that the mononitroplatinum(IV) complexes may 
undergo reduction (in vivo) and then produce a “cisplatin”  type compound and 
nitric oxide in sufficient quantities for a double attack on tumour cells. Another 
study95 has shown that there is evidence of intracellular release of nitric oxide 
(NO2) in the presence of CPA7 (Pt(NH3)2(NO)Cl3) and CPA1 (Pt(en)2(NO)Cl3) but 
not cisplatin and CPA3 (Pt(en)Cl2). This raises the possibility that nitric oxide 
release might represent one of the mechanisms for the antitumour cell activity that 
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is associated with these compounds. 
It was previously shown that cis-diamminedichloro-trans-nitrochloroplatinum(IV), 
CPA7 does inhibit binding of Stat3 to DNA96 (See Figure 5-1 for structure). 
Pt
NO2
H3N Cl
Cl
ClH3N
 
Figure 5-1 The platinum(IV) complex, CPA7 
 
A patent was filed on the synthesis of CPA7 and numerous other 
mononitroplatinum(IV) complexes by Kay et al.97  who was sponsored by an 
American Pharmaceutical firm, RCA. Although numerous complexes were 
mentioned, the purity grades were not given, only infrared data. The same 
industry, however, approached Platco, a company we’re affiliated with, to supply 
pure CPA7 in gram quantities to them.  
5.2  INTRODUCTORY WORK 
In this laboratory, we started our research by employing their published98 method 
as follows: 
Cisplatin was suspended in water and one mole NaCl for every one mole cisplatin 
was added, while NO2 gas bubbled through the solution. The colour changed to 
blue and slowly, upon overnight exposure to air, to yellow - upon which a solid also 
deposited. This was then used as such or recrystallised from methanol, but no 
information of the percentage purity was supplied. 
Our own research showed that the above method produced a mixture, containing 
between 30-40% of the diamminetetrachloroplatinum(IV) species, Pt(NH3)2Cl4, the 
rest being CPA7 as well as small percentages of unreacted cisplatin and 
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hydrolised species were also detected. In Figure 5-2 a chromatogram of the crude 
product was obtained using a C18-column. On this non-polar column, the 
separation is poor.  
The peak at 4.78 is that of CPA7, 4.52 that of Pt(NH3)2Cl4 and at 4.23 a mixture of 
unreacted cisplatin, hydroxo species and salts. 
  
Figure 5-2 Resulting separation of CPA7 using the YMC Hydrosphere C18 column99. 
Better separation was obtained through the use of the more polar PFP column. 
This indicated that the purity of the CPA7 synthesized via this method is only 20%, 
although the yield is approximately 80%99. (See Figure 5-3) 
 
 
 
 
Figure 5-3 LC-UV separation of the crude CPA7 product obtained through use of the 
PFP column. 
The experimental results obtained for the preparation of the Pt(IV)(NO2)Cl species 
by using NO2 gas and some added chloride ions suggest that in the presence of a 
relatively high Cl- concentration, the major product is Pt(NH3)2Cl4. This means that 
the NO2, or species derived from it, act as the oxidant and Cl- as the complexing 
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agent.  
Thus the main reaction is as follows: 
Pt(NH3)2Cl4  +  2e-
N2O4  +  2H+ +  2e- 2HNO2
Pt(NH3)2Cl2  +  2Cl-
 
Pt(NH3)2Cl2  +  2Cl-  +  N2O4  +  2H+ Pt(NH3)2Cl4  +  2HNO2
 
The above reaction can be regarded as an oversimplification, since N2O4 in H2O 
reacts as follows: 
N2O4  +  H2O HNO2  +  HNO3  
 HNO2  +  H+
e-
NO(g)  +  H2O
 
These redox potentials are very similar so that simultaneous reactions can occur. 
5.2.1  ADJUSTMENTS TO THE PUBLISHED METHOD 
In later experiments, acetone was used as solvent and no addition of Cl- was 
made since the chloroplatinum(II) species all ionize to an extent in H2O and polar 
solvents, thus supplying a relatively low chloride concentration in solution. In these 
experiments it was found that no Pt(NH3)2Cl4 was formed and only a small amount 
of hydrolyzed species.  In this method it is using the starting material as the only 
source of chloride ions which resulted in side reactions being greatly limited. 
However, the yield of the required product was limited to a maximum of 50% 
theoretically, since 50% of the starting material must now provide one chloride for 
the other 50% to be able to form the required Pt(IV)NO2Cl complex.  
This method produced a product in 45% yield and of 83% purity. (See Figure 5-4 
and Figure 5-5) 
This experiment thus illustrates effectively that the excess chloride (relatively high 
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Cl- concentration) was the “culprit” in producing multiple side reactions. This, at the 
same time strengthened our belief that oxalatoplatinum(II) species should produce 
higher yields of purer products upon oxidation. 
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Figure 5-4  Mass spectra of CPA7 obtained via variation of published method in 
positive (top) and negative ion (bottom) modes . 
 
 
Pt
NO2
H3N Cl
Cl
ClH3N
Where M  =
m/z380.8
 
 
For interest, the mass-spectra and the chromatogram obtained upon the synthesis 
of the tetrachlorospecies in particular, is also included. (See Figure 5-6 and 
Figure5-7). 
[M-NO2+OH]+ 
[M]NO3- 
[M]Cl- 
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Figure 5-5  LC-UV separation of a sample of CPA7 synthesized via variation on 
published method obtained utilizing a PFP column (250x4.6mm; 5µm) using 2.5%MeCN 
as eluent at a flow rate of 1.0ml/min detected at 210nm. 
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Figure 5-6 Mass-spectra of Pt(NH3)2Cl4 in positive (top) and negative (bottom) ion 
modes99. 
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Figure 5-7 Separation of Pt(NH3)2Cl4, the tetrachloro-species99. 
 
[Pt(NH3)2Cl4]NH4+ 
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5.2.2 EXPERIMENTAL ATTEMPTS TO PRODUCE CATIONIC 
MONONITOCOMPLEXES UPON OXIDATION OF 
CHLOROPLATINUM(II) COMPOUNDS NAMELY OF CISPLATIN 
Before research into the oxidation of oxalatoplatinum(II) complexes could be 
pursued, RCA - who originally patented the nitrocomplexes of chloro-compounds - 
asked us to perform investigations into the syntheses of 
chloroplatinum(IV)mononitro complexes, having trans to the NO2 a neutral amine 
donor ligand - specified to be nicotinamide.  
Pt
NO2
H3N Cl
L
ClH3N NO
H2N
Where L  =
+
 
Figure 5-8 Illustrates the attempted cationic platinum(IV) complex with nicotinamide as 
neutral ligand in the position trans to NO2.  
Efforts were therefore directed to synthesize such species, with nicotinamide as 
the neutral ligand.  We altered an existing synthetic method98 somewhat, instead 
of using pure water as solvent, a 30:70 mixture of water and acetone was used in 
an effort to suppress the ionization of the chloride, which was found to lead to the 
production of a large percentage of the tetrachlorospecies; (Pt(NH3)2Cl4)99. NO2 
gas from a cylinder was not used (very expensive and difficult to handle) instead 
the reaction of concentrated HNO3 with pure copper metal to produce the NO2 gas 
was employed, controlling its evolution by the sequential addition of the acid onto 
the metal in a suitable glassware arrangement (See Chapter 2). 
Attempt A 
The method briefly consisted of the addition of 1.19 mmol of cisplatin to the 30:70 
water/acetone solvent mixture, in the presence of a solution of 1.31 mmol neutral 
ligand. NO2 gas was then bubbled through the reaction mixture for 50 minutes, 
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upon which the colour changed from a milky light yellow suspension to a sea-blue 
clear solution. The next day, upon atmospheric air oxidation, a yellow solution was 
obtained. The product was isolated and characterised via mass-spectral analysis. 
This indicated the presence of unreacted cisplatin and CPA7 and its derivatives.  
No evidence was present to indicate that the neutral donor ligand did coordinate to 
the platinum(IV).  
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Figure 5-9   Mass spectrum of product obtained upon oxidation of cisplatin with NO2 in 
presence of neutral nicotinamide (L). 
The results obtained were, in hindsight, not very surprising, in light of the ionization 
of the chloride observed in the absence of a neutral donor ligand, since the 
presence of such a ligand will enhance the ionization. 
Attempt B 
The same experiment was performed, but in this case as described by Kay97, in a 
70:30 water:1,2 dichloroethane system. After a number of attempts an indication of 
the target species was eventually seen. The method can be briefly described as 
[CPA7]NH4+ 
[CPA7-NO2]+ 
[CPA7]CHO2-/H2O 
[CPA7]CHO2- 
[CPA7-H]+ 
[Cisplatin-H]-
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follows.  
Cisplatin (7.23 mmol) was suspended in 100 cm3 water: 50 cm3 1,2 dichloroethane 
mixture, in the presence of a solution of 1.1 molar equivalents nicotinamide. NO2 
gas was then bubbled through the reaction mixture for ~30min. Before oxidation, 
the reaction mixture presented a milky yellow suspension, but upon initial oxidation 
the reaction mixture becomes murkier though still yellow. After about 7 min, the 
colour changed from yellow to blue and became less murky. After about 12 min 
the reaction mixture is completely blue with some undissolved particles. Towards 
the end (~25min), the reaction mixture was still blue but with no undissolved 
particles visible.  
The reaction mixture was then covered with foil and continued to stir overnight to 
allow for further oxidation by atmospheric air. The next day, the reaction mixture 
was vacuum evaporated to dryness, upon which a yellow residue resulted. This 
yellow residue was redissolved in acetone and filtered (leaving behind a light 
yellow precipitate, see Figure 5-11. The remaining solvent was then also vacuum 
evaporated to dryness and yielded a slightly hygroscopic product (see Figure 5-
10). 
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Figure 5-10 Mass spectra of part of product which was soluble in acetone. Positive ion 
mode (top) and negative ion mode (bottom).  
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Figure 5-11 Mass spectra of part of the product which was not soluble in acetone. 
Positive (top) ion mode and negative (bottom) ion mode. 
Pt
NO2
H3N Cl
L
ClH3N
380.96
WhereTarget  =
+
 
Thus it can be seen that the part of the product which was insoluble in acetone, 
was mostly the target species and derivatives of CPA7 – that is, compared to the 
part of the product which was soluble in acetone, which contained a mixture of 
species. 
However, due to the hygroscopic nature of the product; purification was rather 
difficult and further efforts in this regard were terminated. 
5.3  OXIDATION OF OTHER CHLOROPLATINUM(II) AMINE COMPLEXES  
The research on the chloroplatinum(II) complexes prompted us to extend it by 
using some chloroplatinum(II) compounds which were developed in this work and 
which exhibited some potential as anticancer agents.  In this section yol25.2 and 
yol35.2 were investigated.  
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Oxidation of yol25.2 in the presence of NaBr 
In the case of yol25.2, the chloroplatinum(II) complex was suspended in a 92% 
acetone: 8% water mixture in the presence of 1 molar equivalent of NaBr. NO2 gas 
was bubbled through the reaction mixture for ~75min. During this time the milky 
white reaction mixture changed to murky yellow. Towards the end of the 75 min 
period of oxidation, the reaction mixture was still slightly murky and yellow. The 
reaction mixture was then covered with foil and allowed to continue to stir 
overnight while atmospheric air oxidation was occurring. After about 20hrs, the 
volume of the reaction mixture had reduced, but very little precipitate was present. 
Thus the reaction mixture was vacuum evaporated to dryness, yielding a 
yellow/orange precipitate (see Figure 5-12). 
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Figure 5-12 Mass–spectra of the product obtained upon oxidation of yol25.2 in the 
presence of NO2 and NaBr . Positive ion mode (bottom) and negative ion mode (top). 
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Oxidation of yol35.2 in the absence of NaCl 
In a similar manner as just described, yol35.2 was oxidized. The only difference 
was that this reaction was performed in 100% acetone and due to the ionization of 
chloroplatinum(II) complexes no addition of NaCl was made. The initial milky white 
reaction mixture proceeded to take on a milky yellow colouration, then a yellow-
green colour. After ~75min, the reaction mixture was clear yellow. The reaction 
mixture was then allowed to stir overnight and as in the previous case was 
subsequently vacuum evaporated to dryness. The resultant residue was 
suspended in ethylacetate and filtered off, yielding a yellow product (see Figure 
5-13). 
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Figure 5-13  Mass-spectra of product obtained upon oxidation of yol35.2 in the 
presence of NO2 and Cl. Positive ion mode (bottom) and negative ion mode (top). 
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In both cases, the mass-spectra give evidence of the desired product, however the 
purity of these complexes could not be well established chromatographically.  
Oxidation of Pt(dach)Cl2 in the absence of NaCl 
A final attempt in the oxidation of the platinum(II) chloro compounds was made by 
oxidizing Pt(dach)Cl2 in a similar manner as just described for yol35.2, i.e. only 
acetone was used as solvent and no addition of NaCl was made. After 
approximately 20hrs the volume of the reaction mixture had reduced and the 
resultant precipitate was suspended in methyl acetate, filtered off and dried in an 
oven at 50°C. The mass-spectrum of the product is given in Figure 5-14. 
 
 
 
 
 
 
 
 
 
 
Figure 5-14  Mass-spectra of product obtained by oxidation of Pt(dach)Cl2 with NO2 in 
the absence of additional NaCl. 
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Figure 5-15 LC-UV separation of Pt(dach)Cl3(NO2) (Pt(IV)dachCl2) 
The chromatogram (Figure 5-15) indicated that the resultant product was 79% 
pure.  
To this end, this was the best progress we made in the oxidation of 
chloroplatinum(II) complexes.  
5.4  PREPARATION OF Pt(IV)MONONITROCHLORO-OXALATO SPECIES 
5.4.1 INTRODUCTION 
The results obtained in the oxidation of the chloro species convinced us that a 
major problem in the synthesis was the ionization of the chloroplatinum(II) species. 
The much lesser ionization of the oxalatoplatinum(II) species thus seemed an 
attractive advantage to be pursued. In the patent on the synthesis of the 
mononitroplatinum(IV) complexes97, no mention was made of any oxalato-
analogues, also no example of the nitrooxalatoplatinum(IV) compounds could be 
found in the literature. This could probably be related to the fact that it is known 
that oxalates are reducing agents, which can, under some circumstances, even 
reduce platinum(II) to platinum-metal64,82. If the strong oxidizing action of NO2 in an 
aqueous medium is further borne in mind, the likelihood of its oxidation could be 
considered.  
We therefore decided to use oxalatoplatinum(II) compounds, despite fears of  
possible oxidation/reduction between nitrogen in oxidation state ≥3 and the 
coordinated oxalato-groups. (See reaction sequence below which relates to 
oxidation of oxalate with nitrogen(III)). It was hoped that the diamine would provide 
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enough stabilization for the platinum(IV), to limit the potential of the anticipated 
oxidation/reduction reaction. 
Oxalate as Reducing Agent 
C2O42-  +   2H2O CO2  +  4H
+  +6e-  
Nitrogen(III) as Oxidizing Agent 
NO2-  +  2H+  +  e- NO  +  H2O  
NO+  +  e- NO  
Thus, studies involving the oxidation of platinum(II)oxalato species in the presence 
of NO2 were initiated, since it should greatly improve the synthetic method 
particularly in view of the more inert character of the platinum(II)oxalate.  
5.4.2  PREPARATION OF Pt(dach)(C2O4)(NO2)Cl, MAR4.1.4 
The first effort in this regard was directed at using oxaliplatin, especially in view of 
its well-known effectiveness as an anticancer agent. This idea was pursued since 
it appears as if mononitroplatinum(IV) complexes derived from platinum(II)-
complexes with good anticancer action, result in Pt(IV) analogues with even 
improved properties than their Pt(II) species. (Compare cisplatin with CPA7 later). 
Synthesis 
The investigations using oxalato species met, almost immediately, with success. 
When oxaliplatin was used as starting material, the mononitrochloro platinum(IV) 
analogue could be obtained in a yield in excess of 80% and in a purity in excess of 
95%, thus dramatically different to what was experienced in the case of the 
analogous chloroplatinum(II) species. The light cream product was produced in a 
crystalline form suitable for X-ray structural determinations.  
The method employed, as described in Chapter 2, the use of a mixed solvent 
system (70:30 acetone/water mixture), with 1 mole of chloride added for 1 mole of 
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oxaliplatin present. The mixture was stirred at room temperature and NO2 
introduced using the set-up illustrated in Chapter 2. The reaction mixture almost 
immediately obtained a green tinge, which increased to a bottle green colour upon 
which the NO2 addition was stopped, the reaction mixture covered with foil and 
while stirring, further oxidation by atmospheric air was allowed overnight. This 
resulted in a yellow solution with some small cream coloured crystals. This was 
followed by washing the product with water and acetone and then placing it in the 
oven at 50°C overnight to dry. Figure 5-16 shows the mass-spectra of the product 
obtained. 
 
 
 
 
 
 
 
 
Figure 5-16 Mass-spectra of Pt(dach)(C2O4)(NO2)Cl (Mar4.1.4) m/z 478.7 prepared via 
the oxidation of NO2 in the presence of Cl. Positiove ion mode (top) and negative ion 
mode (bottom) 
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Figure 5-17 LC-UV separation of Mar4.1.4 obtained utilizing a PFP column (250x4.6mm; 
5µm) using 2.5%MeCN as eluent at a flow rate of 1.0ml/min detected at 210nm. 
The minor peaks at m/z363+ and m/z386+ can be attributed to [Pt(dach)Cl2-
Cl+H2O]+ and [Pt(dach)Cl2-Cl+MeCN]+ respectively. This could be due to the 
choride ions replacing the oxalate anion under these oxidizing conditions. The 
same reaction was performed in a purely aqueous medium over a 30min period. 
This resulted in the formation of a white powder with a green tinge in a 40% yield 
and 84% purity. Upon recrystallisation with water at 80°C, a cream-yellow 
crystalline product was obtained with 90% purity. 
 
Stability studies 
TG Analysis 
Thermogravimetric analysis of the solid was performed (see Figure 15). A mass 
loss of 6.9% (transition1) is already indicated at ~80°C; this corresponds to a 
theoretical mass loss of two water molecules (7%).  
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Figure 5-18 Thermogravimetric curve of Mar4.1.4 
Up to ~200°C, no evidence is given of any further mass loss, which implies that 
the solid compound is stable up to this temperature. The derivative curve indicates 
that two transitions are taking place between ~200 - 375°C.  The first of these, 
(transition 2), indicates a mass loss of 30.7%, theoretically this could be the loss of 
the DACH ligand and NO2 gas (31.1%). The second transition (transition 
3; 17.9%), agrees with a theoretical loss of oxalate in the form of 2CO2 gas 
(17.1%). 
5.4.3  FURTHER STUDIES WITH OXALIPLATIN 
Due to the success achieved in the synthesis of Pt(dach)(C2O4)(NO2)Cl Mar4.1.4,  
it was decided to attempt to replace the chloride anion with the bromide anion. 
Synthesis of Pt(dach)(C2O4)(NO2)Br, Mar4.1.4.3 
The same method of synthesis was implemented as for the synthesis of Mar4.1.4, 
with the exception that 1 molar equivalent of sodium bromide was added instead of 
sodium chloride. This resulted in the formation of a lime-yellow powder in a 74% yield 
and 91% purity. Figure 5-15 indicates the mass-spectrum of the product obtained. 
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Figure 5-19  Mass-spectra Pt(dach)(C2O4)(NO2)Br (Mar4.1.4.3) m/z523.2 in both positive 
(top) and negative (bottom) ion modes. 
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Figure 5-20 LC-UV separation of Mar4.1.4.3 utilizingPFP column (250x4.6mm; 5µm) 
using 2.5%MeCN as eluent at a flow rate of 1.0ml/min detected at 210nm. 
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Figure 5-21 Thermogravimetric curve of Mar4.1.4.3 
A very similar trend in stability to that of Mar4.1.4 is observed. Transition 1 (loss of 
5.8%) occurring at ~80°C could again be theoretically related to the loss of two 
water molecules (6.8%).  Similar to Mar4.1.4, the bromo analogue seems stable 
up to ~200°C, after which follow two transitions between ~200-375°C. The first, 
(transition 2 - 20.2%) can be related to a theoretical loss of the DACH ligand 
(20.4%). The further mass loss indicated by transition 3 (30.7%) can theoretically 
be related to the loss of NO2, Br- and CO2 gas (30%). 
Crytallographic data 
Structural determination of Pt(dach)(NO2)Cl, Mar4.1.4  
The crystals were grown out of a dilute aqueous solution at 4C over a few days. 
Although the initial anisotropic refinement of all non-hydrogen atoms and 
application of absorption corrections resulted in reasonable R-indices (0.0416 for 
all data) and goodness-of-fit on F2 (1.09), the N(3) atom of the nitro group was 
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calculated as having a non-positive atomic displacement and an unreasonably 
long Pt-N(3) distance of 2.186 Å.  
The introduction of a disordered chloride atom, Cl(2), at the N(3) position, resulted 
in a significant decrease in the R-factor, as well as the attainment of acceptable 
bond distances. This decision was based on the occasional occurrence of 
contaminating dichloro species, Pt(dach)(C2O4)Cl2, in the product. However, both 
Cl(2) and N(3) atoms then registered as non-positive definites. The two Pt-Cl 
bonds were thus constrained to similar distances and refined with respect to a free 
variable using DANG. These restrictions were chemically valid and were 
sufficiently flexible to allow for the observation of significant variations. 
Furthermore, the anisotropic movement of the N(3) atom, was restricted using 
ISOR. Subsequent refinement of this disordered model, led to all atoms having 
tolerable temperature factors and acceptable bond lengths. Convergence to a final 
R-factor of 0.0397, for all data, with 202 parameters and 8 restraints, was 
achieved. 
The fraction of the complex containing the disordered chloride Cl(2), i.e. 
Pt(dach)(C2O4)Cl2, was calculated at 31%, whilst the the residual 69% consisted of 
the anticipated complex. Details of the crystal data, structure solution and 
refinement, fractional coordinates, isotropic and anisotropic parameters, are 
compiled in the Appendix. The molecular structures and atomic numbering 
scheme is indicated in Figure 5-22, whilst packing in the unit cell is depicted in 
Figure 5-23. Selected bond angles and lengths are tabulated in Table 5-1. 
 
Figure 5-22 Ortep projections of Pt(dach)(C2O4)(NO2)Cl (site occupation 69%) (left) and 
Pt(dach)(C2O4)Cl2 (31%) (right). Thermal ellipsoids drawn at 50% probability. Hydrogen 
atoms have been omitted for clarity. 
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Figure 5-23 Packing diagram of Pt(dach)(C2O4)(NO2)Cl.2H2O and    
Pt(dach)(C2O4)Cl2.2H2O. 
Table 5-1  Selected bond lengths and angles in Pt(dach)(C2O4)(NO2)Cl. 
 
Bond Lengths (Å) Bond Angles (º) 
Bond Length Bond Length Atoms Angle Atoms Angle 
Pt-N(1) 2.032(7) Pt-N(2) 2.045(8) N(1)-Pt-N(2) 83.5(3) N(1)-Pt-O(1) 95.1(3) 
Pt-O(1) 2.023(7) Pt-O(2) 2.036(7) O(1)-Pt-O(2) 83.8(3) O(2)-Pt-N(2) 97.6(3) 
Pt-Cl(1) 2.319(3) Pt-Cl(2) 2.32(2) N(3)-Pt-N(1) 91.4(6) N(3)-Pt-N(2) 92.3(7) 
Pt-N(3) 2.05(2) N(3)-O(31) 1.17(3) N(3)-Pt-O(1) 87.8(9) N(3)-Pt-O(2) 90.6(6) 
N(3)-O(32) 1.26(2) N(1)-C(11) 1.506(11) Cl(1)-Pt-N(1) 89.8(2) Cl(1)-Pt-N(2) 88.6(2) 
N(2)-C(12) 1.503(11) C(11)-C(12) 1.520(12) Cl(1)-Pt-O(1) 92.2(2) Cl(1)-Pt-O(2) 88.2(2) 
C(12)-C(13) 1.55(1) C(13)-C(14) 1.567(13) Cl(1)-Pt-Cl(2) 179.2(8) Cl(1)-Pt-N(3) 178.6(6) 
C(14)-C(15) 1.526(15) C(15)-C(16) 1.516(16) Pt-N(3)-O(32) 117.5(14) Pt-N(3)-O(31) 118.1(16) 
C(16)-C(11) 1.527(12) O(1)-C(1) 1.284(11) O(1)-C(1)-C(2) 117.9(9) O(2)-C(2)-C(1) 144.4(9) 
O(2)-C(2) 1.312(12) O(3)-C(1) 1.238(11) O(3)-C(1)-C(2) 118.6(9) O(4)-C(2)-C(1) 120.9(10) 
O(4)-C(2) 1.190(13) C(1)-C(2) 1.568(13) N(1)-C(11)-C(12) 106.9(7) N(2)-C(12)-C(11)  106.4(7) 
    C(12)-C(11)-C(16)   110.3(7) C(11)-C(12)-C(13) 110.8(8) 
    C(11)-C(16)-C(15)   108.8(8) C(14)-C(15)-C(16) 111.8(9) 
 
The compound crystallized with two water molecules in the lattice, hydrogen-
bonded to the amine nitrogens.  The coordination geometry around the 
145 
 
platinum(IV) metal centre was that of a slightly distorted octahedron; the equatorial 
plane formed by the donor atoms of the bidentate oxalato and 
diaminocyclohexane ligands deviated from planarity (Table 5-2) and exhibited 
bond angles ranging from 83.6 to 97.6º. Axial sites were occupied by either a nitro 
group (NO2) and chloride atom (in 69% of the molecules) or by two chloride atoms 
(31%). Both groups occupied positions approximately perpendicular to the 
equatorial plane and directly opposite to each other: N(3)-Pt-N(1): 91.4(6)º, Cl(1)-
Pt-N(1): 89.8(2)º, Cl(2)-Pt-N(1): 89.5(8)º, Cl(1)-Pt-Cl(2): 179.2(8)º, Cl(1)-Pt-N(3): 
178.6(6)º. 
Table 5-2 Deviations (d) and standard deviations (s)(Å) of selected atoms from the 
weighted least-squares plane of the platinum coordination sphere of Pt(dach)(C2O4)(NO2)Cl. 
 
Platinum Coordination Sphere 
Atom d s 
Pt 0.0001 0.0003 
O(1) 0.0123 0.0066 
O(2) -0.0340 0.0071 
N(1) -0.0386 0.0075 
N(2) 0.0134 0.0071 
  Chi-squared = 56.30 (5.99*) 
The average Pt-N bond length of 2.039(8) Å and N(1)-Pt-N(2) angle of 83.6(3)º 
with the DACH ligand (in a chair conformation) were similar to values reported for 
other platinum(IV) complexes with the same non-leaving group, DACH100,101,102. 
The average Pt-O bond length of 2.03(1) Å was reasonable, comparable to that 
found in square planar complexes and similar to that of the equatorial Pt-N bond 
lengths found here. 
A consequence of the introduced disorder was that the Pt-NO2 distance, 2.05(2) Å, 
could not be determined to a high degree of accuracy. It nonetheless concurred 
with values reported for structurally similar complexes, e.g. 2.04(2) Å in 
                                            
* Theoretical value for two degrees of freedom-perfect planarity 
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[Pt(NH3)2(NO2)Cl3]103. Significant dissimilarities in the N-O bond lengths of the nitro 
group were evident, N(3)-O(32): 1.26(2) Å, N(3)-O(31): 1.17(3) Å, which were 
consistent with that expected for nitro groups104.  
The Pt-Cl(1) bond length of 2.319(3) Å in Pt(dach)(C2O4)(NO2)Cl was shorter than 
expected in relation to other platinum(IV) complexes having trans-coordinated 
nitro/nitrosyl and chloro ligands, e.g. 2.346(5) Å in cis,cis,trans-
[Pt(NH3)2(Cl)2(NO2)Cl]103 and 2.562(5) Å in trans,trans,trans-
[Pt(NO2)2(Cl)2(NO)Cl]104. This made it difficult to ascertain whether the nitro ligand 
had a significant trans-bond-lengthening effect, especially since there were no 
other Pt-Cl bonds in the same complex with which comparsions could be made. 
One way around this would be to compare the relative bond lengths in the dichloro 
analogue which co-crystallized, Pt(dach)(C2O4)Cl2. Any observed discrepancies in 
distances could then be ascribed to a potential trans influence of NO2. The Pt-Cl(2) 
bond in the latter complex was actually slightly, but not significantly, longer at 
2.32(2) Å. This result could unfortunately not be interpreted with much confidence 
due to its large esd, a consequence of the disordered model used and the 
restraints imposed. Analysis of the Pt-Cl bonds in trans-dichloroplatinum(IV) 
complexes, in general, often reveal significant discrepancies in the respective 
distances, especially if there are several dissimilar ligands in the coordination 
sphere, e.g. 2.301(5) and 2.314(5) Å in [Pt(cis-1,4-dach)(trans-Cl2)(CBDCA)]105, 
2.321(3) and 2.327(3) Å in mer-[Pt(en)(C5H6N2OS)Cl3]NO3106; 2.294(2) and 
2.311(2) Å in trans-[Pt(N,N’,O,O’)-(ethylenediamine-N,N’-di-3-propanoato)Cl2]107. 
From this data we concluded that the observed Pt-Cl distances are really a 
function of the co-ligands in the octahedral complex and caution should thus be 
excercised in comparing complexes having varied co-ligands. 
 
Structural determination of Pt(dach)(NO2)Br ( Mar4.1.4.3) 
The crystals were grown out of a dilute aqueous solution at 4C over a few days. 
The refinement of this crystal structure confronted us with analogous problems as 
in the case of Pt(dach)(C2O4)(NO2)Cl, Mar4.1.4. Thus, they were similarly 
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remedied by the addition of a disordered bromide atom, Br(2). However, in this 
case, no restraints were introduced and the structure refined adequately with an 
R-factor of 0.0322, for all data, and a goodness-of-fit on F2 of 1.109. Tables of the 
crystal data and refinement, atomic coordinates, isotropic and anisotropic 
parameters are listed in the Appendix. ORTEP diagrams of the platinum 
complexes with the atomic numbering schemes are shown in Figure 5-24, 
selected bond lengths and bond angles are listed Table 5-3. 
  
Figure 5-24 Ortep projections of Pt(dach)(C2O4)(NO2)Br (77%) (left) and 
Pt(dach)(C2O4)Br2 (23%) (right). 
 
Table 5-3  Selected bond lengths and angles in Pt(dach)(C2O4)(NO2)Br. 
 
Bond Lengths (Å)  Bond Angles (º) 
Bond Length Bond Length  Atoms Angle Atoms Angle 
Pt-N(1) 2.040(6) Pt-N(2) 2.043(7)  N(1)-Pt-N(2) 83.0(3) O(1)-Pt-O(2) 83.2(2) 
Pt-O(1) 2.031(6) Pt-O(2) 2.023(6)  N(3)-Pt-N(1) 93.3(5) N(3)-Pt-N(2) 92.5(6) 
Pt-Br(1) 2.466(1) Pt-Br(2) 2.494(6)  N(3)-Pt-O(1) 87.0(6) N(3)-Pt-O(2) 86.5(5) 
Pt-N(3) 2.07(2) N(3)-O(31) 1.20(2)  Br(1)-Pt-N(1) 92.3(2) Br(1)-Pt-N(2) 90.2(2) 
N(3)-O(32) 1.25(2) N(1)-C(11) 1.493(9)  Br(1)-Pt-O(1) 90.3(2) Br(1)-Pt-O(2) 87.9(2) 
N(2)-C(12) 1.478(10) C(11)-C(12) 1.537(11)  Br(1)-Pt-N(3) 174.0(5) Br(1)-Pt-Br(2) 174.0(2) 
C(12)-C(13) 1.507(12) C(13)-C(14) 1.548(13)  Br(2)-Pt-O(1) 93.4(3) Br(2)-Pt-O(2) 87.8(2) 
C(14)-C(15) 1.496(15) C(15)-C(16) 1.523(12)  Br(2)-Pt-N(1) 91.9(3) Br(2)-Pt-N(2) 86.1(3) 
C(16)-C(11) 1.520(10) O(1)-C(1) 1.291(11)  Pt-N(3)-O(32) 117(1) Pt-N(3)-O(31) 115(1) 
O(2)-C(2) 1.308(9) O(3)-C(1) 1.204(11)  O(1)-C(1)-C(2) 116.0(7) O(2)-C(2)-C(1) 116.0(7) 
O(4)-C(2) 1.214(10) C(1)-C(2) 1.553(12)  O(3)-C(1)-C(2) 118.9(8) O(4)-C(2)-C(1) 120.8(7) 
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Table 5-4  Deviations (d) and standard deviations (s) (Å) of selected atoms from the 
weighted least-squares plane of the platinum coordination sphere of Pt(dach)(C2O4)(NO2)Br. 
 
Platinum Coordination Sphere 
Atom d s 
Pt 0.000 0.0003 
O(1) -0.0094 0.0074 
O(2) -0.0034 0.0075 
N(1) -0.0048 0.0072 
N(2) -0.0073 0.0060 
  Chi-squared = 3.62 (5.99†) 
 
As in the case of Pt(dach)(C2O4)(NO2)Cl this compound too was found to 
crystallize with two water molecules in the lattice, which were hydrogen bonded to 
the amine nitrogens. The coordination geometry around the platinum(IV) metal 
centre was slightly distorted octahedral. As is reflected in the table quoting the 
deviations and standard deviations (see Table 5-4), the coordination plane was 
found to be slightly more planar than in the case of Pt(dach)(C2O4)(NO2)Cl. The 
equatorial plane formed by the donor atoms of the bidentate oxalate and 
diaminocyclohexane ligands, deviated slightly from planarity and exhibited bond 
angles from 83° to 97.6°, as in the case of Pt(dach)(C2O4)(NO2)Cl]. Axial sites 
were occupied by either a NO2 group and a bromide atom (77%) or by two 
bromide atoms (33%). Both groups occupied positions approximately 
perpendicular to the equatorial plane and directly opposite each other: N(3)-Pt(1)-
O(2) = 86.5(5)°, Br(1)-Pt(1)-O(2) = 87.9(2)°; N(3)-Pt(1)-Br(1)=174.0(5)°; Br(1)-
Pt(1)-Br(2)= 174.0(2)°. 
The average Pt-N bond length of 2.042(7)Å and N(1)-Pt(1)-N(2) angle of 83.0(3)° 
with the DACH ligand (chair configurmation) were similar to values reported for 
                                            
† Theoretical value for two degrees of freedom-perfect planarity 
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other platinum(IV) complexes with the same DACH non-leaving group100,101,102. 
Again, the introduced disorder made the assessment of the Pt-NO2 bond distance 
of 2.07(2) Å difficult to resolve with a high degree of accuracy. As in the case of 
Pt(dach)(C2O4)(NO2)Cl, it agreed with values reported for structurally similar 
complexes, e.g. 2.04(2) Å in [Pt(NH3)2(NO2)Cl3]103 and differences in the N-O bond 
distances in the nitro group were evident, N(3)-O(32) =1.25(2)Å and N(3)-O(31) = 
1.20(2)Å and were in agreement with values already reported104. 
The Pt-Br bond length of 2.466(1) Å is similar to values recorded in literature for 
trans,trans-dibromobis(N-methylglycinato)platinum(IV)108 of 2.455(3) Å.  The 
average Pt-O bond distance was found to be 2.03Å, as in the case of Mar4.1.4, 
this is considered reasonable for a Pt-O bond in the equatorial plane. This was 
found to be comparable to similar complexes as in [Pt(cis-1-4dach)(trans-
Cl2)(CBDCA)]105 of 1.987(1) Å and 1.995(1)Å. The Pt-N(3) bond length could not 
be calculated with great accuracy in consequence to the introduced disorder but 
was found to be 2.07(2) Å, very similar to that of 2.05(2) Å in the case of 
Pt(dach)(C2O4)(NO2)(Cl). The N(1)-Pt-N(2) bond angle in this case was found to 
be 83.0(3), only approximately 3 smaller than in the case of its chloro analogue.  
Substitution of the coordinated nitro group appeared to have occurred again with 
the dibromo analogue, Pt(dach)(C2O4)Br2, accounting for 23% of the observed 
molecules in the unit cell, whilst the residual 77% was that of the target complex 
(see Figure 5-25).  
Though HPLC-MS analysis indicated the crude material used for crystallization to 
be 93% pure, with the main contaminant being the platinum(II) precursor 
oxaliplatin, it was probable that ligand exchange occurred during the lengthy 
period of time required to grow suitable crystals.  
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Figure 5-25 Crystal packing diagram of Pt(dach)(C2O4)(NO2)Br.2H2O and 
Pt(dach)(C2O4)Br2.2H2O. 
  
5.4.3.3. Crystal data discussion 
 
The initial product of Mar 4.1.4, upon analysis with HPLC-MS, displayed a purity of 
greater than 95%, there was no eveidence of any of the Pt(dach)(C2O4)Cl2 
species. If, however, this compound was crystallised slowly out of a more dilute 
solution, over a longer period of time, the crystallographic analysis suggested the 
presence of an apparent contaminant, the dichloro species. It should be reiterated 
at this point, that it was the initial crystals, obtained upon redissolution, which were 
tested by a combination of HPLC-MS and which showed a purity of >95%, which 
were used in the cytotoxic evaluation. 
It may be that the increased length of time taken to grow crystals out of a more 
dilute solution, may allow more freedom for the growth of the other species too, as 
opposed to the initial product (used in anticancer testing), which we obtained out 
of a more concentrated solution over a much shorter period of time. 
Thus, this phenomenon could be attributed to the method of crystallisation 
employed. Futher investigations are being undertaken to clarify this issue. The 
anticancer results using the initial crystals, showed that the product was at least as 
effective as oxaliplatin, if not better. This is in agreement with studies (see later) in 
which the product is reduced by thiols – showing that the major byproduct was the 
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platinum(II) complex, oxaliplatin. This evidence strongly suggests that Mar4.1.4 
can be regarded as a prodrug for oxaliplatin, with the additional advantage of it 
having the potential of displaying a higher efficiency. In the same way, the 
occurrence of the coprecipitant, Pt(dach)(C2O4)(NO2)(Br2), can be explained as a 
result of the crystallisation method employed. 
Efforts to replace the anion trans to the NO2 group in the oxidation of oxaliplatin 
Due to the success achieved in the synthesis of Mar4.1.4 and Mar 4.1.4.3 it was 
decided to attempt to replace the position trans to the nitro group with other 
anions. This was done in order to see, in the event of successful synthesis, what 
effect these other anions would have on the anticancer activity of the 
mononitroplatinum(IV) species in particular. Other anions used include I-; ClO4-, 
CH3CO2- , CH3(CH2)2CO2-  and CN-. Attempts in this regard were less successful 
and thus only two of these will be referred to here. 
(i) The Iodide anion 
The same synthetic method was employed as for Mar4.1.4 and Mar4.1.4.3. The 
observation in terms of colour changes, however, differed slightly. Upon oxidation 
(with NO2), the reaction mixture assumes a murky light yellow colour, then it 
changes to a red-orange colour, then light yellow again followed by light green and 
after 30-40min a dark green. After two hours of oxidation it was an avocado green 
colour. The eventual product was a yellow-green slightly hygroscopic residue. The 
mass spectra is given in Figure 5-26. 
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Figure 5-26  The mass-spectrua obtained upon oxidation of oxaliplatin in the presence 
of NO2 and iodide in positive (bottom) and negative (top) ion modes. 
The mass-spectrum thus indicates that there is some unreacted oxaliplatin 
present. In the event where oxaliplatin is oxidized to its platinum(IV) associate, we 
have in the one case OH- and NO2 (m/z503.80-) coordinated to it and in another 
case a dinitro species (m/z529.80-) is present. At m/z522.80+, there is, what could 
be related to an I- coordinated to the oxidized oxaliplatin. The size of the peak 
could imply a lack of coordination. This lack of coordination could be attributed to 
the fact that there exists a possibility that the bulk of the iodide in solution is 
oxidized by NO2 to iodine as reflected in the equations below. 
N2O4  +  2e- 2NO2
- +0.88V
I2  +  2e- 2I- +0.54V  
(ii) The Butyrate anion 
Again the same reaction procedure was followed. In this case the colour changed 
from milky blue to a clear light blue colour (after oxidation of 2 hr). Inspection of 
the resulting mass-spectrum, Figure 5-27, indicates the presence of some 
[Oxaliplatin+NO2 + OH-]CHO2- 
[Oxaliplatin+2NO2 ]CHO2-  
[Oxaliplatin]H
[Oxaliplatin+I]
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unreacted oxaliplatin (m/z397.13+) once again, as well as coordinated NO2 and 
butyrate (m/z529.73+) and also coordinated NO2 and water (m/z500.93+). 
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Figure 5-27 The mass-spectra obtained upon the oxidation of oxaliplatin in the 
presence of NO2/CH3(CH2)2CO2- in the positive (bottom) and negative (top) ion modes. 
5.4.4   THE OXIDATION OF OTHER OXALATOPLATINUM (II) SPECIES 
In light of the successful synthesis of Mar4.1.4 and Mar4.1.4.3, it was decided to 
oxidise two oxalatoplatinum(II) species prepared here, which displayed promising 
anticancer action, to their mononitroplatinum(IV)oxalato counterpart.  The 
synthetic procedure is similar to that described in the oxidation of oxaliplatin (See 
Chapter 2). 
The oxidation of yol25.1 in the presence of NaCl 
The reaction sequence is presented in reaction (1). 
 
Oxaliplat + H2O+But 
Oxaliplat + NO2 + But 
[Oxaliplat]H+ 
[Oxaliplat-H]- 
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Where X = Cl- or Br- 
In the synthesis of the mononitroplatinum(IV)oxalato chloro analogue, the 
observable colour change were similar to that described for Mar4.1.4 and 
Mar4.1.4.3. This reaction yielded a product in 89% purity and 37% yield (see 
Figure 5-28). 
 
Figure 5-28  Chromatogram of yol25.1.4, the single peak indicating the presence of the 
product. 
The oxidation of yol25.1 in the presence of NaBr 
In the synthesis of its bromo analogue, a slightly different colour change was 
observed, in that it changed from a milky yellow to a yellow/orange solution. The 
resulting brown-orange product appeared slightly hygroscopic. The mass-spectra 
(Figure 5-29) revealed the presence of some unreacted oxalatoplatinum(II) 
species as well as the required mononitroplatinum(IV)oxalato bromo species. This 
product, even though obtained in higher yield (80%), was evidently of lower purity 
compared to its chloro analogue. The mass-spectra (Figure 5-29) show mostly the 
unreacted oxalatoplatinum(II) complex. 
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Figure 5-29  Mass-spectra obtained upon oxidation of yol25.1 in the presence of NO2 in 
the presence of Br. Positive ion mode (top) and negative ion mode (bottom). 
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Figure 5-30  Thermal stability of the mononitroPt(IV)L-histidine methyl ester chloro (a) 
and bromo (b) species. 
From the onset temperatures it seems as though the chloro analogue is more 
stable than its bromo counterpart in the solid state. The onset temperature of 
[M]H+ 
[M-H]- 
[M]Na+ [M’]H+ 
[M’-H]- 
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67.2°C of the bromo counterpart confirms the hygroscopic nature of the product; 
thereafter the product just decomposes. The chloro analogue displays a stability 
similar to that of its platinum(II) precursor, with virtually the same onset 
temperatures (143.4 vs 149.1°C). Transition 1(31.2%) in this case, can be related 
to a theoretical mass loss of the ligand (29.2%). 
The oxidation of yol35.1 in the presence of NaCl 
The reaction sequence is similar to that shown in reaction 1, with the exception 
that the ligand in this case is N-cyclohexyl-1,3-propanediammine. Upon oxidation, 
the reaction proceeds to from a milky green suspension. A resulting lime-coloured 
product was recovered in 55% yield.  The mass-spectra, (see Figure 5-31), 
reveals the presence of some unreacted oxalatoplatinum(II) species as well as 
some of the sought after product. Chromatographic determination of the purity of 
this product was not very successful due to lack of resolution. 
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Figure 5-31  Mass-spectra resulting from the oxidation of yol35.1 with NO2 in the 
presence of Cl. Positive ion mode (bottom) and negative ion mode (top).                                                             
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The oxidation of yol35.1 in the presence of NaBr 
 In the synthesis of the bromo-analogue, the colour changed from a yellow-green to a 
clear yellow solution, which resulted in the eventual production of a light yellow 
powdered product in a 69% yield. From the mass-spectra (Figure 5-32) we can see 
that the product is present, as well as some unreacted platinum(II)oxalate species. 
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Figure 5-32  Mass-spectra resulting from the oxidation of yol35.1 in the presence of NO2 and 
Br. Positive ion mode (top) and negative ion mode (bottom). 
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Once again chromatographic determination of the purity of the product was less 
successful. 
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Figure 5-33 Thermogravimetric curves of the chloro (yol35.1.4) and bromo (yol35.1.3) 
analogues obtained upon the oxidation of yol35.1. 
From this we can see that the chloro and bromo analogues follow a similar 
degradation pattern; showing a stability up to ~180ºC. Two transitions are 
apparent in both cases. In the case of the chloro analogue, transition 1 (23.7%) 
can theoretically be related to the loss of NO2, Cl- and CO2 (24%) and transition 2 
(27.1%) can be related to the theoretical loss of ligand (30%). However in the case 
of the bromo analogue, transition 1 (32.9%) can relate to the theoretical loss of 
ligand and CO gas (32.6%), whereas transition 2 (23.9%) can at best be related to 
the theoretical loss of NO2 and Br-(22.3%). 
5.4.6  CHEMISTRY INVOLVED DURING THE REACTION OF NO2 WITH Pt(II) 
COMPLEXES 
As a result of the efforts directed towards the preparation of the mononitro Pt(IV) 
complexes, it seems necessary to present at this point a hypothesis based on 
literature reviews on the chemistry involved in these reactions. 
In general, the reaction of NO2 gas with solutions of Pt(II) complexes are 
characterized by three different colour changes, i.e. an initial intense blue 
colouration, followed by a green colour and ultimately a slower reaction with air 
resulting in a yellow solution and/or yellow precipitate. 
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Blue products 
Initially, persistent dark blue solutions were only obtained when NO2 was bubbled 
through a solution of oxalatoPt(II) complexes (like bis-oxalato(dach)Pt(II)), in an 
effort to synthesize the dinitro Pt(IV) complex (thus in the absence of chloride). 
Abbot et al.109 prepared dark blue crystals of K[Pt(NO2)4(NO)H2O] by the reaction 
of 3:1 H3PO4:H2O solution with K2Pt(NO2)4 under argon at 80°C for 1 minute and 
subsequent cooling at -20°C (solution A).  A crystal structure determination of the 
product (Figure 5-34) showed four planar nitro groups and one bent NO group 
trans to a H2O molecule.  The Pt-N bond length of the NO is slightly longer than 
the Pt-N bonds of the NO2 groups, 2.1Å vs 2.04 and 2.06Å.  The NO bond is 
shorter than those of the NO2 ones 1.19Å vs 1.21 and 1.22.  The Pt-O bond of the 
water molecule is long 2.37(Å).  This suggests a very strong trans directing effect 
of the bent NO.  This seems to be the main reason why dimerization through Pt-Pt 
bonding does not occur as compared to the situation in the platinum blues where 
the multiple bridging of the short distance O-C-N bonds, e.g. in polymeric α-
pyridone platinum complex, forces a Pt-Pt bond distance of 2.78Å, thus resulting in 
Pt-Pt bonds and a compound having a formal oxidation state of 2.25.110 
The [Pt(NO2)4(NO)H2O]- complex is one of the very few dark blue monomeric 
species known, since these blue species are common for dimeric “platinum blues” 
which have Pt-Pt bonds and bridging anions, and are thus formally regarded as 
platinum compounds of intermediate oxidation states (>2<4)111. The above anion 
is very unstable, since the coordinated water molecule is readily replaced by 
coordinating anions like halides Cl-, Br-.  The complex is also very strongly 
reducing. 
The best description of this complex is a platinum(IV) compound, bonded to NO-, 
thus trans-aquo(nitrosyl)tetranitroplatinate(IV).  It seems, therefore, reasonable to 
assume that the blue colour obtained from Pt(II) amine complexes studied in this 
thesis and NO2, can be seen as a similar aqua (nitrosyl) complex of Pt(IV).  The 
extent of the electron withdrawal can be regarded as limited, so that the platinum 
is really closer to that of the milieu in a platinum(III) complex. The blue colour is 
maintained if the H2O molecule is replaced by a weakly coordinating anion like 
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NO3, e.g. K2[PtNO2)4(NO)(NO3)].112 
 
N(5)-O(5b)              1.19Å 
Pt-O(6)   2.37Å 
Pt-N(5)   2.10Å 
Pt-N(5)-O(5b) (angle) 129° 
 
 
Figure 5-34  Crystal structure of trans-aqua(nitrosyl)tetranitroplatinate(IV) anion109. 
Green Complexes 
When 3 moles of KCl were added to the dark blue solution A, the colour turned to 
dark green.  Upon maintaining the temperature of the green solution at -20°C, 
green crystals of K2[Pt(NO2)2(NO)Cl3] gradually form when the solution is kept 
under argon. 
In this complex, two planar nitro groups are replaced by two bonded chlorides and 
the trans H2O molecule is also replaced by a bonded chloride.  The NO is still 
bent, but the Pt-N-O angle changed from 129° in the former, to 119° in the latter. 
The latter suggests a significant electron withdrawal from the NO bond.  The 
shorter Pt-N distance, 2.06Å as compared to 2.10Å in the former, indicates a 
stronger Pt-N bond in the chlorocomplex.  The Pt-Cl bond length of 2.562Å  for the 
trans Cl- is  ~0.25Å longer than the planar chlorides, thus still suggesting a strong 
trans effect. This transition therefore seems to suggest that more electron 
withdrawal from the platinum occurs, which leads to stabilization, approaching 
what can be considered as Pt(IV). 
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N(3)-O(3)  1.19Å 
Pt-Cl(2)  2.320Å 
Pt-Cl(3)  2.562Å 
Pt-N(3)                        2.06Å 
Pt-N(3)-O(3) (angle) 119° 
 
 
Figure 5-35  Crystal structure of trans-dinitro-trans-dichloro-trans-   
nitrosylchloroplatinum(IV) ion109. 
In 1961 Wilkinson et al.113 obtained green complexes, viz. K2[Pt(NO)Cl5] and 
K2[Pt(NO)(NO2)4Cl], by the reaction of NOCl in CHCl3 from K2PtCl4 and 
K2Pt(NO2)4, respectively.  The complexes were described as six-coordinated 
platinum(II) complexes containing NO in the form of NO+, since the NO stretch 
frequency values were found to be in the 1700 cm-1 region.  Literature values in 
the vicinity of 1800 cm-1 are regarded as due to NO+ groups, whereas those in the 
vicinity of 1100 cm-1 can be regarded114 as due to NO-.   Judging from this data, it 
seemed reasonable to assign it to Pt(II) even in light of the extremely rare cases of 
six-coordinate Pt(II) complexes.  The X-ray structures of the more recent 
complexes clearly showed to be bent Pt-N-O structures, thus a better description 
would be NO- groups.  These complexes can be regarded as unstable Pt(IV) 
species.  It was stated that the green complexes were unstable and decomposed 
by water to become stable Pt(IV) species. 
Yellow products 
The colouration to yellow is then associated with the air oxidation of the 
coordinated NO ligand resulting in a nitro ligand, thus further electron withdrawal 
from the platinum to produce an air stable Pt(IV) complex (See crystal structure of 
Mar4.1.4 recently prepared in this laboratory).  
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O1 and O2 are oxygens of two hydrated water molecules 
Figure 5-36  Structure of (trans-ℓ-1,2-diaminoyclohexane)oxalatochloronitro-
platinum(IV)dihydrate, Mar4.1.4. 
In light of the previously mentioned work done as published and similar 
observations noted, it seems reasonable to assume that the reaction sequence 
experienced in this work can be expected to be as follows: (taking the oxaliplatin 
reaction as example) 
Pt(dach)(C2O4)
H2O
NO2
Pt(dach)(C2O4)(NO)(H2O)
Cl-
Pt(dach)(C2O4)(NO)(Cl)
O2 Pt(dach)(C2O4)(NO2)(Cl)
Turquoise Green Yellow  
A recent crystal structure of the fac form of CPA 7,115 shows that the light yellow 
compound consists of a platinum(IV) complex with a NO2 group trans to the chloro 
atom, where the latter bond is significantly longer than the planar Pt-Cl bonds.  
See crystal structure of CPA 7 below.   
 
Figure 5-37 The crystal structure of the fac-isomer of CPA 7115. 
Although NO was not directly synthesized and provided as such, both HNO3 and 
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NO2 gas can be considered as a source of NO as illustrated by the reaction 
sequence given in the equations below. When concentrated HNO3 is used as 
reagent, NO gas is produced by the following sequence of reactions.   
NO3-  +  4H+  +  3e- NO  +  2H2O  
When NO2 gas reacts with a medium containing H2O, NO is similarly formed by 
the equations below.   
2NO2  +  H2O HONO  +  H+ NO3-
3HONO 2NO  +  H+ NO3-  +  H2O  
In the case of NO2 gas, a certain amount of water in the solvent system seemed to 
be a requirement for the secondary formation of NO through the auto ionization 
indicated above. 
In conclusion, it seems that the best description for these reactions is the oxidative 
addition of the NO radical and the simultaneous withdrawal of an electron to 
produce a bonded group, best described as being in the NO- state.  Having a 
weakly bonded H2O trans to it, results in a relatively unstable intermediate specie. 
However, in the presence of excess chloride ions, the H2O molecule is replaced by 
the aforementioned chloride anion.  Further electron transfer occurs from the 
bonded platinum to the chloro atom, followed by oxidation of the bonded NO group 
to a NO2 group, thus completing the stabilization of the platinum(IV) complex.   
The reaction sequence can be regarded as that given below:  
H2O
Pt(NH3)2Cl2
NO
Pt(NH3)2Cl2(NO)(H2O)
Cl-
Pt(NH3)2Cl3(NO)
O2
Pt(NH3)2Cl3(NO2)
Yellow Blue Green Light Yellow  
5.4.7  CYTYTOXIC EVALUATION 
The cytotoxic behaviour of the complexes will be displayed in Table 5-5 to Table 5-
7 and Figures 5-38 to Figure 5-40. 
 
  
Table 5-5  Tabular representation of the effct of the mononitroplatinum(IV)halo complexes Mar4.1.4 and Mar4.1.4.3 on each of the three 
cancer cell lines with reference to both cisplatin and oxaliplatin 
 
Cell lines                   Hela HT29 MCF7 Concentration (µM) 
Cisplatin 67±2 82±1 84±2 50±3 73±1 73±1 68±3 73±2 75±2 12.4 61.9 123.9 
Oxaliplatin 40±3 59±4 63±2 25±10 47±4 65±1 40±2 57±1 59±1 11.6 48.1 115.6 
Mar4.1.4 51±5 62±1 65±1 40±2 45±4 59±3 56±2 62±2 63±3 13.5 67.7 135.4 
Mar4.1.4.3 55±1 62±1 69±0.7 42±2 49±3 62±2 55±3 63±2 69±4 12.5 62.6 125.2 
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Figure 5-38  Graphical representation of the effect of the mononitroplatinum(IV)halo complexes Mar4.1.4 and Mar4.1.4.3 on each of the 
three cancer cell lines with the reference to both cisplatin and oxaliplatin. 
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 Table 5-6  Tabular representation of the effect of the mononitroplatinum(IV)halo complexes4.1.4 and Mar4.1.4.3 as well as some other 
mononitroplatinum(V)oxalatohalo complexes synthesized, on each of the three cancer cell lines with reference to cisplatin. 
 
Cell lines Hela HT29 MCF7 Concentration (µM) 
Cisplatin 67±2 82±0.7 284± 50±3 73±1 73±1 68±3 73±2 75±2 12.4 61.9 123.9 
Mar4.1.4 51±5 62±1 65±1 40±2 45±4 59±3 56±2 62±2 63±3 13.5 67.7 135.4 
Mar4.1.4.3 55±1 62±1 69±0.7 42±2 49±3 62±2 55±3 63±2 69±4 12.5 62.6 125.2 
yol25.1.4 10±5 24±4 32±1 0±6 0.4±3 2±3 17±3 26±4 40±3 5.4 27.2 54.4 
yol25.1.3 0±2 15±7 33±4 0±6 6±4 11±6 5±3 15±4 26±3 5.3 26.3 52.7 
yol35.1.4 7±4 19±8 42±6 2±3 6±2 6±3 10±2 13±6 58±15 2.1 9.8 19.6 
yol35.1.3 1±3 5±4 16±3 0±2 0±6 7±4 4±10 9±6 11±5 1.1 5.72 11.4 
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Figure 5-39  Graphical representation of the effect of the mononitroplatinum(IV)halo complexes4.1.4 and Mar4.1.4.3 as well as some 
other mononitroplatinum(IV)oxalatohalo complexes synthesized, on each of the three cancer cell lines with reference to cisplatin.
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Table 5-7 A tabular representation of the effect of some of the mononitroplatinum(IV)halo complexes with a DACH non-leaving group on 
each of the three cancer cell lines with reference to both cisplatin and CPA7. 
 
Cell lines Hela HT29 MCF7 Concentration (µM) 
Cisplatin 67±4 81±2 85±1 47±7 71±0 71±1 66±4 66±1 69±1 12.1 58.3 120.2 
CPA7 59±3 80±1 80±1 43±2 73±0 73±1 60±1 71±1 69±1 9.1 45.2 95.3 
Mar4.1.4 49±3 55±3 57±4 33±3 48±2 59±2 45±5 55±1 57±3 10.1 60.3 120.4 
Mar4.1.4.3 52±1 57±1 59±5 36±5 49±5 63±4 49±1 55±3 59±2 9.3 55.3 105.1 
Mar4.1.6 53±2 60±1 67±2 37±2 0±12 32±20 52±1 59±2 62±2 10.1 55.4 103.2 
Pt(IV)dachCl2 75±5 84±2 91±0 35±5 60±0 72±1 55±1 58±1 64±4 12.9 62.4 125.3 
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Figure 5-40  Graphical representation of the effect of some of the mononitroplatinum(IV)halo complexes with a DACH non-leaving group 
on each of the three cancer cell lines with reference to both cisplatin and CPA7.
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Interaction of some of the Pt(IV) compounds with biomolecules 
Interaction of Mar 4.1.4 with biomolecules 
In an effort to obtain information of possible reactions which can occur in a 
biological system, a study was made in this laboratory of the interaction of 
Mar4.1.4 with biomolecules.  This is likely to provide information which could lead 
to an understanding of the mechanism of its anticancer action. Upon addition of 
cysteine to Mar4.1.4 the molecular distribution pattern which was obtained upon 
reduction includes the presence of oxaliplatin and oxaliplatin derivatives. This is 
clearly illustrated in Figure 5-41 where the positive ions attributed to Mar4.1.4 
(m/z478&495) are completely replaced by those of oxaliplatin (m/z397). This 
observation implies that the anticancer activity observed in the cell-line test may 
well be due to the in situ formation of oxaliplatin from Mar4.1.4 and thus Mar4.1.4 
can be considered as an oxaliplatin pro-drug. This phenomenon could be related 
to the efficacy of Mar4.1.4. A similar behaviour is noticed in the case of cisplatin 
and CPA7 where the Pt(II)complex is a good anti-cancer agent and the 
platinum(IV) a better one. 
 
Figure 5-41   Combination mass-spectra, the top indicates Mar4.1.4 and oxaliplatin 
mass-fragments before interaction with biomolecules, whereas the bottom is the 
resultant mass-spectrum after interaction with biomolecules. 
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Interaction of yol25.1.4 with biomolecules 
As in the case of Mar4.1.4 it was of interest to see how this compound would 
interact with biomolecules. Similarly to Mar 4.1.4 this compound was reduced to 
its platinum(II) precursor (see Figure 5-42) 
 
Figure 5-42  Combination chromatogram representing yol25.1.4 before (top) 
interaction with biomolecules and of chromatographic peaks obtained after (bottom) 
interaction with biomolecules. 
5.4.7  CYCLIC VOLTAMMETRIC ANALYSIS 
It is generally assumed that in order for the platinum(IV)-complexes to bring into 
effect their anti-cancer action, they have to be reduced to their platinum(II) state. 
Although Pt(IV) complexes are relatively inert to substitution reactions, reduction can 
take place via any small molecules, proteins and enzymes, especially biomolecules 
in the bloodstream93. However, there has been evidence that platinum(IV) 
complexes can themselves bind to nucleotides116 and thus a more direct mode of 
action cannot be completely ruled out at this early stage. This leads to another 
uncertainty pertaining to Pt(IV) complexes, and that is the question of how resistant 
to reduction Pt(IV)-complexes can be and still retain their anticancer activity. For 
instance, it has been reported that some Pt(IV)-complexes with highly negative 
reduction potentials have high activities116. There seems to be no obvious correlation 
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then between activity and the ease with which reduction occurs since iproplatin, 
which is more difficult to reduce and has similar activity to the far more easily 
reducible tetraplatin116.   
It has been reported however, that the ease of reduction of Pt(IV)-complexes can 
be affected by varying the axial groups. Complexes with axial hydroxo-ligands 
were found to be more difficult to reduce than those with either carboxylato-or 
chloro-ligands116. The idea being that the more difficult the Pt(IV) complex is able 
to be reduced, the better its chances of reaching the target site intact, where 
reduction will then take place and exhibit the desired anti-cancer action (high 
activity) with reduced side-effects (low toxicity). 
In an attempt to illucidate on this it was decided to determine the reduction 
potential of some of the Pt(IV) complexes prepared in this laboratory. It should be 
borne in mind that the reduction of Pt(IV) complexes results in the loss of the 
axial ligands, which renders this process irreversible;  consequently the resultant 
Ep values are cathodic half-wave potentials and are kinetic, not thermodynamic 
controlled.  
(A) Considering the effect of the anion trans to NO2 
In this case we employed the use of Mar4.1.4 vs. Mar4.1.4.3 which resulted in the 
following curves (see Figure 5-43).  
-65
-55
-45
-35
-25
-15
-5
5
15
25
35
-1250-1000-750-500-2500250500750100012501500
Potential(mV)
C
u
rr
en
t(
µA
)
Mar4.1.4.3
Mar4.1.4
-243mV
-347mV
                           
170 
 
Figure 5-43  Cyclic voltammograms of Mar4.1.4 and Mar4.1.4.3 
The curves thus indicate that in this case, having the chloride anion trans to the 
NO2 group, the reduction potential is higher (-347mV), which makes it more 
resistant to reduction than its bromo counterpart (-243mV).  
(B) The axial positions: NO2/Cl vs Cl/Cl 
In this instance Mar4.1.4 (NO2/Cl) was compared to Mar4.1.6117 (Cl/Cl)  (which 
was also prepared in this laboratory), (see Figure 5-44). 
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Figure 5-44 Cyclic voltammograms of Mar4.1.4 and Mar4.1.6. 
From the above curves we can deduce that the platinum(IV)-complex with two 
chlorides in the axial position, is much more readily reduced (-140mV) than in the 
case of pairing a chloride trans to an NO2. Thus is seems as though the NO2 has 
a much more stabilizing effect on the platinum(IV) complex.  
(C) The effect of changing the leaving group while keeping the axial ligands the   
same 
In this case we compared: 
Pt
O
O
C
C
O
O
H2
N
N
H2
Pt
Cl
Cl
H2
N
N
H2
Cl
NO2
Cl
NO2
vs.
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Table 5-8  Table of Electrode potential values of Pt(IV)dachCl2 and Mar4.1.4 
 
Complex Ep (mV) 
Pt(IV)dachCl2 -422 
Mar4.1.4 -374 
 
So it seems as though the mononitroplatinum(IV) complex with the two chlorides 
in the equatorial  position is more resistant to reduction than its oxalato analogue. 
This indicates that the equatorial ligands do indeed affect the reduction potential 
of the platinum(IV) complex118. It could be that despite the chelate effect an 
oxalate group induces, the two chloro ions in the equatorial position stabilizes the 
platinum(IV) complex better than the oxalato group in the same position. This 
could also be due to the fact that chloride in less electronegative than oxygen 
thus making it a better lewis base. 
Reduction potential of all Pt(IV)oxalato complexes compared 
The effect of varying the non-leaving group  
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Figure 5-44   Cyclic voltammograms of Mar4.1.4, yol35.1.4 and yol25.1.4 
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Figure 5-45  Cyclic voltammograms of Mar4.1.4.3, yol35.1.3 and yol25.1.3. 
In the case where the equatorial leaving group is changed, a trend is not that 
obvious. In the case of the mononitoplatinum(IV) chloro complexes Mar4.1.4 
displays better resistance to reduction, but in the case of bromo analogues, 
yol25.1.4 (L-hme as leaving group) displays the better resistance, even better 
than its chloro counterpart, yol25.1.3. What is apparent though is that 
mononitroplatinum(IV) complexes containing the DACH leaving group display a 
reduction potential mid-way between these values reported here.  
Table 5-9  Solubility of some of the mononitroplatinum(IV) complexes 
 
Complex Solubility( mM) 
Oxaliplatin 18.28 
Mar4.1.4 4.18 
Mar4.1.4.3 4.17 
Pt(dach)Cl2 0.38 
Pt(dach)Cl2+NO2+Cl 11.35 
yol25.1 0.30 
yol25.1.4 4.24 
yol25.1.3 7.46 
yol35.1 2.31 
yol35.1.4 0.86 
yol35.1.3 0.42 
Cisplatin 3.33 
CPA7 155.27 
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5.4.8 DISCUSSION  
In considering the cytotoxic data, (see Table 5-5 and Figure 5-38), we see that 
Mar4.1.4 and Mar4.1.4.3, display better anticancer action than oxaliplatin, its 
platinum(II) precursor. To some extent, albeit marginally, Mar 4.1.4.3 performs 
better than Mar4.1.4. It can also be seen that CPA7 displayed anticancer action 
comparable to that of cisplatin (see Table 5-7 and Figure 5-40). Independent 
studies performed on our behalf have also confirmed that Mar4.1.4 displayed 
STAT inhibition better than that of CPA7. 
We noted that yol25.1 displayed potential as an anticancer agent, especially in 
the Hela and MCF7 cell lines. However, upon oxidation, its platinum(IV) 
analogue, yol25.1.4 does not seem to perform to the same extent. It could be due 
to the fact that the ligand, L-histidine methyl ester, with its electron withdrawing 
nitrogen and carboxylate group are ineffective at stabalising the platinum(IV) 
complex.  What was interesting to find though was that upon reaction with 
cysteine (see interaction with biomolecules), both Mar4.1.4 and yol25.1.4 were 
reduced to their platinum(II) precursors, with no platinum-cysteine complexes 
present, indicating that these thiols act as reducing agents and not so much as 
complexing agents. This implies that the mechanism of action of these complexes 
is indeed very complicated. The lack of activity of yol25.1.4 could be ascribed to a 
number of factors, such as decreased cellular uptake due to lack of lipophilicity. 
The rest of the complexes, yol25.1.3; yol35.1.4 and yol35.1.3, were tested, 
despite their unconfirmed purity and lower tested concentrations, in order to get 
an indication of their anticancer potential (see Figure 5-39 and Table 5-6). 
Mar4.1.6, better known as tetraplatin, was also synthesized in this laboratory.  It 
displayed anticancer action comparable to that of Mar4.1.4 and Mar4.1.4.3, 
despite its much more positive reduction potential of -140 mV compared to - 347 
and -243 mV in the case of the former two respectively. This then corroborates 
literature findings, which report that there is no obvious correlation between 
activity and ease of reduction of a complex116. However, literature also reports 
that reduction potential of a complex is more affected by the choice of axial 
ligands than equatorial ones119.  If both the axial ligands are replaced in the 
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following order chloride, acetate, hydroxide, the reduction potentials were found 
to increase in that order116,119. A similar trend was also observed, in the case of 
Mar4.1.6 <  Mar4.1.4.3 < Mar4.1.4, showing more negative reduction potential in 
the order given. Thus the chloro ligands trans to each other in the platinum(IV) 
complex were found to be more labile, whereas the nitro group had a more 
stabilizing effect on the bromo and chloro ligand trans to it. Furthermore, it was 
interesting to note that the TG curves of Mar4.1.4 and Mar4.1.4.3 (see Figure 
5-18 and Figure 5-21) displayed similar stability and their solubity was also very 
similar (Table 5-9). The only difference seems to be their difference in reduction 
potential, but despite this their anticancer activity is very similar. 
If one considers the anticancer data given in Table 5-7 and Figure 5-40, we can 
see that the mononitroplatinum(IV) complexes with chloro ions in the equatorial 
position as leaving groups, i.e. CPA7 and Pt(IV)dachCl2, display better anticancer 
action than their oxalatoplatinum(IV) analogues. It could be inferred that chloro 
ions as non-leaving groups, with their lower electronegativity than oxygen in 
oxalate, despite its chelate effect, are much better at stabilizing platinum in 
oxidation state four. Furthermore, these two complexes, CPA7 and Pt(IV)dachCl2, 
also displayed a much more positive reduction potential, -49399 and -422mV 
respectively, thus they were less easier reduced than their oxalato counterparts. 
Based on the reduction potentials and our observation (except in the case of the 
Hela cell line) seen in Table 5-7 and Figure 5-40, CPA7 outperforms 
Pt(IV)(dach)NO2Cl. It could at least be deduced that monodenate ligands as non-
leaving groups (CPA7’s NH3), as opposed to bidentate leaving groups (DACH of 
Pt(IV)(dach)Cl2), also affect the reduction potential of the platinum(IV) complex.  
In a previous study, the delicate structural differences between cis-
trans[PtCl2(OAc)2(NH3)cyclohexylamine] also known as JM216, were compared 
to cis,trans,cis-[PtCl2(OCOCH3)2(chpda)], which is the platinum(IV) complex of 
yol35.2 (and the reason why we studied its oxalato platinum(IV)’s anticancer 
behaviour). It was however, reported that the presence of a bidentate leaving 
group in the equatorial position, caused inferior anticancer action to JM216 when 
tested on the Mouse Leukemia L1210 Cell line120.  
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It should be obvious that a number of factors can affect the anticancer action of 
platinum(IV) complexes. At this stage one can only hypothesise by saying that a 
moderate reduction potential is most propably a requirement, since a too positive 
reduction potential may result in the complex being reduced too easily, whereas a 
too negative reduction potential may result in reduced cellular uptake of the 
complex and less action. Then there are other factors too, such as lipohilicity and 
water-solubility. As displayed in Table 5-9 , with the exception of complexes of 
yol25.1, all the oxalatoplatinum(IV) complexes display a decrease in aqueous 
solubility as opposed to their platinum(II) counterparts. 
Thus an understanding of the features that can be used to control the 
pysiochemical properties may be a key to the development of platinum(IV) 
complexes which exhibit desireable biological activity and will be explored in the 
future. 
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CHAPTER 6   
CONCLUSION 
NON-AQUEOUS PREPARATIVE METHOD FOR OXALIPLATIN 
A novel, essentially non-aqueous non silver method, was developed for the 
synthesis of oxaliplatin. The requirements of such a solvent system could be 
obtained by considering the detailed chemistry involved in this direct ligand 
exchange reaction between Pt(dach)Cl2 and oxalate. Through consideration of 
factors such as; ionization capability of the solvent, limited potential for solvolysis 
(hydrolysis) - since elevated temperatures will be required - donor number of 
solvent, boiling point and solubility of reagents i.e. Pt(dach)Cl2 and an oxalate 
salt. It was decided on a mixed, essentially non-aqueous solvent system of dmf 
(95%) and water (5%) per volume. The utilization of a non-aqueous solvent, 
greatly limited the choice of the oxalate salt. Tetrabutylammonium oxalate proved 
to be suitable. Some water was required to solvate the high charge density 
oxalate ions, while simultaneously promoting ionization.  
Kinetic studies were performed over a temperature range from 75°C to 85°C, in 
5°C increments. The reagent ratios i.e. Pt(dach)Cl2 : moles oxalate were varied 
from 1:1.5; 1:2.5 and 1:5. An optimal solvent ratio of 95:5 dmf/water was 
employed, based on degradation studies of Pt(dach)Cl2 in dmf. The studies 
showed that a maximum of 65% formation of oxaliplatin could be obtained at all 
temperatures studied. Equal concentrations of Pt(dach)Cl2 and oxaliplatin are 
obtained at ~44% formation of product at all temperatures studied. 
In individual degradation studies, of each of oxaliplatin and Pt(dach)Cl2, it was 
shown that the former does not decompose in the presence of excess oxalate, 
but that the latter decomposes increasingly with increase in water content but not 
in pure dmf. Water appears to play a catalytic role, in so far as the concentration 
of [Pt(dach)Cl(H2O)]+ is not detectable, but [Pt(dach)Cl(dmf)]+ and 
[Pt(dach)Cl(MeCN)]+ can readily be detected. However the dmf adduct does not 
form in pure dmf solution. An international patent was taken out for this reaction. 
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The synthesis was tested on a large scale. 
NEW ASPECTS OF DIAMINE PLATINUM COMPLEXES 
The presupposition that a non-leaving group having a planar tail-end, which upon 
coordination has a relatively sharp angle with the coordination plane, has 
recommendable anticancer action is not valid in general, as proved by the poor 
anticancer action of N-benzylethylenediamine (ligand 33) and even in the case of 
2-aminobenzylamine (ligand 29).  
In the case of 2-aminoethylaminoethanol, although the secondary OH-group 
increases the solubility of the complex, it seems to have a negative effect on the 
anticancer action, when the complex of this ligand is compared to that of 
ethylenediamine.  
In the case of complexes with N-cyclohexyl-1,3-propanediamine, the much less 
than anticipated anticancer action can possibly be related to stereochemical 
crowding of the secondary amine, which has a negative effect on anticancer 
action. The crowding is also suggested by the ball and stick models. If all these 
are compared to L-histidine methyl ester, having a protruded aromatic nitrogen 
and a primary amine, this ligand can be regarded as the least crowded. 
The fact that platinum(II) complexes containing L-histidine methyl ester as a non-
leaving group all have good anticancer action towards all the cancer cells (Hela; 
HT29; MCF7), independent of the leaving group tested viz. chloride(Cl-), bromide 
(Br-) and oxalate(C2O42-), is exceptional and only occurs in the case of very few 
other non-leaving groups. 
MONONITROPLATINUM(IV) COMPLEXES 
Recently, the mononitrochloro compound cis-diamminedichloro-trans-nitrochloro 
platinum(IV) (CPA7) was prepared, tested and proved to be very effective as an 
anticancer agent. However, this compound could not be prepared in a high 
degree of purity or high yield. The studies performed here, using trans (1R,2R)-
1,2 diaminecyclohexane (DACH) as a diamine ligand and Pt(dach)Cl2 as starting 
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material, produced a mononitrochloro compound in a much higher yield and a 
high degree of purity. This compound also had very good anticancer behaviour. 
An international patent has been filed on this complex. 
Further studies have been directed towards oxalato species. Using oxaliplatin as 
starting material, a mononitrochloro complex, (trans(R,R)-
1,2-diaminocyclohexane) (oxalato)mononitrochloroplatinum(IV) (Mar 4.1.4), was 
prepared in a yield in excess of 80% and a purity in excess of 95%. The product 
had excellent anticancer behaviour. An international patent has been filed on this 
complex. A full X-ray structural determination of Mar 4.1.4 clearly showed the 
chloride trans to the coordinated NO2 group in an octahedral complex. The bromo 
analogue is similary synthesized and characterized and the Pt(II)/Pt(IV) redox 
potentials were determined and these complexes were observed to be stable. 
This was also indicated by thermogravimetric analysis. 
Efforts to replace the anion trans to the NO2 group by either iodide, perchlorate, 
butyrate, acetate and cyanide, were not successful. 
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A. LIST OF COMMON NAMES AND CHEMICAL FORMULAS 
Tables of chemical formulas and common formulas used for complexes 
prepared 
Ligand: L-histidine methyl ester (L-hme); 25 
 
 H2N
HN
O
O
N
 
Complexes prepared 
                  
 
Ligand: 2-aminobenzylamine (2-aba); 29 
 
Complexes prepared 
              
Chemical Formula  Common Formula 
Pt(L-hme)Cl2 yol25.2 
Pt(L-hme)Br2 yol25.3 
Pt(L-hme)C2O4 yol25.1 
Pt(L-hme)I2 yol25.5 
Pt(L-hme)(C2O4)NO2Cl yol25.1.4 
Pt(L-hme)(C2O4)NO2Br yol25.1.3 
Chemical Formula  Common Formula 
Pt(2-aba)Cl2 yol29.2 
Pt(2-aba)Br2 yol29.3 
Pt(2-aba)C2O4 yol29.1 
Pt(2-aba)I2 yol29.5 
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Ligand: 2-aminoethylaminoethanol (2-aeae); 31 
 
H
N
NH2HO  
Complexes prepared 
 
 
Ligand: N-benzylethylenediamine (N-beda); 33 
 
 
H
N
H2N  
Complexes prepared 
 
 
Chemical Formula  Common Formula 
Pt(2-aeae)Cl2 yol31.2 
Pt(2-aeae)Br2 yol31.3 
Pt(2-aeae)C2O4 yol31.1 
Pt(2-aeae)I2 yol31.5 
Chemical Formula  Common Formula 
Pt(N-beda)Cl2 yol33.2 
Pt(N-beda)Br2 yol33.3 
Pt(N-beda)C2O4 yol33.1 
Pt(N-beda)I2 yol33.5 
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Ligand: N-cyclohexane-1,3-propanediamine (N-chpd); 35 
 
NH
H2N
 
Complexes prepared  
 
 
Ligand: (1R,2R)-cyclohexane-1,2diamine  (DACH) 
 
H2N
H2N  
Complexes prepared 
 
 
  
 
Chemical Formula  Common Formula 
Pt(N-chpd)Cl2 yol35.2 
Pt(N-chpd)Br2 yol35.3 
Pt(N-chpd)C2O4 yol35.1 
Pt(N-chpd)I2 yol35.5 
Pt(N-chpd)C2O4(NO2)Cl yol35.1.4 
Pt(N-chpd)C2O4(NO2)Br yol35.1.3 
Chemical Formula  Common Formula 
Pt(dach)(C2O4)(NO2)(Cl) Mar4.1.4 
Pt(dach)(C2O4)(NO2)Br Mar4.1.4.3 
Pt(dach)(C2O4)(Cl)2 Mar4.1.6 
Pt(dach)(Cl3)NO Pt(IV)(dach)Cl2 
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B.  DATA ANALYSIS – C, H & N 
Chloroplatinum(II) complexes 
The elemental analysis of the chloroplatinum(II) complexes is provided in Table B-
1 
Table B-1 Presentation of Elemental analysis of the chloroplatinum(II) complexes 
%C %H %N 
COMPLEX 
Exp Calc Exp Calc Exp Calc 
yol25.2 19.1 19.3 2.5 2.6 9.6 9.7 
yol29.2 20.9 21.7 2.5 2.6 6.8 7.2 
yol31.2 12.9 12.9 3.5 3.3 7.6 7.6 
yol33.2 25.6 25.9 3.6 3.4 6.1 6.7 
yol35.2 21.9 25.6 4.6 4.8 5.5 6.6 
Table B-1 reflects that the elemental analysis is acceptable and confirmed their 
carbon, hydrogen and nitrogen stoichiometries. Only in the case of yol35.2 is 
there a discrepancy in the number of C atoms, it shows to be two carbon atoms 
less than the expected value. That being said, even though the percentage 
carbon analysis for yol32.5 is low the mass-spectrum determination agreed with 
the required molar value.  
Bromoplatinum(II) complexes 
The elemental analysis of each of the bromoplatinum(II) complexes is represented 
in Table B-2. 
Table B-2 Tabular representation of the elemental analysis data of the                  
bromoplatinum(II) complexes 
%C %H %N 
COMPLEX 
Exp Calc Exp Calc Exp Calc 
yol25.3 15.8 16.02 2.6 2.1 7.6 8.0 
yol29.3 17.4 17.6 2.0 2.1 5.4 5.9 
yol31.3 10.3 10.5 2.7 2.6 5.6 6.1 
yol33.3 20.1 21.4 2.7 2.8 5.0 5.6 
yol35.3 21.4 25.6 4.2 3.9 5.3 5.5 
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The analytical data presented in Table B-2 is acceptable and except for two slight 
discrepancies, reinstates the carbon, hydrogen and nitrogen stoichiometries. In 
the case of yol35.3 (as in the case of its chloro analogue; yol35.2), two carbon 
atoms per platinum were unaccounted, which could imply an impurity in sample 
and in the case of yol25.3 there is two more hydrogen atoms than expected. 
Despite this, mass-spectral analysis confirmed the presence of the product in both 
cases. 
Oxalatoplatinum(II) complexes 
As before, the elemental analysis of the oxalatoplatinum(II) complexes are given 
in Table B-3 
Table B-3 Presentation of the elemental analysis of the oxalatoplatinum(II) complexes 
%C %H %N 
COMPLEX 
Exp Calc Exp Calc Exp Calc 
yol25.1 22.8 23.9 2.7 2.5 8.5 9.3 
yol29.1 24.8 26.7 2.5 2.5 6.3 6.9 
yol31.1 21.3 18.6 2.5 3.1 7.7 7.2 
yol33.1 25.9 30.5 3.2 3.3 5.9 6.5 
yol35.1 30.1 30.1 4.9 4.6 6.1 6.4 
Table B-3 reflects that the elemental analysis is reasonable and confirms their 
carbon, hydrogen and nitrogen stoichiometries. However, in the case of yol31.1 
there is a discrepancy in that there is 1 more carbon atom than expected and in 
the case of yol33.1 there are 2 carbon atoms that were unaccounted for during 
the analysis, both these occurrences could be ascribed to an impurity effect. 
Despite these discrepancies, the elemental analysis is still reasonably sound and 
mass-spectral analysis confirmed the presence of the products. 
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Pt(IV) complexes 
Table B-4 Presentation of the elemental analysis of the mononitroplatinum(IV)oxalate 
complexes 
%C %H %N COMPLEX 
Exp Calc Exp Calc Exp Calc 
Mar 4.1.4 18.8 18.7 3.9 3.5 8.4 8.2 
Mar 4.1.4.3 17.2 17.2 3.8 3.2 7.1 7.5 
yol25.1.4 19.8 20.2 3.8 2.1 10.7 10.5 
yol35.1.4 24.3 25.4 5.2 3.9 8.2 8.1 
yol35.1.3 22.6 23.4 3.8 3.6 6.9 7.4 
 
C. INFRARED SPECTROSCOPY 
 (Infrared-data of the platinum(II)diamine complexes were prepared.  
Firstly, the infrared spectrum of the amine ligand, L-histidine methyl ester (ligand 
25), was quite complicated due to it being present as a hydrochloride salt. This 
made the assignment of ligand vibrations very difficult in a few ways. 
For instance, the presence of the broad symmetric and asymmetric –NH3+ and 
NAr- H+…Cl stretches in the in the 2600-3200 cm-1 effectively masked any alkyl C-H 
stretches. Furthermore, this broad band also masks the presence of the 
asymmetric stretch of the methyl ester which should be present at 2960 cm-1 
(although the deformation band associated near 1440 cm-1 seems to be present). 
The identification of the imidazole ring stretches (of which there should be four or 
five in the 1300-1650 region)121 was made quite difficult due to the presence of 
the NH3+ in-plane deformations. This was of particular concern in assigning the 
C=N ring stretch, the frequency of which would be diagnostic in establishing 
coordination through the imidazole nitrogen. According to Carlson et al.122 the ring 
stretching would undergo sizeable shifts to higher frequencies upon formation of 
the imidazolium ion. This is because the imidazole nitrogen forms a -bond to the 
high charge density H+, with subsequent -electron density redistributed in the 
ring. This could lead to altered bond strengths and thus altered vibrations, similar 
to that obtained upon metal coordination, making determination of the latter 
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somewhat difficult.  
The infrared spectrum of the dihydrochloride salt of L-histidine methyl ester is 
given in the figure below (Figure C1). 
At 2000cm-1 there appears to be a combination band present due to NH3+ 
asymmetric deformation and NH3+ hindered rotation123 and at 1431-1462 there 
appears a symmetrical CH3 deformation present associated with the O-CH3 
group. 
The infrared spectra of the other diamine ligands were less complicated and thus, 
what will follow, are tables relating to selected infra-red data for the each diamine 
ligand and its relevant platinum(II)complexes. 
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Figure C-1 The infrared spectrum of the dihydrochloride salt of L-histidine methyl ester 
(ligand 25) 
General comments 
The infrared spectra (3800-200 cm-1) of the complexes were measured in the 
Combination of 
NH +asymmetric deformation and 
υ(NH3+) & υ(NArH+) 
(NH3) defs / υ(C=N) 
 υ(C=O) 
 υ(C=C) 
 υ (C-O) 
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solid phase. Assignments of selected vibrations are given in Tables C-1 to C-5.  It 
should be noted that tentative assignments were made for all peaks. In general 
the following points can be noted.  
All complex spectra which indicated a broad band in the υ(O-H),~3400-3500 cm-1 
region, can be attributed to water being absorbed during the acquisition of 
spectra, except in the case of Pt(2-aeae)C2O4; (yol31.1) which indicated the loss 
of water upon TG analysis.  
A difficult task is in determining whether the amines of the ligand have indeed 
coordinated. 
In each spectrum, a broad band is present in the region, ~3300-3400 cm-1.  This 
can either be related to water (as mentioned above) being acquired during the 
acquisition of the spectrum, or the other possibility is that it implies coordination of 
the amine. Another indication of amine coordination could be the shift attributed to 
the δ(NH2) peak.  
For the oxalato complexes, the carboxylate region is applicable, viz. υ(C=O) and 
υ(C-O) occuring at 1740-1680cm-1 and 1315-1280cm-1 respectively. We see, in 
the case of complexes with L-histidine methyl ester (ligand 25), that there is an 
shift in frequency for these bonds, which could imply coordination of the ligand. 
For the rest of the diamine ligands we observe that their platinum(II)oxalato 
complexes, do signal the appearance of the aforementioned peaks in the 
aforesaid regions. 
The υ(Pt-N) and  υ(Pt-O) vibrations are usually medium to weak bands, which are 
difficult to assign. Literature values for the Pt-N stretches varied from 510 cm-1 for 
cis-Pt(NH3)2Cl2  to 610 cm-1 for Pt(imidazole)2Cl2124’125. The identification of the Pt-
N stretch is extremely tenuous and was assigned in the region 453-476 cm-1 or 
570-624 cm-1, where a new band occurred. The appearance of a new band in the 
region 557-613cm-1 was assigned to the Pt-O vibration; this confirmed the 
coordination of oxygen donors. It was interesting to note that in the case of the of 
the platinum(II)chlorides and platinum(II)bromide complexes the Pt-N band 
188 
 
appears in the same region,  whereas for the platinum(II)oxalates, this frequency 
either increases or decreases depending on the amine ligand. 
The υ(Pt-Cl) and υ(Pt-Br) bonds were equally difficult to assign. The υ(Pt-Cl) is 
usually assigned in the region 323-357cm-1, where a new band occurs. The υ(Pt-
Br) bond could not be assigned, since due to its interaction with platinum(II), its 
stretching frequency will appear much lower down in spectrum and thus went 
undetected. Below are some example spectra. 
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Figure C-2 Infrared spectrum of the chloroplatinum(II) complex,  Pt(L-hme)Cl2 (yol25.2)  
(KBr disk). 
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Figure C-3 Infrared spectrum of the bromoplatinum(II) complex, Pt(N-beda)C2O4 (yol35.1) 
(KBr disk). 
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Table C-1 Selected infrared data of the free ligand, L-histidine methyl ester (25) and its platinum(II)complexes 
 
 
 
LIGAND/ 
COMPLEX 
υ (OH)/ 
υ (NH) 
υ (NH3+)/    
υ (NARH+) 
υ (C-H) 
(ring) 
υ (C-H) 
(alkyl) 
δ (NH2)/ 
δ (NH3+) 
 
υ  (C=N) υ (C=C) υ (Pt-N) υ (Pt-Cl) υ (Pt-O) υ (C=O) υ (C-O) 
L-hme·2HCl 
 - 
2600-3200 
(br) - - 1591(m) 1624 (m) 1504(m) - - - 1762(s) 1143 (s) 
Pt(L-hme)Cl2 
(yol25.2) 3469(br) - 
3253(m); 
3196(m) 
2920(w); 
2956(w) 1652(w) 1652(w) 1506(w) 621(m) 351(m) - 1735(s) 1232(s) 
Pt(L-hme)Br2 
(yol25.3) - - 
3267(w); 
3327(w) 2555(w) 1653(w) 1653(w) 1507(w) 614(m) - - 1722(s) 1243(s) 
 
Pt(L-hme)C2O4 
(yol25.1) 
3508(br) - 3211(w); 3234(w) 2916(w) - 1558 (w) 1506(w) 624(m) - 563(w) 
1734(s); 
1674(s) 1249(s) 
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Table C-2   Selected infrared data of the free ligand, 2-aminobenzylamine ( 29) and its platinum(II)complexes 
LIGAND/ 
COMPLEX 
υ(OH)/ 
υ(NH) 
υ(CH2) 
sym/ 
asym 
δ(CH2) υ(C-N)  
δ(NH2)/ 
δ(NH3+) 
 
υ (C-H) 
ring 
υ (NH2) 
sym/asym υ(Pt-N) 
υ(Pt-
Cl) υ(Pt-O) υ(C=O) υ(C-O) 
2-aba 3400(w) 2850(w); 3000(w) 1425(m) 
1098-
1068(w); 
1330(s) 
1650(m) 2850(w)  
3300(s) 
 - - - - 
- 
Pt(2-aba)Cl2 
(yol29.2) 
3468(br); 
3286(w) 3107(m) 1492(m) 
1124(s); 
1290(m) 1558(s) - 
3246(s); 
3201(s) 453(m) 327(s) - - - 
Pt(2-aba)C2O4 
(yol29.1) 3464(br) 2916(w) 1496(m) 
1186(m);                                                                                   
1217(m) 1608(w) - 
3196(s);
3130(s) 476(m) - 567(m) 
1710(s); 
1660(s) 1388(s) 
 
H2N
H2N
 
                                                                                                Ligand 29 = 2-aba 
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Table C-3 Selected Infrared data of the free ligand, 2-aminoethylaminoethanol (31) and its platinum(II)complexes 
LIGAND/ 
COMPLEX 
υ(OH)/ 
υ(NH) 
υ(CH2) 
sym/asym 
δ(CH2) 
 
υ(NH2) 
asym/ 
sym 
δ(NH2)/ 
δ(NH3+) 
 
υ (C-N)/ 
υ(C-O) of 
alcohol 
δ (OH) υ(Pt-N) υ(Pt-Cl) υ(Pt-O) υ(C=O) υ(C-O) 
2-aeae 3147-3359(br) 
2841-
2939(b) 
1465(m
) - 1610(m) 
1068(m); 
1075(w) 1365* (w) - - - - - 
Pt(2aeae)Cl2 
(yol31.2) 3267(sh) 
2875(m) 
2924(w) 
1448(w
) 
3194(w);31
26(w) 1593(w) 
1060(s); 
1172(m) 
1170-
1384(w)* 570 (w) 316(w) - - - 
Pt(2aeae)Br2 
(yol31.3) 
3516(br) 
/3282(m) 
2889(w); 
2958(w) 1436(s) 
3217(w) 
3190(m) 1573(s) 
1066(s) 
1151(s) 
1151-
1292(m)* 576(m) - - - - 
Pt(2aeae)C2O4 
(yol31.1) 3489(br) 
2850(w); 
2920(w) - 
3325(w); 
3263(w) 
 
1570(w) 
1041(w) 
1087(s) 
 
- 464(w)  613(s) 1650(m); 1720 (s); 
1244(s); 
1431(m) 
 
*Coupled with CH2 wagging 
 
H
N
NH2HO  
Ligand 31 = 2aeae 
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Table C-4  Selected Infrared data of the free ligand, N-benzylethylenediamine (33) and its platinum(II)complexes 
LIGAND/ 
COMPLEX 
υ(OH)/ 
υ(NH) 
υ(CH2) 
sym/asy
m 
*δ 
(CH2) 
 
υ(NH2) 
asym/ 
sym 
*δ(NH2)/ 
 
 
υ (C-N) υ(Pt-N) υ(Pt-Cl) υ(Pt-O) υ(C=O) υ(C-O) 
N-beda 3369(sh) 2839(b) 
2935(b) 
1454(s) 3298(w) 1606(m) 1074 (m); 
1124 (m) 
- - - - - 
Pt(N-beda)Cl2 
(yol33.2) 
3467(br)/ 
3295(s); 
 
2952(w); 
2875(w) 
1452(m) 3182(m); 
3121(s) 
1581(m) 1018(m); 
1192(m) 
481(w) 323(w) - - - 
Pt(N-beda)Br2 
(yol33.3) 
3485(br)/ 
3290(m); 
 
2957(w); 
2890(w) 
1457(m) 3178(m); 
3129(s) 
1576(w) 1061(w); 
1162(w) 
481(w) - - - - 
Pt(N-beda)C2O4 
(yol33.1) 
3487(br)/ 
3298(w) 
3130(w) 
3097(w) 
- 3255(vw)  1066(w) 516(w) - 561(w) 1652 (s); 
1699(s) 
1392 (s) 
*In same region υ (C-H) of aromatic ring can also occur. 
 
 
H
N
H2N  
Ligand 33 = N-beda 
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Table C-5   Selected Infrared data of the free ligand, N-cyclohexyl-1,3-propanediamine (35) and its platinum(II)complexes 
LIGAND/ 
COMPLEX 
υ(OH)/ 
υ(NH) 
υ(CH2) 
sym/asy
m 
δ(CH2) 
 
υ(NH2) 
asym/ 
sym 
 δ(NH2)/ 
δ(NH3+) 
 
υ (C-N) υ(Pt-N) υ(Pt-Cl) υ(Pt-O) υ(C=O) υ(C-O) 
N-chpd 3367(sh) 2941(s); 2856(s) 1450(s) 3286(w) 1616(w) 
1130(s) 
 - - - - - 
Pt(N-chpd)Cl2 
(yol35.2) 
3464(br) 
/3250(w) 
2854(m); 
2935(s) 1452(s) 
3161(m);
3211(m) 1602(s) 
1016(m); 
1176(m) 570(w) 327(s) - - - 
Pt(N-chpd)Br2 
(yol35.3) 
3500(br)/
3249(w) 
2861(m); 
2937(s) 1450s) 
3144-
3197(s) 1588(s) 
1014(m); 
1147(m) 571(w) - - - - 
Pt(N-chpd)C2O4 
(yol35.1) 
3450(br)/ 
3265(m) 
2858-
2939(s) - 
3143(s); 
3230(w) - 
1031(m); 
1252(m) 472(w)  557(w) 
1672(s); 
1705(s) 
1252(m); 
1386(s) 
 
 
 
NH
H2N
 
Ligand 35 = N-chpd 
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Where M =
HN
NHPtCl
Cl
387.62
Pt
H2
N Cl
ClNH
HO 369.60
Where M =
D. ADDITION TO EI-MS DATA 
The following mass-spectra and chromatograms are those not displayed in the 
relevant chapter(s) due to space constraints. The data was however presented in 
a table therein. 
Chloroplatinum(II) complexes 
            
          
 
  
 
 
Figure D-1   Mass-spectra of Pt(2-aba)Cl2 (yol29.2) m/z 387.6, obtained in positive (top) and 
negative (bottom) ion modes. 
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Figure D-2   Mass-spectra of Pt(2-aeae)Cl2, (yol31.2) m/z369.6, obtained in positive (top) and 
negative (bottom) ion modes. 
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NH Cl
ClNH2
415.67
Where M =
NH2
HN
O
O
Pt
N
Br
Br
Where M   =
523.49
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Figure D-3  Mass-spectra of Pt(N-beda)Cl2; yol33.2 m/z415.7, obtained in positive (top) and 
negative (bottom) ion modes. 
 
Bromoplatinum(II) complexes 
 
 
 
 
 
 
 
Figure D-4  Mass-spectra of Pt(L-hme)Br2; yol25.3 m/z523.5, obtained in positive (bottom) 
and negative ion (top) ion modes. 
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Where M = Pt
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N Br
BrNH
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Figure D-5  Mass-spectra of Pt(2-aeae)Br2; yol31.3 m/z458.8, obtained in positive (top) and 
negative (bottom) ion modes. 
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Figure D-6  Mass-spectra of Pt(N-beda)Br2; yol33.3 m/z504.6, obtained in positive (top) and 
negative (bottom) ion modes. 
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Figure D-7  Mass-spectra of Pt(N-chpd)Br2; yol35.3 m/z510.6, obtained in positive (top) and 
negative (bottom) ion modes. 
Oxalatoplatinum(II) complexes 
 
 
 
 
 
 
 
Figure D-8  Mass-spectra of Pt(2-aba)C2O4; yol29.1 m/z404.7, obtained in positive (top) and 
negative (bottom) ion modes. 
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Figure D-9  LC-UV separation obtained for Pt(2-aba)C2O4; yol29.1 of 92% purity  utilizing a 
YMC Hydrosphere C18 (250x4.6mm 5µm ) with 20% MeCN as eluent at a flow rate of 
1.0ml/min at 210nm  
 
 
 
 
 
 
 
Figure D-10  Mass-spectra of Pt(L-2aeae)C2O4; yol31.1 m/z386.7, in positive (top) and 
negative(bottom) ion modes. 
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Figure D-11  LC-UV separation obtained for Pt(L-2aeae)C2O4; yol31.1 of 93% purity utilizing a 
YMC Hydrosphere C18 (250x4.6mm 5µm) with 20% MeCN as eluent at a flow rate of 
1.0ml/min at 210nm. 
25 30 35 40 45 50 55 60 m/z 
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
 
388.1
387.1
389.0
391.0
403.7
338.1 294.1 315.1 428.8 342.2277.3 385.1 494.7 453.2267.3 595.0467.0 550.7522.6 566.1
431.9
430.9
432.8
434.8 
386.1
517.5429.2258.9 473.8389.2 435.8 499.5 557.6297.1 521.7315.2287.3 383.1 594.9586.5358.8340.5
NL: 
3.72E6
31_1 pos#8-28  
RT: 0.09-0.32  
AV: 21 T: + p ms 
[ 200.00-750.00] 
NL: 
7.97E5
31_1 neg#2-9  
RT: 0.02-0.10  
AV: 8 T: - p Full 
ms [ 
200.00-750.00] 
50% MeCN pos 
50% MeCN neg 
[M+H] + 
[M+NH4] + 
[M+HCOO] - 
[M-H] - 
R
el
at
iv
e 
Ab
un
da
nc
e 
199 
 
Pt
NH O
ONH2
432.78
C
C
O
O
Where M =
 
 
 
 
 
 
 
Figure D-12  Mass-spectra of Pt(N-beda)C2O4; yol33.1 m/z432.7, in positive (top) and negative 
(bottom) ion modes. 
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Figure D-13  LC-UV separation of Pt(N-beda)C2O4; yol33.1 of 95% purity (utilizing a YMC 
Hydrosphere C18 (250x4.6mm 5µm) and 20% MeCN as eluent at a flow rate of 1.0ml/min at 
210nm)
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E. CRYSTALLOGRAPHIC DATA OF MAR4.1.4 AND MAR 4.1.4.3 
Table E.1  Crystal data and structure refinement of Pt(dach)(C2O4)(NO2)Cl.2H2O. 
Crystal Data 
 Empirical formula   C8H14N3O8ClPt  (69%) & 
C8H14N2O6Cl2Pt (31%) 
 Formula weight   510.75 g/mol & 500.19 g/mol 
 Crystal size   0.40  0.38  0.23 mm 
 Crystal description   Beige prism 
 Crystal system   Orthorhombic 
 Space group   P212121 
 Unit cell dimensions  a = 9.1340(6) 
   b = 10.9136(8) 
   c = 15.1028(10) 
   = 90.00 
   = 90.00 
   = 90.00 
 Volume   1505.52 Å3 
 Z   4 
 Wavelength   0.71073 Å 
 Density (calculated)   2.242 g/cm3 
 Absorption coefficient    9.577 cm-1 
 F(000)   962 
Data Collection 
 Temperature   223(2) K 
 Max. 2    56.55 
 Index ranges   -12  h  10, -13  k  14, -12  l  20 
 Reflections collected   7179 
 Independent reflections   3741 [Rint = 0.0571] 
 T min  0.0636 
 Absorption correction T max  0.1834 
Solution and Refinement 
 Data / restraints / parameters   3741 / 8 / 202 
 Goodness-of-fit on F2   1.117 
 R indices [I > 4(I)]  R1 = 0.0389 
  All data  R2 = 0.0397, wR2 = 0.0925 
 Weights a  0.0182 
  b  16.22 
201 
 
 Highest peak   1.28 eÅ-3 (0.91 Å from O1W) 
 Deepest hole   -1.79 eÅ-3 (0.69 Å from Pt) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table E-2  Atomic coordinates, site occupation factors, anisotropic and isotropic displacement parameters for all atoms in 
Pt(dach)(C2O4)(NO2)Cl(1) & Pt(dach)(C2O4)(NO2)Cl(1)Cl(2). Estimated standard deviations are included in parenthesis. 
ATOM x y z sof U11 U22 U33 U23 U13 U12 Ueq 
0.66457 0.48853 0.02249 1 0.02491 0.01648 0.03259 0.00114 0.00316 -0.00243 0.02466 
Pt1 
(3) (3) (2) (0) (13) (12) (14) (12) (13) (12) (9) 
0.57246 0.56476 0.15456 1 0.05334 0.04477 0.07985 -0.00326 0.02621 0.00625 0.05932 
Cl1 
(38) (32) (26) (0) (175) (170) (221) (159) (167) (142) (87) 
0.48344 0.38597 0.00128 1 0.0294 0.02484 0.04053 0.00344 0.00082 -0.00451 0.03159 
O1 
(76) (59) (43) (0) (317) (303) (374) (235) (268) (263) (146) 
0.54892 0.62084 -0.04195 1 0.03015 0.02247 0.0501 0.01107 -0.00473 -0.00696 0.03424 
O2 
(74) (60) (48) (0) (335) (309) (433) (277) (288) (259) (161) 
0.77364 0.35642 0.09069 1 0.03232 0.01424 0.02924 0.0001 0.0027 0.00087 0.02527 
N1 
(84) (66) (50) (0) (386) (318) (369) (272) (296) (288) (153) 
0.85118 0.588 0.04405 1 0.02517 0.02098 0.03159 0.00029 0.00287 -0.00117 0.02591 
N2 
(84) (64) (46) (0) (356) (302) (358) (244) (287) (298) (148) 
0.75966 0.41162 -0.10848 0.31305 0.07331 0.05426 0.0426 -0.02028 0.02587 -0.02469 0.05672 
Cl2 
(317) (237) (137) (2650) (1983) (1123) (894) (718) (992) (1079) (1092) 
0.74145 0.42239 -0.09609 0.68695 0.01119 0.02454 0.03376 0.00803 -0.01299 -0.00202 0.02316 
N3 
(248) (228) (145) (2650) (600) (732) (854) (623) (612) (491) (483) 
0.67227 0.44145 -0.15986 0.68695 0.06122 0.06422 0.03146 -0.00333 -0.00852 -0.0023 0.0523 
O31 
(172) (118) (88) (2650) (771) (762) (663) (496) (694) (793) (370) 
0.86112 0.36418 -0.09507 0.68695 0.03437 0.05504 0.03285 -0.01169 -0.00047 0.02645 0.04075 
O32 
(140) (117) (69) (2650) (716) (730) (530) (463) (426) (575) (346) 
0.2577 0.40832 -0.05137 1 0.03202 0.02676 0.05045 -0.00921 0.00218 -0.00959 0.03641 
O3 
(79) (64) (50) (0) (349) (346) (431) (291) (306) (279) (164) 
202 
  
0.31793 0.65455 -0.07976 1 0.03096 0.02683 0.04819 -0.00233 -0.00537 0.00332 0.03533 
O4 
(81) (59) (47) (0) (343) (301) (385) (267) (328) (300) (144) 
0.38022 0.44998 -0.03329 1 0.03551 0.0194 0.02603 0.00028 0.00489 0.00081 0.02698 
C1 
(102) (77) (59) (0) (430) (352) (396) (318) (338) (305) (173) 
0.41219 0.58812 -0.05417 1 0.03932 0.02788 0.0333 -0.00099 0.00275 -0.00096 0.0335 
C2 
(121) (95) (66) (0) (547) (478) (475) (368) (412) (408) (214) 
0.93023 0.39436 0.10572 1 0.02957 0.01731 0.02449 0.00137 -0.00017 -0.00124 0.02379 
C11 
(102) (78) (58) (0) (423) (387) (381) (310) (339) (334) (166) 
0.92981 0.53192 0.1215 1 0.02229 0.02882 0.02921 -0.00149 -0.00442 -0.00723 0.02677 
C12 
(93) (87) (57) (0) (349) (453) (387) (343) (303) (346) (174) 
1.08754 0.58179 0.12966 1 0.03927 0.03009 0.03475 0.00468 -0.00196 -0.0004 0.0347 
C13 
(117) (99) (67) (0) (541) (507) (492) (388) (413) (422) (217) 
1.16029 0.51293 0.2094 1 0.04367 0.04293 0.04489 -0.00418 -0.01315 -0.00071 0.04383 
C14 
(126) (100) (64) (0) (484) (515) (472) (439) (451) (659) (212) 
1.15501 0.37446 0.19598 1 0.04056 0.04181 0.03574 -0.00076 -0.01187 0.01068 0.03937 
C15 
(131) (94) (66) (0) (544) (508) (459) (386) (475) (519) (218) 
0.99961 0.32851 0.18442 1 0.03919 0.02532 0.03544 0.00147 -0.00135 0.00976 0.03332 
C16 
(120) (85) (63) (0) (504) (426) (455) (349) (423) (414) (196) 
0.02601 0.594 -0.11691 1 0.03027 0.08798 0.0501 0.00643 -0.00247 -0.01143 0.05611 
O1W 
(87) (98) (58) (0) (400) (707) (460) (469) (354) (432) (237) 
0.59549 0.27893 0.23012 1 0.17807 0.08502 0.12413 0.04922 0.10785 0.02443 0.12907 
O2W 
(194) (128) (100) (0) (1655) (897) (1113) (827) (1177) (925) (718) 
            
H1A 0.72896 0.3436 0.14374 1       0.03032 
H1B 0.77131 0.28497 0.05966 1       0.03032 
203 
  
H2A 0.90926 0.58613 -0.00489 1       0.0311 
H2B 0.82817 0.66743 0.05596 1       0.0311 
H11 0.98789 0.37635 0.05176 1       0.02855 
H12 0.87525 0.55016 0.17658 1       0.03213 
H13A 1.08611 0.67028 0.14063 1       0.04164 
H13B 1.14232 0.56632 0.07499 1       0.04164 
H14A 1.2624 0.53926 0.21527 1       0.0526 
H14B 1.10892 0.53427 0.26424 1       0.0526 
H15A 1.21258 0.35279 0.1435 1       0.04724 
H15B 1.19945 0.33389 0.24725 1       0.04724 
H16A 0.94281 0.34469 0.23821 1       0.03998 
H16B 1.00011 0.23989 0.17393 1       0.03998 
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Table E-3  Crystal data and structure refinement of Mar4.1.4.3 Pt(dach)(C2O4)(NO2)Br.2H2O. 
Crystal Data 
 Empirical formula   C8H14N3O8BrPt  (77%) & 
C8H14N2O6Br2Pt (23%) 
 Formula weight   555.20 g/mol & 589.09 g/mol 
 Crystal size   0.40  0.38  0.23 mm 
 Crystal description   Yellow prism 
 Crystal system   Orthorhombic 
 Space group   P212121 
 Unit cell dimensions  a = 9.8036(2) 
   b = 10.4699(2) 
   c = 14.8319(4) 
   = 90.00 
   = 90.00 
   = 90.00 
 Volume   1522.39(6) Å3 
 Z   4 
 Wavelength   0.71073 Å 
 Density (calculated)   2.388 g/cm3 
 Absorption coefficient    11.877 cm-1 
 F(000)   1024 
Data Collection 
 Temperature   173(2) K 
 Max. 2    56.69 
 Index ranges   -13  h  12, -13  k  13, -19  l  
19 
 Reflections collected   35504 
 Independent reflections   3796 [Rint = 0.0760] 
 T min  0.0662 
 Absorption correction T max  0.1417 
Solution and Refinement 
 Data / restraints / parameters   3796 / 0 / 202 
 Goodness-of-fit on F2   1.109 
 R indices [I > 4(I)]  R1 = 0.0315 
  All data  R2 = 0.0322, wR2 = 0.0893 
 Weights a  0.0455 
  b  12.73 
 Highest peak   1.81 eÅ-3 (0.82 Å from Pt) 
 Deepest hole   -3.21 eÅ-3 (0.45 Å from Br(1)) 
 
 
 
 
 
  
 
Table E-4  Atomic coordinates, site occupation factors, anisotropic and isotropic displacement parameters for all atoms in 
Pt(dach)(C2O4)(NO2)Br(1) & Pt(dach)(C2O4)(NO2)Br(1)Br(2). Estimated standard deviations are included in parenthesis. 
ATOM x y z sof U11 U22 U33 U23 U13 U12 Ueq 
0.73988 0.281 0.15456 1 0.01243 0.0141 0.01632 -0.0009 -0.00046 0.00157 0.01428 
Pt1 
(2) (2) (2) (0) (11) (12) (12) (9) (10) (10) (8) 
0.72224 0.36948 0.00091 1 0.04444 0.03741 0.03545 0.00494 0.00772 0.00458 0.0391 
Br1 
(12) (9) (7) (0) (58) (46) (44) (38) (43) (43) (23) 
0.73138 0.19584 0.31147 0.22669 0.04029 0.02895 0.0163 0.002 -0.00432 0.00258 0.02851 
Br2_a 
(81) (68) (43) (825) (373) (445) (296) (220) (242) (282) (215) 
0.74943 0.22561 0.28804 0.77331 0.03221 0.02433 0.01958 0.00639 0.00888 -0.0001 0.02537 
N3 
(186) (166) (111) (825) (599) (743) (775) (454) (564) (619) (343) 
0.7902 0.3058 0.33889 0.77331 0.06486 0.05264 0.0211 -0.0023 -0.01738 0.00068 0.0462 
O31 
(116) (103) (56) (825) (638) (590) (385) (389) (409) (490) (256) 
0.69598 0.12141 0.30797 0.77331 0.06526 0.04148 0.02017 0.00562 0.00192 -0.0032 0.0423 
O32 
(128) (142) (64) (825) (732) (687) (432) (440) (429) (579) (253) 
0.89728 0.40099 0.18192 1 0.01487 0.02121 0.04786 -0.0083 -0.0028 0.0005 0.02798 
O1 
(59) (61) (51) (0) (260) (296) (414) (272) (247) (222) (146) 
0.6255 0.42982 0.19766 1 0.01554 0.01443 0.02387 -0.00408 -0.00203 -0.00063 0.01795 
O2 
(55) (55) (41) (0) (249) (257) (272) (225) (208) (197) (109) 
0.85508 0.13055 0.1116 1 0.01232 0.01538 0.02678 -0.00208 0.00265 0.00488 0.01816 
N1 
(64) (63) (49) (0) (281) (302) (332) (259) (244) (227) (128) 
N2 0.58182 0.15945 0.12802 1 0.0163 0.01604 0.02029 0.00372 -0.00114 -0.00077 0.01754 
206 
  
 
ATOM x y z sof U11 U22 U33 U23 U13 U12 Ueq 
(66) (66) (44) (0) (285) (290) (299) (246) (221) (245) (123) 
0.85749 0.50291 0.22319 1 0.02358 0.02258 0.02454 -0.00363 -0.00278 0.00002 0.02357 
C1 
(90) (84) (59) (0) (407) (422) (400) (334) (317) (305) (169) 
0.70078 0.52139 0.23116 1 0.02394 0.01376 0.01714 -0.00215 -0.00094 0.00162 0.01828 
C2 
(82) (73) (52) (0) (368) (314) (325) (266) (278) (268) (143) 
0.93185 0.58343 0.25383 1 0.02524 0.02528 0.05538 -0.01556 -0.00847 -0.00184 0.0353 
O3 
(69) (66) (54) (0) (317) (333) (452) (318) (301) (256) (162) 
0.65344 0.61731 0.26492 1 0.02495 0.01801 0.03622 -0.00168 0.01 0.00148 0.02639 
O4 
(63) (57) (46) (0) (297) (281) (339) (247) (257) (224) (128) 
0.77224 0.01109 0.1162 1 0.02121 0.01327 0.013 -0.00149 0.00005 0.00289 0.01583 
C11 
(79) (61) (45) (0) (368) (275) (269) (224) (273) (273) (129) 
0.63124 0.04619 0.07825 1 0.01898 0.02049 0.01799 -0.00397 0.00145 -0.00179 0.01915 
C12 
(79) (78) (54) (0) (347) (370) (336) (291) (284) (288) (147) 
0.53722 -0.06682 0.08796 1 0.02754 0.0258 0.03331 -0.01164 0.00544 -0.00836 0.02888 
C13 
(92) (88) (66) (0) (424) (418) (457) (364) (352) (342) (184) 
0.59799 -0.18449 0.03917 1 0.03366 0.02613 0.04522 -0.01302 0.00956 -0.01199 0.035 
C14 
(103) (90) (75) (0) (471) (449) (535) (399) (422) (353) (215) 
0.73929 -0.21405 0.07109 1 0.05171 0.01727 0.02729 -0.00647 0.00894 -0.00137 0.03209 
C15 
(106) (73) (56) (0) (520) (326) (359) (283) (396) (507) (177) 
0.83513 -0.09987 0.06486 1 0.02742 0.01855 0.0313 -0.00766 0.00511 0.00512 0.02576 
C16 
(92) (81) (62) (0) (422) (377) (443) (318) (336) (321) (176) 
O1W 0.89724 0.13478 -0.08338 1 0.02002 0.02875 0.02432 -0.00049 0.00378 -0.00193 0.02437 
207 
  
 
ATOM x y z sof U11 U22 U33 U23 U13 U12 Ueq 
(60) (61) (41) (0) (272) (314) (282) (240) (222) (231) (120) 
0.68062 0.15844 -0.19206 1 0.0286 0.02234 0.04272 -0.00131 -0.00455 -0.00342 0.03122 
O2W 
(66) (61) (48) (0) (309) (293) (350) (282) (266) (253) (134) 
H1A 0.88334 0.14439 0.05326 1       0.02179 
H1B 0.93121 0.12256 0.14742 1       0.02179 
H2A 0.54213 0.13403 0.18129 1       0.02105 
H2B 0.5168 0.20105 0.09428 1       0.02105 
H11 0.76168 -0.01409 0.18086 1       0.01899 
H12 0.64045 0.06818 0.01293 1       0.02298 
H13A 0.44703 -0.04598 0.06178 1       0.03466 
H13B 0.52423 -0.08663 0.15266 1       0.03466 
H14A 0.53862 -0.25945 0.04991 1       0.042 
H14B 0.59996 -0.16806 -0.02655 1       0.042 
H15A 0.77682 -0.2849 0.0345 1       0.03851 
H15B 0.73505 -0.24321 0.13453 1       0.03851 
H16A 0.92491 -0.12191 0.09116 1       0.03091 
H16B 0.84895 -0.07589 0.00094 1       0.03091 
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